
<html lang="en"     class="pb-page"  data-request-id="bfdfebc2-a21c-4b85-a128-529a8143e735"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.1c00713;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor" /></meta><meta name="dc.Creator" content="Liangxing  Wu" /></meta><meta name="dc.Creator" content="Colin  Zhang" /></meta><meta name="dc.Creator" content="Chunhong  He" /></meta><meta name="dc.Creator" content="Dingquan  Qian" /></meta><meta name="dc.Creator" content="Liang  Lu" /></meta><meta name="dc.Creator" content="Yaping  Sun" /></meta><meta name="dc.Creator" content="Meizhong  Xu" /></meta><meta name="dc.Creator" content="Jincong  Zhuo" /></meta><meta name="dc.Creator" content="Phillip C. C.  Liu" /></meta><meta name="dc.Creator" content="Ronald  Klabe" /></meta><meta name="dc.Creator" content="Richard  Wynn" /></meta><meta name="dc.Creator" content="Maryanne  Covington" /></meta><meta name="dc.Creator" content="Karen  Gallagher" /></meta><meta name="dc.Creator" content="Lynn  Leffet" /></meta><meta name="dc.Creator" content="Kevin  Bowman" /></meta><meta name="dc.Creator" content="Sharon  Diamond" /></meta><meta name="dc.Creator" content="Holly  Koblish" /></meta><meta name="dc.Creator" content="Yue  Zhang" /></meta><meta name="dc.Creator" content="Maxim  Soloviev" /></meta><meta name="dc.Creator" content="Gregory  Hollis" /></meta><meta name="dc.Creator" content="Timothy C.  Burn" /></meta><meta name="dc.Creator" content="Peggy  Scherle" /></meta><meta name="dc.Creator" content="Swamy  Yeleswaram" /></meta><meta name="dc.Creator" content="Reid  Huber" /></meta><meta name="dc.Creator" content="Wenqing  Yao" /></meta><meta name="dc.Description" content="Aberrant activation of FGFR has been linked to the pathogenesis of many tumor types. Selective inhibition of FGFR has emerged as a promising approach for cancer treatment. Herein, we describe the d..." /></meta><meta name="Description" content="Aberrant activation of FGFR has been linked to the pathogenesis of many tumor types. Selective inhibition of FGFR has emerged as a promising approach for cancer treatment. Herein, we describe the d..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 16, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00713" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00713" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00713" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00713" /></link>
        
    
    

<title>Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00713" /></meta><meta property="og:title" content="Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0016.jpeg" /></meta><meta property="og:description" content="Aberrant activation of FGFR has been linked to the pathogenesis of many tumor types. Selective inhibition of FGFR has emerged as a promising approach for cancer treatment. Herein, we describe the discovery of compound 38 (INCB054828, pemigatinib), a highly potent and selective inhibitor of FGFR1, FGFR2, and FGFR3 with excellent physiochemical properties and pharmacokinetic profiles. Pemigatinib has received accelerated approval from the U.S. Food and Drug Administration for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement. Additional clinical trials are ongoing to evaluate pemigatinib in patients with FGFR alterations." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00713"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00713">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00713&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00713&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00713&amp;href=/doi/10.1021/acs.jmedchem.1c00713" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.1c00596" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c02051" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Liangxing Wu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liangxing Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#d6baa1a396bfb8b5afa2b3f8b5b9bb"><span class="__cf_email__" data-cfemail="afc3d8daefc6c1ccd6dbca81ccc0c2">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liangxing++Wu">Liangxing Wu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-8524-0799" title="Orcid link">https://orcid.org/0000-0001-8524-0799</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Colin Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Colin Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Colin++Zhang">Colin Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chunhong He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chunhong He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chunhong++He">Chunhong He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dingquan Qian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dingquan Qian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dingquan++Qian">Dingquan Qian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liang Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liang Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liang++Lu">Liang Lu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yaping Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yaping Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yaping++Sun">Yaping Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Meizhong Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Meizhong Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Meizhong++Xu">Meizhong Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jincong Zhuo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jincong Zhuo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jincong++Zhuo">Jincong Zhuo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Phillip C. C. Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Phillip C. C. Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Phillip+C.+C.++Liu">Phillip C. C. Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ronald Klabe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ronald Klabe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ronald++Klabe">Ronald Klabe</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Wynn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Wynn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Wynn">Richard Wynn</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maryanne Covington</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maryanne Covington</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maryanne++Covington">Maryanne Covington</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karen Gallagher</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karen Gallagher</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Gallagher">Karen Gallagher</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lynn Leffet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lynn Leffet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lynn++Leffet">Lynn Leffet</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kevin Bowman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin Bowman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Bowman">Kevin Bowman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sharon Diamond</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sharon Diamond</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sharon++Diamond">Sharon Diamond</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Holly Koblish</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Holly Koblish</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Holly++Koblish">Holly Koblish</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yue Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yue Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yue++Zhang">Yue Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maxim Soloviev</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maxim Soloviev</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maxim++Soloviev">Maxim Soloviev</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gregory Hollis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gregory Hollis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gregory++Hollis">Gregory Hollis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Timothy C. Burn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Timothy C. Burn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+C.++Burn">Timothy C. Burn</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peggy Scherle</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peggy Scherle</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peggy++Scherle">Peggy Scherle</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Swamy Yeleswaram</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Swamy Yeleswaram</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Swamy++Yeleswaram">Swamy Yeleswaram</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Reid Huber</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Reid Huber</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Reid++Huber">Reid Huber</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Wenqing Yao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenqing Yao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenqing++Yao">Wenqing Yao</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00713&amp;href=/doi/10.1021%2Facs.jmedchem.1c00713" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 16, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 April 2021</li><li><span class="item_label"><b>Published</b> online</span>16 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00713" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00713</a></div><div class="article_header-article-copyright"><strong>© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLiangxing%2BWu%252C%2BColin%2BZhang%252C%2BChunhong%2BHe%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.1c00713%26title%3DDiscovery%2Bof%2BPemigatinib%253A%2BA%2BPotent%2Band%2BSelective%2BFibroblast%2BGrowth%2BFactor%2BReceptor%2B%2528FGFR%2529%2BInhibitor%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00713"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">990</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00713" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Liangxing&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Colin&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Chunhong&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Dingquan&quot;,&quot;last_name&quot;:&quot;Qian&quot;},{&quot;first_name&quot;:&quot;Liang&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Yaping&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Meizhong&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Jincong&quot;,&quot;last_name&quot;:&quot;Zhuo&quot;},{&quot;first_name&quot;:&quot;Phillip&quot;,&quot;last_name&quot;:&quot;C. C. Liu&quot;},{&quot;first_name&quot;:&quot;Ronald&quot;,&quot;last_name&quot;:&quot;Klabe&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Wynn&quot;},{&quot;first_name&quot;:&quot;Maryanne&quot;,&quot;last_name&quot;:&quot;Covington&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Gallagher&quot;},{&quot;first_name&quot;:&quot;Lynn&quot;,&quot;last_name&quot;:&quot;Leffet&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Bowman&quot;},{&quot;first_name&quot;:&quot;Sharon&quot;,&quot;last_name&quot;:&quot;Diamond&quot;},{&quot;first_name&quot;:&quot;Holly&quot;,&quot;last_name&quot;:&quot;Koblish&quot;},{&quot;first_name&quot;:&quot;Yue&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Maxim&quot;,&quot;last_name&quot;:&quot;Soloviev&quot;},{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;Hollis&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;C. Burn&quot;},{&quot;first_name&quot;:&quot;Peggy&quot;,&quot;last_name&quot;:&quot;Scherle&quot;},{&quot;first_name&quot;:&quot;Swamy&quot;,&quot;last_name&quot;:&quot;Yeleswaram&quot;},{&quot;first_name&quot;:&quot;Reid&quot;,&quot;last_name&quot;:&quot;Huber&quot;},{&quot;first_name&quot;:&quot;Wenqing&quot;,&quot;last_name&quot;:&quot;Yao&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00713&quot;},&quot;abstract&quot;:&quot;Aberrant activation of FGFR has been linked to the pathogenesis of many tumor types. Selective inhibition of FGFR has emerged as a promising approach for cancer treatment. Herein, we describe the discovery of compound 38 (INCB054828, pemigatinib), a highly potent and selective inhibitor of FGFR1, FGFR2, and FGFR3 with excellent physiochemical properties and pharmacokinetic profiles. Pemigatinib has received accelerated approval from the U.S. Food and Drug Administration for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement. Additional clinical trials are ongoing to evaluate pemigatinib in patients with FGFR alterations.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00713&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00713" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00713&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00713" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00713&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00713" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00713&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00713&amp;href=/doi/10.1021/acs.jmedchem.1c00713" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00713" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00713" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00713%26sid%3Dliteratum%253Aachs%26pmid%3D34269576%26genre%3Darticle%26aulast%3DWu%26date%3D2021%26atitle%3DDiscovery%2Bof%2BPemigatinib%253A%2BA%2BPotent%2Band%2BSelective%2BFibroblast%2BGrowth%2BFactor%2BReceptor%2B%2528FGFR%2529%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292329" title="Pyrroles">Pyrroles</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Aberrant activation of FGFR has been linked to the pathogenesis of many tumor types. Selective inhibition of FGFR has emerged as a promising approach for cancer treatment. Herein, we describe the discovery of compound <b>38</b> (INCB054828, pemigatinib), a highly potent and selective inhibitor of FGFR1, FGFR2, and FGFR3 with excellent physiochemical properties and pharmacokinetic profiles. Pemigatinib has received accelerated approval from the U.S. Food and Drug Administration for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement. Additional clinical trials are ongoing to evaluate pemigatinib in patients with FGFR alterations.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74830" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74830" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases with an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tyrosine kinase domain. Binding of fibroblast growth factor (FGF) ligands to the extracellular domain of FGFRs causes dimerization of the receptor, which then activates the intracellular tyrosine kinase domain. This leads to receptor autophosphorylation and activation of multiple downstream signaling pathways including RAS-MAPK, PI3K-AKT, STAT, and PLCγ. FGFR/FGF signaling plays an essential role in cell proliferation, survival, and motility. FGFRs are composed of four highly conserved members (FGFR1, FGFR2, FGFR3, and FGFR4) that are expressed in a variety of cells.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a></div><div class="NLM_p">Genetic alterations such as gene amplification, point mutation or chromosomal translocation/fusion can result in constitutive activation of FGFRs or abnormal ligand-dependent signaling, which can potentially lead to tumor formation. There is strong evidence that dysregulation of FGFRs is involved in diverse tumor types.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3−6)</a> For example, chromosomal translocation of FGFR1 at the 8p11 locus with partner genes has been reported to be responsible for 8p11 myeloproliferative syndrome.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Similarly, fusion of FGFR2 with other genes is reported in 10–15% of intrahepatic cholangiocarcinoma cases.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Activating point mutations in FGFR3 have been found to be enriched in bladder cancer and could be one of the potential driving oncogenes.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Furthermore, FGFR1<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and FGFR2<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> amplification are found to be prevalent in squamous cell lung cancer and gastric cancer, respectively, and are potentially associated with tumor growth.</div><div class="NLM_p">Due to the prevalence of abnormal FGFR activity across a variety of cancer types, FGFR inhibition represents an attractive therapeutic approach for the treatment of cancers with genetic FGFR alterations.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Several small molecule FGFR inhibitors such as dovitinib<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and brivanib alaninate<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) have progressed into clinical studies and demonstrated promising activities.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> However, these first generation FGFR inhibitors also potently inhibited a broad range of other kinases including VEGFR2. The lack of selectivity may cause dose-limiting toxicity, thereby potentially reducing the therapeutic window for FGFR-driven cancers with these early inhibitors.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative FGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Small molecules that selectively inhibit FGFRs could offer favorable toxicity profile and improved therapeutic window. Therefore, we set out to discover potent and highly selective FGFR inhibitors for the treatment of tumors with FGFR alterations. At the time we initiated our discovery campaign, little was known on how to develop selective small molecule FGFR inhibitors due to the high structural similarity of FGFRs with several other kinases, such as VEGFR2. A literature review of FGFR X-ray crystal structures and reported FGFR inhibitors revealed a tool compound PD173074 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which appeared to exhibit decent FGFR potency with reasonable selectivity over other kinases including VEGFR2.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> After studying the cocrystal structure of PD173074 with FGFR1, we reasoned that the high affinity and selectivity for FGFR1 might result from the filling of a complementary hydrophobic pocket near the FGFR gatekeeper region with a 3,5-dimethoxyphenyl substituent. These findings provided a good starting point for the development of second-generation FGFR selective inhibitors with representative examples shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Herein, we report our discovery efforts including structure-based drug design, structure–activity relationship (SAR) studies, and improvement of physiochemical properties and pharmacokinetics (PK) that culminated in the identification of the clinical candidate compound <b>38</b> (INCB054828, pemigatinib), a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of representative pan-FGFR selective inhibitors in clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38041" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38041" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To identify a novel starting point for potent and selective FGFR inhibitors, we first conducted a high-throughput screen of our in-house compound library (a focused library of about 20 000 compounds from in-house historical projects) using a HTRF enzymatic assay with the FGFR1 enzyme. Among the various hits from the screening campaign, compound <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) showed strong inhibition of FGFR1 (IC<sub>50</sub> = 6 nM) with good selectivity over VEGFR2 (IC<sub>50</sub> = 2058 nM) and seemed to be a promising starting point. We hypothesized that the pyrrolopyrimidine moiety in compound <b>1</b> might bind to the hinge of FGFR1 through two hydrogen bonds and offered an intriguing scaffold for further exploration. While compound <b>1</b> was a potent inhibitor for FGFR1, it also potently inhibited JAK2 (IC<sub>50</sub> < 1 nM) and several other kinases. Preliminary SAR indicated that a major challenge for this pyrrolopyrimidine series would be improving general kinase selectivity.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structure of screening hit <b>1</b> and subsequent design of a tricyclic series as potent and selective FGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We reasoned that introduction of a 3,5-dimethoxyphenyl group into the pyrrolopyrimidine scaffold of compound <b>1</b> could potentially improve kinase selectivity. After examining the superimposition of pyrrolopyrimidine <b>1</b> with PD173074, we hypothesized that the pyrimidine nitrogen of compound <b>1</b> could be a good position to attach the 3,5-dimethoxyphenyl substituent. To test this hypothesis, we prepared a hybrid compound <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), which was found to significantly improve selectivity over JAK2 and maintained decent selectivity over VEGFR2, albeit with a loss in FGFR1 potency relative to <b>1</b>. After careful conformational analysis of compound <b>2</b>, we hypothesized that FGFR activity might be restored by cyclizing the ethylene linker onto the pyrrolopyridine core to rigidify the structure and properly project the 3,5-dimethoxyphenyl group into the hydrophobic pocket near the FGFR gatekeeper region. Thus, tricyclic compound <b>3</b> was prepared, which featured a polar cyclic urea linker with some sp<sup>3</sup> character that we envisioned could be beneficial for future improvement of physiochemical properties.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Indeed, compound <b>3</b> showed promising FGFR1 potency while maintaining good selectivity over JAK2, and more importantly it also exhibited good selectivity over the closely related VEGFR2. Having demonstrated encouraging biochemical potency and selectivity, compound <b>3</b> was selected as a promising starting point for further investigation.</div><div class="NLM_p">To guide SAR studies, the following in vitro assays were developed: (1) biochemical enzymatic assays for FGFR1, FGFR2, FGFR3, and VEGFR2 to gauge selectivity; (2) proliferation assays using FGFR1-dependent H1581 cell line and FGFR2-dependent KatoIII cell line; and (3) a whole blood (WB) assay to estimate compound potency in an in vivo biological system, measuring inhibition of pFGFR2 with KatoIII cells spiked into human whole blood. Compound <b>3</b> was found to inhibit FGFR1, FGFR2 and FGFR3 with good enzymatic activities (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). It was further evaluated in cellular assays and demonstrated moderate activity. In an effort to further improve potency, we targeted SAR exploration in the gatekeeper region to maximize the interactions in the hydrophobic pocket by modification of the 3,5-dimethoxyphenyl group. Introduction of a lipophilic chlorine atom at the <i>ortho</i>-position of the dimethoxyphenyl ring gave compound <b>4</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and resulted in 3-fold improvement in potency while maintaining good selectivity over VEGFR2. Compound <b>4</b> also demonstrated improved cellular activities with encouraging WB activity (IC<sub>50</sub> = 81 nM). Addition of a second <i>ortho</i>-chlorine atom (compound <b>5</b>) led to further improvements in potency as well as VEGFR2 selectivity. In contrast, addition of a second chlorine atom at the <i>para</i>-position (compound <b>6</b>) caused a significant loss in potency. Mono-<i>ortho</i>-fluoro substitution of the 3,5-dimethoxyphenyl ring (compound <b>7</b>) gave comparable potency to the corresponding chloro analogue (<b>4</b>). Interestingly, introduction of bis-<i>ortho</i>-fluorine (compound <b>8</b>) dramatically increased FGFR potency. Compound <b>8</b> demonstrated sub-nanomolar activity in enzymatic and cellular assays with good selectivity over VEGFR2. We were also excited that compound <b>8</b> showed single-digit nanomolar activity against KatoIII cells in the WB assay. The combination of <i>ortho</i>-fluoro and -chloro substitution provided a moderately less potent compound <b>9</b>, which displayed a 3-fold loss in WB potency compared to the difluoro analogue (<b>8</b>). The source for this WB potency loss may be related to the difference in plasma protein binding for these two compounds (2.4% and 4.7% free for <b>9</b> and <b>8</b>, respectively).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Investigation of the 3,5-Dimethoxylphenyl Substituent to Improve Potency</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0008.gif" alt="" id="GRAPHIC-d7e550-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" char="." /></col><col align="center" char="." /></col><col align="center" char="." /></col><col align="center" char="." /></col><col align="center" char="." /></col><col align="center" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">enzyme IC<sub>50</sub> (nM)</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">cellular IC<sub>50</sub> (nM)</th><th class="rowsep1 colsep0" align="center">WB IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center" char=".">FGFR1</th><th class="colsep0 rowsep0" align="center" char=".">FGFR2</th><th class="colsep0 rowsep0" align="center" char=".">FGFR3</th><th class="colsep0 rowsep0" align="center" char=".">VEGFR2</th><th class="colsep0 rowsep0" align="center" char=".">H1581</th><th class="colsep0 rowsep0" align="center" char=".">KatoIII</th><th class="colsep0 rowsep0" align="center">KatoIII</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center" char=".">7.5</td><td class="colsep0 rowsep0" align="center" char=".">4.4</td><td class="colsep0 rowsep0" align="center" char=".">5.7</td><td class="colsep0 rowsep0" align="center" char=".">452</td><td class="colsep0 rowsep0" align="center" char=".">40</td><td class="colsep0 rowsep0" align="center" char=".">42</td><td class="colsep0 rowsep0" align="center">–<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center" char=".">1.9</td><td class="colsep0 rowsep0" align="center" char=".">1.4</td><td class="colsep0 rowsep0" align="center" char=".">2.2</td><td class="colsep0 rowsep0" align="center" char=".">131</td><td class="colsep0 rowsep0" align="center" char=".">11</td><td class="colsep0 rowsep0" align="center" char=".">4.3</td><td class="colsep0 rowsep0" align="center">81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center" char=".">1.1</td><td class="colsep0 rowsep0" align="center" char=".">1.0</td><td class="colsep0 rowsep0" align="center" char=".">1.2</td><td class="colsep0 rowsep0" align="center" char=".">162</td><td class="colsep0 rowsep0" align="center" char=".">4.7</td><td class="colsep0 rowsep0" align="center" char=".">1.8</td><td class="colsep0 rowsep0" align="center">65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="center" char=".">82</td><td class="colsep0 rowsep0" align="center" char=".">97</td><td class="colsep0 rowsep0" align="center" char=".">108</td><td class="colsep0 rowsep0" align="center" char=".">>2000</td><td class="colsep0 rowsep0" align="center" char=".">538</td><td class="colsep0 rowsep0" align="center" char=".">356</td><td class="colsep0 rowsep0" align="center">–<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center" char=".">1.1</td><td class="colsep0 rowsep0" align="center" char=".">1.4</td><td class="colsep0 rowsep0" align="center" char=".">1.4</td><td class="colsep0 rowsep0" align="center" char=".">92</td><td class="colsep0 rowsep0" align="center" char=".">5.5</td><td class="colsep0 rowsep0" align="center" char=".">4.7</td><td class="colsep0 rowsep0" align="center">67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center" char=".">0.12</td><td class="colsep0 rowsep0" align="center" char=".">0.15</td><td class="colsep0 rowsep0" align="center" char=".">0.27</td><td class="colsep0 rowsep0" align="center" char=".">24</td><td class="colsep0 rowsep0" align="center" char=".">1.3</td><td class="colsep0 rowsep0" align="center" char=".">0.86</td><td class="colsep0 rowsep0" align="center">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center" char=".">0.17</td><td class="colsep0 rowsep0" align="center" char=".">0.3</td><td class="colsep0 rowsep0" align="center" char=".">0.49</td><td class="colsep0 rowsep0" align="center" char=".">40</td><td class="colsep0 rowsep0" align="center" char=".">2.1</td><td class="colsep0 rowsep0" align="center" char=".">1.3</td><td class="colsep0 rowsep0" align="center">18</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">–: not tested.</p></div></div></div><div class="NLM_p">Having achieved good FGFR potency and selectivity over VEGFR2, additional characterization was carried out for compound <b>8</b>. The general kinase selectivity was evaluated internally in a 56-kinase panel, and <b>8</b> demonstrated good selectivity with only three kinases displaying IC<sub>50</sub> values less than 1 μM (c-KIT: 12 nM; PDGFRβ: 406 nM; and TRKA: 458 nM). The in vitro absorption, distribution, metabolism, and excretion (ADME) properties of compound <b>8</b> were also encouraging. We observed good permeability in the Caco-2 assay (6.4 × 10<sup>–6</sup> cm/s) and low intrinsic clearance in human liver microsomes testing (H-Cl: 0.5 L/h/kg) with no hERG liability for compound <b>8</b>. On the basis of these results, compound <b>8</b> was advanced into in vivo PK studies. When administered intravenously (IV: 1 mg/kg) to rats in a cassette study, compound <b>8</b> exhibited low clearance (10% of hepatic blood flow (HBF)), a moderate volume of distribution (<i>V</i><sub>dss</sub>: 0.8 L/kg), and a decent half-life (<i>t</i><sub>1/2</sub>) of 2.8 h. At a dose of 2 mg/kg, excellent oral exposure was observed with an AUC of 10 600 nM·h and 58% oral bioavailability. Despite the excellent rat PK profile, compound <b>8</b> performed relatively poor in cynomolgus monkey (cyno) PK with several potential issues: (1) a low oral exposure of 1690 nM·h at 2 mg/kg dose and poor bioavailability (15%); (2) a short <i>t</i><sub>1/2</sub> of 1.1 h, indicating that the compound would require a more frequent dosing regimen to maintain desired exposure and avoid high <i>C</i><sub>max</sub> driven side effects;<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> and (3) a small <i>V</i><sub>dss</sub> of 0.3 L/kg, which was conceived to give rise to poor tissue penetration and limited in vivo efficacy.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The chloro analogue <b>9</b> was also evaluated in PK studies (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00713/suppl_file/jm1c00713_si_001.pdf" class="ext-link">Tables S5 and S6</a>) and demonstrated very similar PK profiles as compound <b>8</b>.</div><div class="NLM_p">Given that compound <b>8</b> demonstrated good Caco-2 permeability and low clearance in cyno PK, we hypothesized that the poor exposure and low oral bioavailability may be the consequence of low aqueous solubility.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Upon further investigation, we discovered compound <b>8</b> indeed exhibited poor solubility (0.3 μg/mL) in fasted state simulated intestinal fluid (FaSSIF). To improve upon compound <b>8</b>, we focused our efforts on the addition of polar functionality to the N1 position (R<sup>4</sup>) of the cyclic urea. We proposed that addition of polarity from this vector may lead to increased solubility and reduced lipophilicity and could potentially also lower clearance to extend <i>t</i><sub>1/2</sub>.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> A variety of polar groups appended to the cyclic urea were found to be well tolerated with only a minor effect on potency. Addition of an ethyl-linked hydroxyl group (<b>10</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) increased solubility by 10-fold while also maintaining good Caco-2 permeability (5.1 × 10<sup>–6</sup> cm/s) albeit slightly higher in vitro clearance (0.9 L/h/kg). However, <b>10</b> exhibited worse rat PK compared to <b>8</b>, with a shorter <i>t</i><sub>1/2</sub> and lower exposure. While typically only the compounds with good rat PK properties would be advanced into cyno PK studies, <b>10</b> was progressed to investigate possible improvements resulting from improved aqueous solubility. Unfortunately, compound <b>10</b> showed very poor cyno PK properties with low exposure and oral absorption. Intrinsic clearance was slightly lowered (0.8 L/h/kg) by rigidifying the structure to the cyclopentyl alcohol (<b>11</b>), which also gave another 10-fold improvement in FaSSIF solubility. Disappointingly such modification led to even worse rat PK profile. Basic amine groups such as ethylene linked methylpiperazine (<b>12</b>) were also examined.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Compound <b>12</b> showed significantly improved solubility and decent in vitro ADME properties. When advanced to a rat PK study, we were surprised again to observe very poor exposure and oral bioavailability. Compound <b>13</b> featured reduced flexibility by directly linking a piperidine group to the cyclic urea. This change resulted in slightly decreased intrinsic clearance but ultimately provided a poor rat PK profile with low exposure and oral bioavailability. Extensive SAR studies with other polar groups aimed to improve solubility also did not translate to improvement in PK properties.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Modification of Urea Substitution to Improve Solubility and PK Properties</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0009.gif" alt="" id="GRAPHIC-d7e1038-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0010.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Dosed in cassette studies, 1 mg/kg IV and 2 mg/kg PO.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">0.5 mg/kg IV and 2 mg/kg PO; “–” not tested.</p></div></div><div></div></div><div class="NLM_p">A second strategy we explored was the incorporation of nonpolar groups to potentially decrease the planarity of the molecule and disrupt crystal packing thereby increasing solubility.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Addition of a cyclopropyl group (compound <b>14</b>) was found to increase the solubility (11 μg/mL) relative to compound <b>8</b> while also maintaining good rat PK properties. Compound <b>14</b> was advanced to cyno PK, where we observed a poor profile as compared to compound <b>8</b>. Further increasing lipophilicity with other nonpolar groups was found to be detrimental for PK properties. The improvement of physiochemical properties from the R<sup>4</sup> vector did not translate into positive PK results, therefore we redirected our focus to other regions of the molecular scaffold.</div><div class="NLM_p">We hypothesized that a potential cause for the repeatedly poor cyno PK could be the electron-rich pyrrole ring in the scaffold, which could be metabolically labile and susceptible to oxidation.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> We proposed that replacing the pyrrole ring with a pyrazole might not only stabilize the molecule but the additional polar nitrogen may also improve solubility. Indeed, the pyrazole analogue <b>15</b> demonstrated improved solubility of 4 μg/mL in FaSSIF while maintaining decent potency and a good ADME profile (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compound <b>15</b> showed an excellent rat PK profile but failed to provide any significant improvement in cyno PK relative to the pyrrole analogue <b>8</b>. Conversion of the pyrrole ring to imidazole (compound <b>16</b>) led to further improvement in FaSSIF solubility (21 μg/mL). Compound <b>16</b> had good in vitro ADME properties and excellent rat PK profile but, disappointingly, inferior exposure in cyno PK compared to the pyrrole compound <b>8</b>. Serendipitously, we discovered that the pyrrole ring could be oxidized to the corresponding lactam while trying to introduce a fluoro substitution using Selectfluor. After improving the reaction conditions, we were able to efficiently convert the pyrrole of compound <b>8</b> to the lactam (<b>17</b>) in the presence of pyridinium tribromide followed by reduction with zinc in high yield. We were pleased to find that <b>17</b> maintained decent potency with excellent in vitro ADME properties and rat PK profile. Encouragingly, compound <b>17</b> had slightly improved cyno PK properties compared to the pyrrole precursor <b>8</b> with a longer <i>t</i><sub>1/2</sub> (2.8 h), higher exposure (2109 nM·h) and better bioavailability (24%). With the lactam core, we quickly revisited substitution on the cyclic urea. Replacement of the <i>N</i>-methyl in <b>17</b> with an ethyl group provided compound <b>18</b> and led to nearly a 2-fold improvement in WB potency. We were also thrilled to discover that this modification led to significant improvement in cyno PK exposure (12 122 nM·h at 2 mg/kg dose) with high oral bioavailability (73%). However, the improvement in PK properties by ethyl substitution appeared to be preferable for the lactam series, as converting compound <b>15</b> to the ethyl derivative <b>19</b> provided no significant improvement in PK profiles.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Scaffold Hopping to Improve PK Properties</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0011.gif" alt="" id="GRAPHIC-d7e1142-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center">CL (HBF%)/<i>V</i><sub>dss</sub> (L/kg)/<i>t</i><sub>1/2</sub> (h)/AUC (nM·h)/F%</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">X<sup>1</sup>–X<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup><b>4</b></sup></th><th class="colsep0 rowsep0" align="center" char=".">WB_ KatoIII IC<sub>50</sub>(nM)</th><th class="colsep0 rowsep0" align="center" char=".">Sol in FaSSIF (μg/mL)</th><th class="colsep0 rowsep0" align="center" char=".">Caco-2  (×10<sup>–6</sup>cm/s)</th><th class="colsep0 rowsep0" align="center" char=".">H-Cl (L/h/kg)</th><th class="colsep0 rowsep0" align="center">rat PK profile<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">cyno PK profile<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">CH═N</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">8.1</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">27/0.64/0.8/8300/>100</td><td class="colsep0 rowsep0" align="left">21/0.40/0.8/1775/21<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">N═CH</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">6.8</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="left">29/0.99/1.9/10800/>100</td><td class="colsep0 rowsep0" align="left">29/0.27/0.9/442/6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>CO</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char="."><0.5</td><td class="colsep0 rowsep0" align="left">34/1.33/1.3/3500/74</td><td class="colsep0 rowsep0" align="left">12/0.68/2.8/2109/24<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>CO</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="left">11/0.51/1.1/27300/–</td><td class="colsep0 rowsep0" align="left">11/0.46/2.1/12122/73<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">CH═N</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">8.3</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="left">20/0.47/0.7/8000/>100</td><td class="colsep0 rowsep0" align="left">12/0.25/1.6/2635/16</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Dosed in cassette studies, 1 mg/kg IV and 2 mg/kg PO.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">0.5 mg/kg IV and 2 mg/kg PO.</p></div></div></div><div class="NLM_p">Given its good potency and excellent PK profiles, compound <b>18</b> became our compound of interest for further in vitro and in vivo evaluations. In enzymatic assays, <b>18</b> displayed strong FGFR1, FGFR2, and FGFR3 inhibition activity with IC<sub>50</sub> of 1.3 nM, 2 nM, and 2.7 nM, respectively. In the cell proliferation assays, IC<sub>50</sub> values of 17 nM (H1581) and 4.8 nM (KatoIII) were observed. Additionally, this compound exhibited low hERG patch clamp activity (0% inhibition at 5 μM) and was not a potent inhibitor of cytochrome P450 (CYP) with IC<sub>50</sub> values >25 μM for the major CYP isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Kinase profiling with an in-house 56-kinase panel revealed that compound <b>18</b> was highly selective, inhibiting just two other kinases with IC<sub>50</sub> less than 1 μM (VEGFR2: 288 nM and c-KIT: 407 nM). Data supported compound <b>18</b> to be scaled up for in vivo pharmacology and toxicology studies. During the scale up, crystalline material was obtained that was later shown to give significantly lower oral exposure and bioavailability in both rat and cyno (5 mg/kg oral dosing in rat: AUC 8700 nM·h, F% = 17; 5 mg/kg oral dosing in cyno: AUC = 6410 nM·h, F% = 17) compared to the earlier studies performed with amorphous material. Moreover, dose escalation studies in rat with the crystalline material only achieved a 2.8-fold increase in AUC when the dose was increased by 10-fold to 50 mg/kg. These observations would impair the ability to achieve suitable exposures for future studies. We reasoned that the limited exposure could potentially be associated with reduced solubility for the crystalline material (1 μg/mL in FaSSIF, compared to 10 μg/mL for the amorphous material). Extensive formulation studies including addition of surfactant, nanosuspension, or nonaqueous formulation with polyethylene glycol did not provide any significant improvement in exposure.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Properties of the crystalline material hampered further development of compound <b>18</b>. We subsequently prioritized our SAR efforts to identify lactam analogues with improved aqueous solubility.</div><div class="NLM_p">Given our experiences on the pyrrole-containing scaffold, we focused our initial effort to improve aqueous solubility on the addition of polarity to the R<sup>4</sup> position of the cyclic urea. However, we quickly discovered that polar groups were not tolerated in this region for the lactam series (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). For example, addition of a hydroxyl (<b>20</b>) or basic morpholine (<b>21</b>) to the ethyl group in compound <b>18</b> caused significant loss of activity in both the enzymatic and cellular assays. A variety of other polar groups were also found to be detrimental for potency. We then investigated whether the addition of lipophilic substitution could increase aqueous solubility while preserving activity. After systematic SAR studies, 2,3-difluorophenyl derivative (<b>22</b>) was identified as a promising compound with good potency and improved aqueous solubility. We reasoned that the 2,3-difluorophenyl group could potentially disrupt molecular symmetry and planarity, thereby weakening crystal packing and leading to improved solubility.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> More encouragingly, compound <b>22</b> maintained a reasonable cyno PK profile with low clearance (7% HBF) and decent half-life (<i>t</i><sub>1/2</sub>) of 3.7 h, albeit a small volume of distribution (<i>V</i><sub>dss</sub>: 0.26 L/kg), in a 0.5 mg/kg IV dosing study. Good oral exposure was observed with an AUC of 5529 nM·h at a dose of 2 mg/kg and a moderate oral bioavailability (21%). Disappointingly, <b>22</b> was later found to display time-dependent inhibition (TDI) of human CYP3A4. Specifically, preincubation of 20 μM of compound <b>22</b> with human CYP3A4 for 30 min led to a 30% loss of the enzyme activity. Given that TDI of human CYP3A4 indicated the potential formation of reactive metabolites that may lead to toxicity or cause drug–drug interactions (DDI) in patients, we next focused on mitigating the TDI issue.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The ethyl analogue <b>18</b> had minimal effect of CYP3A4 activity under the same conditions, suggesting that the 2,3-difluorophenyl moiety in compound <b>22</b> might be responsible for the observed TDI. Therefore, our efforts were focused on modification of the 2,3-difluorophenyl group. We did not observe a clear SAR trend for TDI except that reducing lipophilicity seemed to alleviate the issue. This presented a significant challenge for the lactam series as we had observed with our earlier SAR that polar groups in the R<sup>4</sup> region were found to be detrimental for potency. For example, the addition of a <i>para</i>-cyano group to the phenyl ring (compound <b>23</b>) eliminated the TDI activity but led to a loss of potency. Extensive SAR efforts in this region failed to mitigate the TDI liability while preserving other properties.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR to Improve Solubility for the Lactam Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0012.gif" alt="" id="GRAPHIC-d7e1525-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0013.gif" alt="" id="gr9" /></img><div></div></div><div class="NLM_p">Returning our focus to the goal of enhancing solubility while maintaining good activity, we proposed modification of the α-carbon of the lactam carbonyl with spirocyclic or geminal substitution as a means to decrease molecular planarity and increase sp<sup>3</sup>-character. Attachment of a spirocyclopropyl ring (compound <b>24</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) led to significant decrease in FGFR potency. Interestingly, converting the ethyl in <b>24</b> to a methyl group (<b>25</b>) recovered the potency; however, compound <b>25</b> exhibited very poor aqueous solubility (0.3 μg/mL in FaSSIF). Opening of the cyclopropyl ring to the <i>gem</i>-dimethyl analogue <b>26</b> decreased the potency precipitously. Attempts to enhance aqueous solubility via addition of polar substituents, such as spiropiperidine (compound <b>27</b>), were also found to be detrimental for potency. Although the lactam series offered several promising compounds, we were unable to discover a molecule with the desired balance of potency, solubility, ADME properties, and PK profiles.</div><div class="NLM_p">At this point, we decided to revisit the pyrrole series, hypothesizing that introduction of substitution on the pyrrole moiety to fine-tune the steric and electronic properties may reduce the structural liability and improve PK profiles.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Furthermore, these modifications may also help to improve aqueous solubility. Functionalization of the 3-position (R<sup>7</sup>) of the pyrrole ring with a pyrazole substituent (<b>28</b>, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) was found to mostly preserve potency and increase solubility compared to the parent compound <b>8</b>. Unfortunately, <b>28</b> exhibited potent inhibition of CYP2C9 with an IC<sub>50</sub> of 2 μM. Modification of R<sup>7</sup> did not lead to an appropriately balanced profile of potency, ADME properties, CYP inhibition, and solubility.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR Efforts to Improve PK Properties for Pyrrole Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0014.gif" alt="" id="GRAPHIC-d7e1591-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0015.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Dosed in cassette studies (IV: 1 mg/kg; PO: 2 mg/kg).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">0.5 mg/kg IV and 2 mg/kg PO.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Dosed discretely (IV: 1 mg/kg; PO: 2 mg/kg).</p></div></div><div></div></div><div class="NLM_p">We redirected our focus to the 2-position (R<sup>8</sup>) of the pyrrole ring, which would project substitution toward the solvent-exposed region. We proposed that this pocket could accommodate various structural modifications to improve ADME and PK properties. Indeed, many substituents at R<sup>8</sup> were found to be well tolerated for potency. Aromatic substitution at this position led to very potent compounds. For example, addition of a pyrazole ring gave compound <b>29</b> that displayed cellular IC<sub>50</sub> values of 0.06 and 0.7 nM in the H1581 and KatoIII proliferation assays, respectively. However, this modification significantly reduced general kinase selectivity such that <b>29</b> potently inhibited a variety of off-target kinases including VEGFR2 (IC<sub>50</sub> = 1.3 nM), TRKA (IC<sub>50</sub> < 1 nM), AURKB (IC<sub>50</sub> = 2.5 nM), c-KIT (IC<sub>50</sub> = 3.9 nM), and PDGFRβ (IC<sub>50</sub> = 5.7 nM). We shifted our attention to examine if polar amide substituents would be tolerated and potentially could decrease the electron-density of the pyrrole ring to reduce perceived metabolic liabilities. Dimethyl amide derivative <b>30</b> maintained FGFR potency, displayed good general kinase selectivity, and showed slightly improved solubility (2 μg/mL). Compound <b>30</b> presented excellent rat PK with high oral exposure and good bioavailability; however, <b>30</b> showed no measurable oral exposure and bioavailability in cyno PK. Functionalization of the amide with piperazine (<b>31</b>) led to enhanced solubility. While <b>31</b> showed improved cyno PK properties with slightly better exposure and bioavailability, we were disappointed that further modification of the amide did not yield additional improvement. Direct attachment of a saturated heterocycle such as piperidine (compound <b>32</b>) to the pyrrole ring led to decreased potency. Compound <b>32</b> still advanced into a rat PK study due to its good aqueous solubility (44 μg/mL in FaSSIF) and in vitro ADME properties (Caco-2: 2.9 × 10<sup>–6</sup> cm/s; H-Cl: 0.5 L/h/kg). Disappointingly, <b>32</b> performed very poorly in rat PK. After numerous SAR studies, we discovered that the attachment of <i>N</i>-ethylpiperazine via a C<sub>1–3</sub> alkyl linker (compound <b>33</b>–<b>35</b>) led to excellent aqueous solubility and decent potency. Interestingly, while the analogues with 3-carbon linker (<b>33</b>) and 2-carbon linker (<b>34</b>) demonstrated very poor rat PK profiles, the structurally similar 1-carbon linker derivative <b>35</b> showed a much improved rat PK. More notably, compound <b>35</b> exhibited an excellent oral exposure of 5873 nM*h at a dose of 2 mg/kg in cyno and decent oral bioavailability (26%) with a long <i>t</i><sub>1/2</sub> of 12 h in the IV arm of the study. This represented a major breakthrough in our search for compounds with acceptable cyno PK profiles in the pyrrole series. It came as a great disappointment to discover later that compound <b>35</b> showed TDI of CYP3A4 (14% and 45% inhibition at compound concentrations of 10 μM and 25 μM, respectively).</div><div class="NLM_p">We first hypothesized that the benzylic amine of <b>35</b> might be responsible for the observed TDI.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Surprisingly, removal of the benzylic amine (compound <b>36</b>) led to an undesirable increase in TDI of CYP3A4 (22% inhibition at 10 μM of <b>36</b>) and exhibited very poor rat PK. An alternative cause for the TDI of compound <b>35</b> could be the distal basic nitrogen. We were pleased to discover that replacement of the nitrogen with oxygen to give compound <b>37</b> seemed to mitigate the TDI issue with only 4% inhibition of CYP3A4 at 10 μM compound concentration. Gratifyingly, the morpholine analogue <b>37</b> also afforded much-improved rat and cyno PK profiles (AUC = 8193 and 11804 nM·h in rat and cyno, respectively) compared to the ethylpiperazine derivative <b>35</b>, albeit with lower solubility (17 μg/mL in FaSSIF). Conversion of the methyl substitution on the cyclic urea to ethyl (compound <b>38</b>) led to nearly a 3-fold improvement in WB potency and retained excellent rat and cyno PK profiles. Compound <b>38</b> was also clean of TDI, indicating that the morpholine replacement had mitigated the TDI issue. Furthermore, detailed metabolite profiling of compound <b>38</b> did not reveal the formation of reactive metabolites.</div><div class="NLM_p">With the new analogues from the pyrrole series, we successfully resolved the oral exposure and half-life issues in cyno PK. Nevertheless, there was still some concern that the <i>V</i><sub>dss</sub> was a little bit low (0.58 L/kg in monkey for compound <b>38</b>) and could potentially lead to poor in vivo efficacy. During the course of our SAR studies, extensive efforts were undertaken to increase <i>V</i><sub>dss</sub>. A variety of strategies including increasing lipophilicity, introducing basic amines, and increasing plasma free fraction were investigated to improve <i>V</i><sub>dss</sub>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> All endeavors turned out to be counterproductive. Despite its <i>V</i><sub>dss</sub>, in subsequent studies, compound <b>38</b> showed good PK/PD correlation and achieved good in vivo efficacy. Thus, the low-to-moderate <i>V</i><sub>dss</sub> did not seem to impose a major deterrent to achieving in vivo activity.</div><div class="NLM_p">Based on our previous challenges associated with crystalline material impacting PK properties for the initial lead compound <b>18</b>, we were interested in evaluating compound <b>38</b> as the crystalline material. During the scale up, crystalline free base of <b>38</b> was obtained that still exhibited good solubility especially under acidic conditions (8 μg/mL in FaSSIF and >6 mg/mL in simulated gastric fluid (SGF)). More encouragingly, the crystalline free base gave comparable exposures in rat and cyno to the earlier studies using the amorphous material, and exhibited dose-dependent increase in exposures in pharmacology and toxicology studies. On the basis of these results, compound <b>38</b> (INCB054828, pemigatinib) was selected as the lead candidate of the project to be progressed into preclinical studies.</div><div class="NLM_p">The synthesis of compound <b>38</b> carried out by the discovery team is outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. A nucleophilic aromatic substitution reaction replaced the chloride in the commercially available starting material <b>39</b> with ethylamine producing compound <b>40</b>. Condensation of aldehyde <b>40</b> with 2,6-difluoro-3,5-dimethoxyaniline <b>41</b> formed an imine intermediate, which was then reduced to give the diamine <b>42</b>. Tricyclic urea <b>43</b> was obtained by cyclization of diamine <b>42</b> with triphosgene. Protection of the pyrrole nitrogen in <b>43</b> with a benzenesulfonyl group (<b>44</b>), followed by selective deprotonation with LDA and quenching with DMF, gave the aldehyde <b>45</b>. Reductive amination of aldehyde <b>45</b> with morpholine, followed by removal of the sulfonyl protecting group afforded compound <b>38</b> in good yield.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>38</b> (INCB054828, Pemigatinib)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethylamine, 2-methoxyethanol, 130 °C, 92%; (b) camphorsulfonic acid, xylenes, reflux; (c) LiAlH<sub>4</sub>, THF, 50 °C, 82% (two steps); (d) triphosgene, THF, RT, 92%; (e) NaH, PhSO<sub>2</sub>Cl, DMF, 0 °C, 98%; (f) lithium diisopropylamide (LDA), DMF, THF, −78 °C, 91%; (g) morpholine, acetic acid, Na(OAc)<sub>3</sub>BH, DCM, RT, 95%; (h) tetra-<i>n</i>-butylammonium fluoride (TBAF), THF, 50 °C.</p></p></figure><div class="NLM_p">Detailed preclinical characterization of compound <b>38</b> was initially reported in an earlier publication.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Specifically, <b>38</b> potently inhibited FGFR1, FGFR2, and FGFR3 (IC<sub>50</sub> = 0.4, 0.5, and 1 nM, respectively) with weaker activity for FGFR4 (IC<sub>50</sub> = 30 nM) in enzymatic assays with recombinant human FGFR kinases. The molecule also demonstrated good cellular activity and selectively inhibited the growth of FGFR1, FGFR2, and FGFR3 dependent tumor cell lines with IC<sub>50</sub> values in the low nM range (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00713/suppl_file/jm1c00713_si_001.pdf" class="ext-link">Table S1</a>). Compound <b>38</b> exhibited good selectivity over other kinases in our in-house panel of 56 diverse kinases with only VEGFR2 (IC<sub>50</sub> = 71 nM) and c-KIT (IC<sub>50</sub> = 266 nM) being identified with IC<sub>50</sub> values less than 1000 nM (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00713/suppl_file/jm1c00713_si_001.pdf" class="ext-link">Table S8</a>). Subsequent profiling against a broader panel of 161 kinases (PerkinElmer, Akron OH) and a panel of 70 ion channels, receptors, and enzymes (PerkinElmer Discovery Services Customized Screening Program) showed no significant inhibitory activity by <b>38</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00713/suppl_file/jm1c00713_si_001.pdf" class="ext-link">Tables S9 and S10</a>). In addition, compound <b>38</b> was not a CYP inhibitor with IC<sub>50</sub> values greater than 25 μM for all CYP isoforms tested (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) and showed low hERG patch clamp activity (9% inhibition at 5 μM). In vitro ADME profiling showed compound <b>38</b> had a high permeability (11 × 10<sup>–6</sup> cm/s) across Caco-2 cell monolayers, suggesting the potential for high oral absorption. Compound <b>38</b> exhibited moderate metabolic stability in human liver microsomes (intrinsic clearance: 0.8 L/h/kg) with a free fraction of 11% in the human plasma protein binding study. Given the good rat and monkey PK profiles (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), compound <b>38</b> was further evaluated in dogs. When dosed intravenously (1 mg/kg) in beagle dogs, <b>38</b> exhibited low systemic clearance (10% of hepatic blood flow) with moderate volume distribution (3.49 L/kg), resulting in a long half-life of 15.7 h. Following oral dosing (2 mg/kg), <b>38</b> exhibited high exposure (22100 μM*h) with almost complete oral bioavailability (98%). The preclinical PK profiles in rats, monkeys and dogs suggested a potential of once a day dosing for this compound.</div><div class="NLM_p">Based on our SAR data and the X-ray cocrystal structure of PD173074 with FGFR1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI">2FGI</a>), we proposed the binding mode of compound <b>38</b> with FGFR1 as shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. Compound <b>38</b> binds in the ATP-binding pocket of FGFR1 with the pyrrolopyridine fragment making hydrogen bonds with the NH and CO of Ala564 in the hinge region of FGFR1 at the distance of approximately 1.8 and 2.0 Å, respectively. The tricyclic urea scaffold exhibits favorable van der Waals interactions with the side chains of Val492, Leu484, and Leu630 with the approximate distance of 3.9, 4.1, and 3.5 Å, respectively, forming sandwich-type hydrophobic interactions. The 2,6-difluoro-3,5-dimethoxylphenyl ring is perpendicular to the tricyclic scaffold and fills a complementary hydrophobic pocket in the region near the gatekeeper Val561 which is located at approximately 3.6 Å to the phenyl ring. One methoxy group is at 1.9 Å to the NH of Asp641 and could potentially form a hydrogen bond. The ethyl group in <b>38</b> occupies the same hydrophobic pocket as the ATP ribose. The morpholine group extends toward the solvent exposed region.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Proposed binding mode of compound <b>38</b> in the ATP pocket of FGFR1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To test the effect of compound <b>38</b> on FGFR signaling in vivo, compound <b>38</b> was dosed orally in KatoIII tumor-bearing mice and it showed dose-proportional plasma exposures after a single oral dose of 0.1, 1, and 10 mg/kg (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00713/suppl_file/jm1c00713_si_001.pdf" class="ext-link">Figure S2</a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Based on these results, a pharmacodynamics (PD) study was designed to analyze the effect of FGFR inhibition in KatoIII tumor-bearing mice by compound <b>38</b> at dose levels of 0.01–1.0 mg/kg. The total plasma-exposure and pharmacodynamics curve indicated an in vivo IC<sub>50</sub> of 22 nM for target inhibition (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a). The antitumor effect of compound <b>38</b> was also investigated in a mouse xenograft model employing KatoIII tumor cells. Once-daily oral dosing (0.03–1 mg/kg) achieved significant and dose-dependent tumor growth inhibition. Maximum activity was observed with doses equal to or greater than 0.3 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). Throughout the studies, all the doses were well tolerated with no significant body weight loss observed. Compound <b>38</b> also showed significant in vivo antitumor activity in several other xenograft mice models with FGFR genetic alterations, such as KG1 (FGFR1) and RT112 (FGFR3).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Given the excellent in vitro and in vivo profiles, compound <b>38</b> was progressed into preclinical safety evaluation. The favorable safety profile in rats and monkeys observed for compound <b>38</b> justified its advancement into human clinical trials.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Data were initially published in ref <a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a>. (a) PK/PD analyses for compound <b>38</b>. KatoIII human gastric xenografts were established in female severe combined immunodeficient (SCID) mice in 5 independent experiments. Once tumors were well established, mice (<i>n</i> = 3–5/group) were treated with a single oral dose of compound <b>38</b> at dose levels of 0.01, 0.03, 0.1, 0.3, and 1 mg/kg. Four hours after the single dose, mice were sacrificed and the tumors were collected to analyze levels of pFGFR2 relative to vehicle treated controls. In addition, plasma samples were collected for PK analysis. Data were process from all studies. (b) Efficacy of compound <b>38</b> in female SCID mice bearing KatoIII tumors. Compound <b>38</b> was administered orally once daily for 10 days. The mean tumor size is plotted for each group of 8 mice. ***<i>P</i> < 0.001 vs vehicle. Adapted from Liu, P. C., et al. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2 and 3, displays activity against genetically defined tumor models. <i>PLoS One</i>, <b>2020</b>, 15(4), e0231877, <a href="https://doi.org/10.1371/journal.pone.0231877" class="extLink">10.1371/journal.pone.0231877</a>, under Creative Commons Attribution License (<a href="https://creativecommons.org/licenses/by/4.0/" class="ext-link">https://creativecommons.org/licenses/by/4.0/</a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the phase I dose escalation study, pemigatinib (compound <b>38</b>, INCB054828) exhibited dose-dependent PK over the dose range of 1–20 mg with the terminal half-life of 15 h supporting once-daily dosing. Sustained inhibition of FGFR signaling was observed at the RP2D of 13.5 mg once daily.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In an open-label single-arm phase II study, among 107 patients with locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements whose disease had progressed following at least one prior therapy, 38 patients achieved an objective response after treatment with pemigatinib (13.5 mg orally once daily, 2 weeks on/1 week off). The majority of patients showed evidence of tumor shrinkage after the treatment (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The most common adverse event was hyperphosphataemia.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Based on these data, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pemigatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement. Additional clinical studies of pemigatinib in patients with cancer harboring genetic FGFR alterations are ongoing.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Best percentage change from baseline in target lesion size for individual patients with FGFR2 fusions or rearrangements treated with pemigatinib. (Colored bars indicate confirmed responses accessed by RECIST 1.1. *Patient had a decrease in target lesion size but was not evaluable for response using RECIST.) Reprinted from <i>Lancet Oncol.</i>, <b>2020</b>, 21, Abou-Alfa, G. K., et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicenter, open-label, phase 2 study, 671–684, Copyright (2020), with permission from Elsevier.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78000" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78000" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have rationally designed a series of tricyclic urea compounds as potent and selective FGFR inhibitors based on an in-house screening hit using structure-guided drug design. By leveraging interactions with the hydrophobic pocket near the FGFR gatekeeper region, we were able to achieve good potency and selectivity in this series. Systematic SAR studies to address low solubility, poor cyno PK and TDI of CYP3A4 challenges finally led to the discovery of a potent and highly selective FGFR1, FGFR2, and FGFR3 inhibitor <b>38</b> (INCB054828, pemigatinib) with excellent PK profiles and balanced properties. PK/PD studies of <b>38</b> in preclinical xenograft tumor models confirmed FGFR target engagement, and strong antitumor effects were observed across multiple tumor models harboring genetic alterations of FGFR. Pemigatinib is being studied in multiple clinical trials for patients with FGFR alterations and has demonstrated a favorable safety profile with early signs of clinical activity. FDA has granted accelerated approval to pemigatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement. Efforts to further demonstrate the clinical potential of pemigatinib are ongoing.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35852" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35852" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> General Synthetic Procedures</h3><div class="NLM_p last">All reactions were carried out under an atmosphere of dry nitrogen. All starting materials and solvents were used without further purification as acquired from commercial sources. Purification by flash chromatography was performed on RediSep columns using Isco CombiFlash SG100c. Reverse-phase preparative HPLC purifications were performed on Waters FractionLynx system using UV-triggered or mass directed fractionation and compound-specific method optimization.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> All final compounds for biological testing were purified by reverse phase prep-HPLC to >95% purity as determined by analytical LC-MS. NMR spectra were obtained using either a Varian Mercury-300, Mercury-400, Inova-500, or Bruker Avance-600 MHz spectrometer.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Synthesis of Compound <b>38</b> (INCB054828, Pemigatinib): Step 1. 4-(Ethylamino)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carbaldehyde (<b>40</b>)</h3><div class="NLM_p last">A mixture of 4- chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carbaldehyde (3.0 g, 17 mmol) and ethylamine (10 M in water, 8.3 mL, 83 mmol) in 2-methoxyethanol (20 mL, 200 mmol) was heated to 130 °C and stirred overnight. The mixture was cooled to room temperature and then concentrated under reduced pressure. The residue was treated with 1 N HCl (30 mL) and stirred at room temperature for 1 h and then neutralized with saturated NaHCO<sub>3</sub> aqueous solution. The precipitate was collected via filtration and then washed with water and dried to provide the desired product (2.9 g, 92%) which was used in the next step without further purification. LC-MS calculated for C<sub>10</sub>H<sub>12</sub>N<sub>3</sub>O [M + H]<sup>+</sup><i>m</i>/<i>z</i>: 190.1; found: 190.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.80 (s, 1H), 9.75 (s, 1H), 9.29 (s, 1H), 8.19 (s, 1H), 7.19 (d, <i>J</i> = 3.6 Hz, 1H), 6.71 (d, <i>J</i> = 3.6 Hz, 1H), 3.77–3.65 (m, 2H), 1.30 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Step 2. 5-{[(2,6-Difluoro-3,5-dimethoxyphenyl)amino]methyl}-<i>N</i>-ethyl-1<i>H</i>-pyrrolo[2, 3-<i>b</i>]pyridin-4-amine (<b>42</b>)</h3><div class="NLM_p last">A mixture of 4-(ethylamino)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carbaldehyde (7.0 g, 37 mmol), 2,6-difluoro-3,5-dimethoxyaniline (9.1 g, 48 mmol), and [(1<i>S</i>)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid (2 g, 7 mmol) in xylenes (250 mL) was heated to reflux with azeotropic removal of water using a Dean-Stark apparatus for 2 days, at which time LC-MS analysis showed the reaction was complete. Then, the mixture was cooled to room temperature and the solvent was removed under reduced pressure. The residue was dissolved in tetrahydrofuran (500 mL) and then 2.0 M lithium tetrahydroaluminate in THF (37 mL, 74 mmol) was added slowly and the resulting mixture was stirred at 50 °C for 3 h and then cooled to room temperature. The reaction was quenched by addition of water followed by 15% aqueous NaOH. The mixture was filtered and washed with THF. The filtrate was concentrated and the residue was washed with CH<sub>2</sub>Cl<sub>2</sub> and then filtered to provide the pure product (11 g, 82%). LC-MS calculated for C<sub>18</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: 363.2; found: 363.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.03 (s, 1H), 7.62 (s, 1H), 7.09–6.99 (m, 1H), 6.53–6.45 (m, 1H), 6.26 (t, <i>J</i> = 7.8 Hz, 1H), 6.02–5.91 (m, 1H), 5.41–5.31 (m, 1H), 4.31 (d, <i>J</i> = 6.9 Hz, 2H), 3.74 (s, 6H), 3.66–3.55 (m, 2H), 1.27–1.17 (m, 3H).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Step 3: 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2<i>H</i>-pyrrolo[3′,2’:5,6] pyrido[4,3-<i>d</i>]pyrimidin-2-one (<b>43</b>)</h3><div class="NLM_p last">A solution of triphosgene (5.5 g, 18 mmol) in tetrahydrofuran (30 mL) was added slowly to a mixture of 5-{[(2,6- difluoro- 3,5-dimethoxyphenyl)amino]methyl}-<i>N</i>-ethyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-amine (5.6 g, 15 mmol) in tetrahydrofuran (100 mL) at 0 °C, and then the mixture was stirred at room temperature for 6 h. The mixture was cooled to 0 °C, and then 1.0 M sodium hydroxide in water (100 mL, 100 mmol) was added slowly. The reaction mixture was stirred at room temperature overnight. The formed precipitate was collected via filtration and then washed with water and dried to provide the first batch of the pure desired product. The organic layer in the filtrate was separated, and the aqueous layer was extracted with methylene chloride. The combined organic layer was concentrated and the residue was triturated with methylene chloride and then filtered and dried to provide another batch of the product (total 5.5 g, 92%). LC-MS calculated for C<sub>19</sub>H<sub>19</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: 389.1; found: 389.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.86 (s, 1H), 7.99 (s, 1H), 7.52–7.46 (m, 1H), 7.04 (t, <i>J</i> = 8.2 Hz, 1H), 6.67–6.62 (m, 1H), 4.76 (s, 2H), 4.18 (q, <i>J</i> = 6.9 Hz, 2H), 3.89 (s, 6H), 1.34 (t, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Step 4: 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2<i>H</i>-pyrrolo[3′,2’:5,6]pyrido[4,3-<i>d</i>]pyrimidin-2-one (<b>44</b>)</h3><div class="NLM_p last">To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2<i>H</i>-pyrrolo[3′,2’:5,6]pyrido[4,3-<i>d</i>]pyrimidin-2-one (900 mg, 2.32 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (20 mL) cooled to 0 °C was added sodium hydride (185 mg, 4.63 mmol, 60 wt % in mineral oil). The resulting mixture was stirred at 0 °C for 30 min, and then benzenesulfonyl chloride (0.444 mL, 3.48 mmol) was added. The reaction mixture was stirred at 0 °C for 1.5 h, at which time LC-MS analysis showed completion of the reaction to the desired product. The reaction mixture was quenched with saturated NH<sub>4</sub>Cl solution and diluted with water. The white precipitate was collected via filtration and then washed with water and hexanes and dried to afford the desired product (1.2 g, 98%) as a white solid which was used in the next step without further purification. LC-MS calculated for C<sub>25</sub>H<sub>23</sub>F<sub>2</sub>N<sub>4</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i>: 529.1; found: 529.1. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.14–8.10 (m, 2H), 8.09 (s, 1H), 7.94 (d, <i>J</i> = 4.3 Hz, 1H), 7.75–7.71 (m, 1H), 7.65–7.61 (m, 2H), 7.04 (t, <i>J</i> = 8.1 Hz, 1H), 6.97 (d, <i>J</i> = 4.3 Hz, 1H), 4.76 (s, 2H), 4.10 (q, <i>J</i> = 7.0 Hz, 2H), 3.88 (s, 6H), 1.28 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Step 5: 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1<i>H</i>-pyrrolo[3′,2’:5,6]pyrido[4,3-<i>d</i>]pyrimidine-8-carbaldehyde (<b>45</b>)</h3><div class="NLM_p last">To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2<i>H</i>-pyrrolo[3′,2’:5,6]pyrido[4,3-<i>d</i>]pyrimidin-2-one (1.75 g, 3.31 mmol) in tetrahydrofuran (80 mL) at −78 °C was added freshly prepared lithium diisopropylamide (1 M in tetrahydrofuran (THF), 3.48 mL, 3.48 mmol). The resulting mixture was stirred at −78 °C for 30 min, and then <i>N</i>,<i>N</i>-dimethylformamide (1.4 mL, 18 mmol) was added slowly. The reaction mixture was stirred at −78 °C for 30 min then quenched with water, warmed to room temperature, and extracted with EtOAc. The organic extracts were combined and washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by flash chromatography (0 to 20% EtOAc in CH<sub>2</sub>Cl<sub>2</sub>) to give the desired product as a white solid (1.68 g, 91%). LC-MS calculated for C<sub>26</sub>H<sub>23</sub>F<sub>2</sub>N<sub>4</sub>O<sub>6</sub>S (M+H)<sup>+</sup><i>m</i>/<i>z</i>: 557.1; found: 556.9. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.45 (s, 1H), 8.26 (s, 1H), 8.25–8.22 (m, 2H), 7.78–7.74 (m, 1H), 7.68–7.63 (m, 2H), 7.62 (s, 1H), 7.05 (t, <i>J</i> = 8.1 Hz, 1H), 4.79 (s, 2H), 4.14 (q, <i>J</i> = 7.0 Hz, 2H), 3.89 (s, 6H), 1.28 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Step 6: 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2<i>H</i>-pyrrolo[3′,2’:5,6]pyrido[4,3-<i>d</i>]pyrimidin-2-one (<b>46</b>)</h3><div class="NLM_p last">To a solution 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1<i>H</i>-pyrrolo[3′,2’:5,6]pyrido[4,3-<i>d</i>]pyrimidine-8-carbaldehyde (1.73 g, 3.11 mmol) in dichloromethane (50 mL) was added morpholine (0.95 mL, 11 mmol), followed by acetic acid (2 mL, 30 mmol). The resulting yellow solution was stirred at room temperature overnight, and then sodium triacetoxyborohydride (2.3 g, 11 mmol) was added. The mixture was stirred at room temperature for 3 h, at which time LC-MS showed the reaction went to completion to the desired product. The reaction was quenched with saturated NaHCO<sub>3</sub> and then extracted with ethyl acetate (EtOAc). The organic extracts were combined and washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by flash chromatography (0 to 40% EtOAc in CH<sub>2</sub>Cl<sub>2</sub>) to give the desired product as a yellow solid (1.85 g, 95%). LC-MS calculated for C<sub>30</sub>H<sub>32</sub>F<sub>2</sub>N<sub>5</sub>O<sub>6</sub>S (M + H)<sup>+</sup><i>m</i>/<i>z</i>: 628.2; found: 628.0. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.45–8.37 (m, 2H), 8.06 (s, 1H), 7.75–7.69 (m, 1H), 7.68–7.60 (m, 2H), 7.08–7.01 (m, 1H), 6.89 (s, 1H), 4.75 (s, 2H), 4.10 (q, <i>J</i> = 6.9 Hz, 2H), 3.93 (s, 2H), 3.89 (s, 6H), 3.65–3.54 (m, 4H), 2.52–2.49 (m, 4H, overlapped with DMSO), 1.32–1.26 (m, 3H).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Step 7: 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2<i>H</i>-pyrrolo[3′,2’:5,6]pyrido[4,3-<i>d</i>]pyrimidin-2-one (<b>38</b>)</h3><div class="NLM_p last">To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2<i>H</i>-pyrrolo[3′,2’:5,6]pyrido[4,3-<i>d</i>]pyrimidin-2-one (1.5 g, 2.4 mmol) in tetrahydrofuran (40 mL) was added tetra-<i>n</i>-butylammonium fluoride (1 M in THF, 7.2 mL, 7.2 mmol). The resulting solution was stirred at 50 °C for 1.5 h and then cooled to room temperature and quenched with water. The mixture was extracted with dichloromethane and the organic extracts were combined and washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by flash chromatography (0 to 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to give the desired product as a white solid, which was further purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O + TFA) to give the desired product as the TFA salt. LC-MS calculated for C<sub>24</sub>H<sub>28</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub> (M + H)<sup>+</sup><i>m</i>/<i>z</i>: 488.2; found: 488.0. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.09 (s, 1H), 8.06 (s, 1H), 7.05 (t, <i>J</i> = 8.1 Hz, 1H), 6.87 (s, 1H), 4.78 (s, 2H), 4.50 (s, 2H), 4.17 (q, <i>J</i> = 6.8 Hz, 2H), 3.97 (br, 2H), 3.89 (s, 6H), 3.65 (br, 2H), 3.37 (br, 2H), 3.15 (br, 2H), 1.37 (t, <i>J</i> = 6.8 Hz, 3H).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00713" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60680" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60680" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00713?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00713</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental details for in vitro and in vivo studies; synthetic procedures and characterization for compounds <b>1</b>–<b>37</b>; in vitro potency, ADME properties and PK profiles for compounds <b>2</b>-<b>38</b>; Detailed characterization for compound <b>38</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00713/suppl_file/jm1c00713_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and in vitro biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00713/suppl_file/jm1c00713_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00713/suppl_file/jm1c00713_si_001.pdf">jm1c00713_si_001.pdf (1.82 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00713/suppl_file/jm1c00713_si_002.csv">jm1c00713_si_002.csv (3.61 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00713" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78556" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78556" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liangxing Wu</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-8524-0799" title="Orcid link">https://orcid.org/0000-0001-8524-0799</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0c607b794c65626f757869226f6361"><span class="__cf_email__" data-cfemail="325e4547725b5c514b46571c515d5f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Colin Zhang</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunhong He</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dingquan Qian</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liang Lu</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yaping Sun</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meizhong Xu</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jincong Zhuo</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Phillip C. C. Liu</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ronald Klabe</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Wynn</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maryanne Covington</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Gallagher</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lynn Leffet</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Bowman</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sharon Diamond</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Holly Koblish</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yue Zhang</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maxim Soloviev</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory Hollis</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy C. Burn</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peggy Scherle</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Swamy Yeleswaram</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Reid Huber</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenqing Yao</span> - <span class="hlFld-Affiliation affiliation">Incyte Research
Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was prepared by L.W. with contributions from all authors.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26226" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26226" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank all colleagues at Incyte who were involved in the pemigatinib project. We thank Karl Blom, Laurine Galya, and Mei Li for their analytical assistance; Ravi Jalluri for the molecular modeling; Alex Margulis, Darlise DiMatteo, Yanlong Li, Xin He, Hong Chang, Kamna Katiyar, Krista A. Burke, and Ruth Yong-Sciame for their expert technical assistance; Joe Zhou and his team for the scale up of pemigatinib; Sarah Winterton, Joshua Hummel, Matthew McCammant, and Rory McAtee for proofreading the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">AURKB</td><td class="NLM_def"><p class="first last">Aurora B kinase</p></td></tr><tr><td class="NLM_term">cyno</td><td class="NLM_def"><p class="first last">cynomolgus monkey</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">U.S. Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FaSSIF</td><td class="NLM_def"><p class="first last">fasted state simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-go-go related gene</p></td></tr><tr><td class="NLM_term">HBF</td><td class="NLM_def"><p class="first last">hepatic blood flow</p></td></tr><tr><td class="NLM_term">H-Cl</td><td class="NLM_def"><p class="first last">intrinsic clearance in human liver microsomes</p></td></tr><tr><td class="NLM_term">IV</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">c-KIT</td><td class="NLM_def"><p class="first last">proto-oncogene c-KIT receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen activated protein kinase</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PLCγ</td><td class="NLM_def"><p class="first last">phospholipase C gamma</p></td></tr><tr><td class="NLM_term">PDGFRβ</td><td class="NLM_def"><p class="first last">platelet derived growth factor receptor beta</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PO</td><td class="NLM_def"><p class="first last">oral administration</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">RAS</td><td class="NLM_def"><p class="first last">rat sarcoma virus oncogene</p></td></tr><tr><td class="NLM_term">RP2D</td><td class="NLM_def"><p class="first last">recommended phase II dose</p></td></tr><tr><td class="NLM_term">RECIST</td><td class="NLM_def"><p class="first last">response evaluation criteria in solid tumors</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">SGF</td><td class="NLM_def"><p class="first last">simulated gastric fluid</p></td></tr><tr><td class="NLM_term">TRKA</td><td class="NLM_def"><p class="first last">Tropomyosin receptor kinase A</p></td></tr><tr><td class="NLM_term">TDI</td><td class="NLM_def"><p class="first last">time dependent inhibition</p></td></tr><tr><td class="NLM_term">t1/2</td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">VEGFR2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor 2</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>dss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr><tr><td class="NLM_term">WB</td><td class="NLM_def"><p class="first last">whole blood</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74438" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74438" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eswarakumar, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lax, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cellular signaling by fibroblast growth factor receptors</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2005.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1016%2Fj.cytogfr.2005.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=15863030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=139-149&author=V.+P.+Eswarakumarauthor=I.+Laxauthor=J.+Schlessinger&title=Cellular+signaling+by+fibroblast+growth+factor+receptors&doi=10.1016%2Fj.cytogfr.2005.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular signaling by fibroblast growth factor receptors</span></div><div class="casAuthors">Eswarakumar, V. P.; Lax, I.; Schlessinger, J.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-149</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The 22 members of the fibroblast growth factor (FGF) family of growth factors mediate their cellular responses by binding to and activating the different isoforms encoded by the four receptor tyrosine kinases (RTKs) designated FGFR1, FGFR2, FGFR3 and FGFR4.  Unlike other growth factors, FGFs act in concert with heparin or heparan sulfate proteoglycan (HSPG) to activate FGFRs and to induce the pleiotropic responses that lead to the variety of cellular responses induced by this large family of growth factors.  A variety of human skeletal dysplasias have been linked to specific point mutations in FGFR1, FGFR2 and FGFR3 leading to severe impairment in cranial, digital and skeletal development.  Gain of function mutations in FGFRs were also identified in a variety of human cancers such as myeloproliferative syndromes, lymphomas, prostate and breast cancers as well as other malignant diseases.  The binding of FGF and HSPG to the extracellular ligand domain of FGFR induces receptor dimerization, activation and autophosphorylation of multiple tyrosine residues in the cytoplasmic domain of the receptor mol.  A variety of signaling proteins are phosphorylated in response to FGF stimulation including Shc, phospholipase-Cγ, STAT1, Gab1 and FRS2α leading to stimulation of intracellular signaling pathways that control cell proliferation, cell differentiation, cell migration, cell survival and cell shape.  The docking proteins FRS2α and FRS2β are major mediators of the Ras/MAPK and PI-3 kinase/Akt signaling pathways as well as neg. feedback mechanisms that fine-tune the signal that is initiated at the cell surface following FGFR stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4Sa2I4Dn5d7Vg90H21EOLACvtfcHk0lhLZRLPiN3jgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOns7k%253D&md5=996be3a82a79a00173bc4e9d38dcb993</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2005.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2005.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DEswarakumar%26aufirst%3DV.%2BP.%26aulast%3DLax%26aufirst%3DI.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCellular%2520signaling%2520by%2520fibroblast%2520growth%2520factor%2520receptors%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2005%26volume%3D16%26spage%3D139%26epage%3D149%26doi%3D10.1016%2Fj.cytogfr.2005.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powers, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeskey, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellstein, A.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factors, their receptors and signaling</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1677/erc.0.0070165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1677%2Ferc.0.0070165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=11021964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot1Wrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=165-197&author=C.+J.+Powersauthor=S.+W.+McLeskeyauthor=A.+Wellstein&title=Fibroblast+growth+factors%2C+their+receptors+and+signaling&doi=10.1677%2Ferc.0.0070165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factors, their receptors and signaling</span></div><div class="casAuthors">Powers, C. J.; McLeskey, S. W.; Wellstein, A.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">165-197</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review with ∼300 refs.  Fibroblast growth factors (FGFs) are small polypeptide growth factors, all of whom share in common certain structural characteristics, and most of whom bind heparin avidly.  Many FGFs contain signal peptides for secretion and are secreted into the extracellular environment, where they can bind to the heparan-like glycosaminoglycans (HLGAGs) of the extracellular matrix (ECM).  From this reservoir, FGFs may act directly on target cells, or they can be released through digestion of the ECM or the activity of a carrier protein, a secreted FGF binding protein.  FGFs bind specific receptor tyrosine kinases in the context of HLGAGs and this binding induces receptor dimerization and activation, ultimately resulting in the activation of various signal transduction cascades.  Some FGFs are potent angiogenic factors and most play important roles in embryonic development and wound healing.  FGF signaling also appears to play a role in tumor growth and angiogenesis, and autocrine FGF signaling may be particularly important in the progression of steroid hormone-dependent cancers to a hormone-independent state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobr9vLkJC5X7Vg90H21EOLACvtfcHk0lhLZRLPiN3jgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot1Wrs7c%253D&md5=bc2a29bca57b545886a177913d762f6c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0070165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0070165%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DC.%2BJ.%26aulast%3DMcLeskey%26aufirst%3DS.%2BW.%26aulast%3DWellstein%26aufirst%3DA.%26atitle%3DFibroblast%2520growth%2520factors%252C%2520their%2520receptors%2520and%2520signaling%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2000%26volume%3D7%26spage%3D165%26epage%3D197%26doi%3D10.1677%2Ferc.0.0070165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, C.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor signaling in tumorigenesis</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2005.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1016%2Fj.cytogfr.2005.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=15863033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=179-186&author=R.+Groseauthor=C.+Dickson&title=Fibroblast+growth+factor+signaling+in+tumorigenesis&doi=10.1016%2Fj.cytogfr.2005.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signaling in tumorigenesis</span></div><div class="casAuthors">Grose, Richard; Dickson, Clive</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-186</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors and their signaling receptors have been assocd. with multiple biol. activities, including proliferation, differentiation and motility.  Consequently, they have evoked interest as candidate oncogenes with the potential to initiate and/or promote tumorigenesis.  This has resulted in a large literature describing the presence of these growth factors and their receptors in cancer cell lines and primary tumors of diverse origin.  However, it is only recently that compelling evidence has emerged to implicate the fibroblast growth factors (Fgfs) and their receptors in the genesis of human cancers.  Here, the authors outline the model systems that demonstrate the potential oncogenic nature of Fgf signaling and summarize recent evidence that implicates aberrant Fgf signaling as important in the natural history of some common human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq61HT0TPuctLVg90H21EOLACvtfcHk0lhLZRLPiN3jgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOnsL4%253D&md5=89f3283bea5a1ef1db871e5d98a03c1b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2005.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2005.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DGrose%26aufirst%3DR.%26aulast%3DDickson%26aufirst%3DC.%26atitle%3DFibroblast%2520growth%2520factor%2520signaling%2520in%2520tumorigenesis%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2005%26volume%3D16%26spage%3D179%26epage%3D186%26doi%3D10.1016%2Fj.cytogfr.2005.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knights, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, S. J.</span></span> <span> </span><span class="NLM_article-title">De-regulated FGF receptors as therapeutic targets in cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2009.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1016%2Fj.pharmthera.2009.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=19874848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyiu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2010&pages=105-117&author=V.+Knightsauthor=S.+J.+Cook&title=De-regulated+FGF+receptors+as+therapeutic+targets+in+cancer&doi=10.1016%2Fj.pharmthera.2009.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">De-regulated FGF receptors as therapeutic targets in cancer</span></div><div class="casAuthors">Knights, Victoria; Cook, Simon J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-117</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) acting through their cognate receptors (FGFRs) play vital roles in development and de-regulation of FGF/FGFR signaling is assocd. with many developmental syndromes.  In addn. there is much interest in inhibiting FGF/FGFR signaling as a therapeutic approach to cancer.  FGF/FGFR signaling is certainly important in tumor angiogenesis but studies in the last few years have uncovered increasing evidence that FGFRs are driving oncogenes in certain cancers and act in a cell autonomous fashion to maintain the malignant properties of tumor cells.  These observations make FGFRs increasingly attractive as targets for therapeutic intervention in cancer.  In this article, we review FGFR signaling and describe recent advances in cancer genomics and cancer cell biol. that demonstrate that specific tumor types are dependent upon or addicted to de-regulated FGFR.  We also describe the range of therapeutic strategies currently employed or in development to antagonize de-regulated FGFRs including antibodies and small mol. tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruZBKTl9d0BbVg90H21EOLACvtfcHk0liy094X38Bx2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyiu77P&md5=5712b2b98c18ffc56cd59ea09b3fe0d2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnights%26aufirst%3DV.%26aulast%3DCook%26aufirst%3DS.%2BJ.%26atitle%3DDe-regulated%2520FGF%2520receptors%2520as%2520therapeutic%2520targets%2520in%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D125%26spage%3D105%26epage%3D117%26doi%3D10.1016%2Fj.pharmthera.2009.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beenken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span> <span> </span><span class="NLM_article-title">The FGF family: biology, pathophysiology and therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1038/nrd2792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1038%2Fnrd2792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=19247306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVShur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=235-253&author=A.+Beenkenauthor=M.+Mohammadi&title=The+FGF+family%3A+biology%2C+pathophysiology+and+therapy&doi=10.1038%2Fnrd2792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The FGF family: biology, pathophysiology and therapy</span></div><div class="casAuthors">Beenken, Andrew; Mohammadi, Moosa</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-253</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The family of fibroblast growth factors (FGFs) regulates a plethora of developmental processes, including brain patterning, branching morphogenesis and limb development.  Several mitogenic, cytoprotective and angiogenic therapeutic applications of FGFs are already being explored, and the recent discovery of the crucial roles of the endocrine-acting FGF19 subfamily in bile acid, glucose and phosphate homeostasis has sparked renewed interest in the pharmacol. potential of this family.  This review discusses traditional applications of recombinant FGFs and small-mol. FGF receptor kinase inhibitors in the treatment of cancer and cardiovascular disease and their emerging potential in the treatment of metabolic syndrome and hypophosphatemic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmidKyrdG0lbVg90H21EOLACvtfcHk0liy094X38Bx2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVShur4%253D&md5=4789ed4cb521a92114063a400a138645</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd2792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2792%26sid%3Dliteratum%253Aachs%26aulast%3DBeenken%26aufirst%3DA.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DThe%2520FGF%2520family%253A%2520biology%252C%2520pathophysiology%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D235%26epage%3D253%26doi%3D10.1038%2Fnrd2792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor signaling: from development to cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signaling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0liy094X38Bx2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signaling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, N. C.</span></span> <span> </span><span class="NLM_article-title">The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1</span>. <i>Acta Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1159/000046639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1159%2F000046639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=11919391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD38XitlGmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2002&pages=101-107&author=D.+Macdonaldauthor=A.+Reiterauthor=N.+C.+Cross&title=The+8p11+myeloproliferative+syndrome%3A+a+distinct+clinical+entity+caused+by+constitutive+activation+of+FGFR1&doi=10.1159%2F000046639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of FGFR1</span></div><div class="casAuthors">MacDonald, Donald; Reiter, Andreas; Cross, Nicholas C. P.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Haematologica</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-107</span>CODEN:
                <span class="NLM_cas:coden">ACHAAH</span>;
        ISSN:<span class="NLM_cas:issn">0001-5792</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Several recurrent translocations that involve chromosome band 8p11 have been described in myeloid malignancies.  These translocations target two distinct genes: (1) FGFR1, a receptor tyrosine kinase for fibroblast growth factors, and (2) MOZ, a putative histone acetyltransferase whose precise function remains to be defined.  Disruption of FGFR1 is assocd. with a disease entity known as the 8p11 myeloproliferative syndrome (EMS)/stem cell leukemia-lymphoma syndrome, a chronic myeloproliferative disorder that frequently presents with eosinophilia and assocd. T-cell lymphoblastic lymphoma.  The disease is aggressive and rapidly transforms to acute leukemia, usually of myeloid phenotype.  Currently, only allogeneic stem cell transplantation appears to be effective in eradicating or suppressing the malignant clone.  To date, four gene fusions assocd. with distinct translocations have been described in EMS: the t(8;13)(p11;q12), t(8;9)(p11;q33), t(6;8)(q27;p11) and t(8;22)(p11q22) fuse ZNF198, CEP110, FOP and BCR, resp., to FGFR1.  The resulting fusion proteins have constitutive tyrosine kinase activity and activate multiple signal transduction pathways.  These pathways and the fusion proteins are attractive targets for targeted signal transduction therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTYUEf9Qh_kLVg90H21EOLACvtfcHk0lgMRMHe4CEBog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitlGmsLY%253D&md5=8e053c10889b3854ebf4d009f5f16221</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1159%2F000046639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000046639%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DD.%26aulast%3DReiter%26aufirst%3DA.%26aulast%3DCross%26aufirst%3DN.%2BC.%26atitle%3DThe%25208p11%2520myeloproliferative%2520syndrome%253A%2520a%2520distinct%2520clinical%2520entity%2520caused%2520by%2520constitutive%2520activation%2520of%2520FGFR1%26jtitle%3DActa%2520Haematol.%26date%3D2002%26volume%3D107%26spage%3D101%26epage%3D107%26doi%3D10.1159%2F000046639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okusaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosuge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, T.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1434</span>, <span class="refDoi"> DOI: 10.1002/hep.26890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1002%2Fhep.26890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=24122810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVGls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=1427-1434&author=Y.+Araiauthor=Y.+Totokiauthor=F.+Hosodaauthor=T.+Shirotaauthor=N.+Hamaauthor=H.+Nakamuraauthor=H.+Ojimaauthor=K.+Furutaauthor=K.+Shimadaauthor=T.+Okusakaauthor=T.+Kosugeauthor=T.+Shibata&title=Fibroblast+growth+factor+receptor+2+tyrosine+kinase+fusions+define+a+unique+molecular+subtype+of+cholangiocarcinoma&doi=10.1002%2Fhep.26890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma</span></div><div class="casAuthors">Arai, Yasuhito; Totoki, Yasushi; Hosoda, Fumie; Shirota, Tomoki; Hama, Natsuko; Nakamura, Hiromi; Ojima, Hidenori; Furuta, Koh; Shimada, Kazuaki; Okusaka, Takuji; Kosuge, Tomoo; Shibata, Tatsuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1427-1434</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Cholangiocarcinoma is an intractable cancer, with limited therapeutic options, in which the mol. mechanisms underlying tumor development remain poorly understood.  Identification of a novel driver oncogene and applying it to targeted therapies for molecularly defined cancers might lead to improvements in the outcome of patients.  We performed massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients without KRAS/BRAF/ROS1 alterations and identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1.  In reverse-transcriptase polymerase chain reaction (RT-PCR) screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%), rarely in colorectal (1/149) and hepatocellular carcinoma (1/96), and none in gastric cancer (0/212).  The rearrangements were mutually exclusive with KRAS/BRAF mutations.  Expression of the fusion kinases in NIH3T3 cells activated MAPK and conferred anchorage-independent growth and in vivo tumorigenesis of s.c. transplanted cells in immune-compromised mice.  This transforming ability was attributable to its kinase activity.  Treatment with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074 effectively suppressed transformation.  Conclusion: FGFR2 fusions occur in 13.6% of intrahepatic cholangiocarcinoma.  The expression pattern of these fusions in assocn. with sensitivity to FGFR inhibitors warrant a new mol. classification of cholangiocarcinoma and suggest a new therapeutic approach to the disease. (Hepatol. 2014;59:1427-1434).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEDCAkciiWArVg90H21EOLACvtfcHk0lgMRMHe4CEBog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVGls7w%253D&md5=2fd4e9cffd55540fae88e9771864954b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fhep.26890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26890%26sid%3Dliteratum%253Aachs%26aulast%3DArai%26aufirst%3DY.%26aulast%3DTotoki%26aufirst%3DY.%26aulast%3DHosoda%26aufirst%3DF.%26aulast%3DShirota%26aufirst%3DT.%26aulast%3DHama%26aufirst%3DN.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DOjima%26aufirst%3DH.%26aulast%3DFuruta%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DK.%26aulast%3DOkusaka%26aufirst%3DT.%26aulast%3DKosuge%26aufirst%3DT.%26aulast%3DShibata%26aufirst%3DT.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%25202%2520tyrosine%2520kinase%2520fusions%2520define%2520a%2520unique%2520molecular%2520subtype%2520of%2520cholangiocarcinoma%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D1427%26epage%3D1434%26doi%3D10.1002%2Fhep.26890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Rhijn, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tilborg, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lurkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiery, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Kwast, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwarthoff, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radvanyi, F.</span></span> <span> </span><span class="NLM_article-title">Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal Disorders</span>. <i>Eur. J. Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">824</span>, <span class="refDoi"> DOI: 10.1038/sj.ejhg.5200883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1038%2Fsj.ejhg.5200883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=12461689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD38XptFKmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2002&pages=819-824&author=B.+W.+van%0ARhijnauthor=A.+A.+van+Tilborgauthor=I.+Lurkinauthor=J.+Bonaventureauthor=A.+de+Vriesauthor=J.+P.+Thieryauthor=T.+H.+van+der+Kwastauthor=E.+C.+Zwarthoffauthor=F.+Radvanyi&title=Novel+fibroblast+growth+factor+receptor+3+%28FGFR3%29+mutations+in+bladder+cancer+previously+identified+in+non-lethal+skeletal+Disorders&doi=10.1038%2Fsj.ejhg.5200883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders</span></div><div class="casAuthors">van Rhijn, Bas W. G.; van Tilborg, Angela A. G.; Lurkin, Irene; Bonaventure, Jacky; de Vries, Annie; Thiery, Jean-Paul; van der Kwast, Theodorus H.; Zwarthoff, Ellen C.; Radvanyi, Francois</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">819-824</span>CODEN:
                <span class="NLM_cas:coden">EJHGEU</span>;
        ISSN:<span class="NLM_cas:issn">1018-4813</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in the fibroblast growth factor receptor 3 (FGFR3) gene are responsible for several autosomal dominant craniosynostosis syndromes and chondrodysplasias, i.e., hypochondroplasia, achondroplasia, SADDAN and thanatophoric dysplasia - a neonatal lethal dwarfism syndrome.  Recently, activating FGFR3 mutations have also been present in cancer, i.e., at high frequency in carcinoma of the bladder and rarely in multiple myeloma and carcinoma of the cervix.  Almost all reported mutations in carcinomas corresponded to the mutations identified in thanatophoric dysplasia.  The authors here screened a series of 297 bladder tumors and found three FGFR3 somatic mutations (G380/382R; K650/652M and K650/652T) that were not previously identified in carcinomas or thanatophoric dysplasia.  Another novel finding was the occurrence of two simultaneous FGFR3 mutations in four tumors.  Two of the three new mutations in bladder cancer, the G380/382R and the K650/652M mutations, were previously reported in achondroplasia and SADDAN, resp.  These syndromes entail a longer life span than thanatophoric dysplasia.  The K650/652T mutation has not previously been detected in patients with skeletal disorders, but affects a codon that has been shown to be affected in some cases of thanatophoric dysplasia, SADDAN and hypochondroplasia.  From a clin. perspective, the patients with FGFR3-related, non-lethal skeletal disorders might be at a higher risk for development of bladder tumors than the general population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOHiG-fm4F8rVg90H21EOLACvtfcHk0lgMRMHe4CEBog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptFKmtbw%253D&md5=2162a6066af5ba88aa0ba2eb57d6970f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fsj.ejhg.5200883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ejhg.5200883%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BRhijn%26aufirst%3DB.%2BW.%26aulast%3Dvan%2BTilborg%26aufirst%3DA.%2BA.%26aulast%3DLurkin%26aufirst%3DI.%26aulast%3DBonaventure%26aufirst%3DJ.%26aulast%3Dde%2BVries%26aufirst%3DA.%26aulast%3DThiery%26aufirst%3DJ.%2BP.%26aulast%3Dvan%2Bder%2BKwast%26aufirst%3DT.%2BH.%26aulast%3DZwarthoff%26aufirst%3DE.%2BC.%26aulast%3DRadvanyi%26aufirst%3DF.%26atitle%3DNovel%2520fibroblast%2520growth%2520factor%2520receptor%25203%2520%2528FGFR3%2529%2520mutations%2520in%2520bladder%2520cancer%2520previously%2520identified%2520in%2520non-lethal%2520skeletal%2520Disorders%26jtitle%3DEur.%2520J.%2520Hum.%2520Genet.%26date%3D2002%26volume%3D10%26spage%3D819%26epage%3D824%26doi%3D10.1038%2Fsj.ejhg.5200883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zander, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soltermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schottle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leenders, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabow, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Querings, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heukamp, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balke-Want, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baessmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorimier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sollberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brustugun, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel-Riedel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timens, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sietsma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thunnissen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heideman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligorio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damiani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beroukhim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernestus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoelben, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurnberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span> <span> </span><span class="NLM_article-title">Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">62ra93</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3001451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1126%2Fscitranslmed.3001451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=21160078" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=62ra93&author=J.+Weissauthor=M.+L.+Sosauthor=D.+Seidelauthor=M.+Peiferauthor=T.+Zanderauthor=J.+M.+Heuckmannauthor=R.+T.+Ullrichauthor=R.+Menonauthor=S.+Maierauthor=A.+Soltermannauthor=H.+Mochauthor=P.+Wagenerauthor=F.+Fischerauthor=S.+Heynckauthor=M.+Kokerauthor=J.+Schottleauthor=F.+Leendersauthor=F.+Gablerauthor=I.+Dabowauthor=S.+Queringsauthor=L.+C.+Heukampauthor=H.+Balke-Wantauthor=S.+Ansenauthor=D.+Rauhauthor=I.+Baessmannauthor=J.+Altmullerauthor=Z.+Wainerauthor=M.+Conronauthor=G.+Wrightauthor=O.+Russellauthor=B.+Solomonauthor=E.+Brambillaauthor=C.+Brambillaauthor=P.+Lorimierauthor=S.+Sollbergauthor=O.+T.+Brustugunauthor=W.+Engel-Riedelauthor=C.+Ludwigauthor=I.+Petersenauthor=J.+Sangerauthor=J.+Clementauthor=H.+Groenauthor=W.+Timensauthor=H.+Sietsmaauthor=E.+Thunnissenauthor=E.+Smitauthor=D.+Heidemanauthor=F.+Cappuzzoauthor=C.+Ligorioauthor=S.+Damianiauthor=M.+Hallekauthor=R.+Beroukhimauthor=W.+Paoauthor=B.+Kleblauthor=M.+Baumannauthor=R.+Buettnerauthor=K.+Ernestusauthor=E.+Stoelbenauthor=J.+Wolfauthor=P.+Nurnbergauthor=S.+Pernerauthor=R.+K.+Thomas&title=Frequent+and+focal+FGFR1+amplification+associates+with+therapeutically+tractable+FGFR1+dependency+in+squamous+cell+lung+cancer&doi=10.1126%2Fscitranslmed.3001451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3001451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3001451%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DSeidel%26aufirst%3DD.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DUllrich%26aufirst%3DR.%2BT.%26aulast%3DMenon%26aufirst%3DR.%26aulast%3DMaier%26aufirst%3DS.%26aulast%3DSoltermann%26aufirst%3DA.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DWagener%26aufirst%3DP.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSchottle%26aufirst%3DJ.%26aulast%3DLeenders%26aufirst%3DF.%26aulast%3DGabler%26aufirst%3DF.%26aulast%3DDabow%26aufirst%3DI.%26aulast%3DQuerings%26aufirst%3DS.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DBalke-Want%26aufirst%3DH.%26aulast%3DAnsen%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DBaessmann%26aufirst%3DI.%26aulast%3DAltmuller%26aufirst%3DJ.%26aulast%3DWainer%26aufirst%3DZ.%26aulast%3DConron%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DRussell%26aufirst%3DO.%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DBrambilla%26aufirst%3DE.%26aulast%3DBrambilla%26aufirst%3DC.%26aulast%3DLorimier%26aufirst%3DP.%26aulast%3DSollberg%26aufirst%3DS.%26aulast%3DBrustugun%26aufirst%3DO.%2BT.%26aulast%3DEngel-Riedel%26aufirst%3DW.%26aulast%3DLudwig%26aufirst%3DC.%26aulast%3DPetersen%26aufirst%3DI.%26aulast%3DSanger%26aufirst%3DJ.%26aulast%3DClement%26aufirst%3DJ.%26aulast%3DGroen%26aufirst%3DH.%26aulast%3DTimens%26aufirst%3DW.%26aulast%3DSietsma%26aufirst%3DH.%26aulast%3DThunnissen%26aufirst%3DE.%26aulast%3DSmit%26aufirst%3DE.%26aulast%3DHeideman%26aufirst%3DD.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DDamiani%26aufirst%3DS.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DErnestus%26aufirst%3DK.%26aulast%3DStoelben%26aufirst%3DE.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DNurnberg%26aufirst%3DP.%26aulast%3DPerner%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DFrequent%2520and%2520focal%2520FGFR1%2520amplification%2520associates%2520with%2520therapeutically%2520tractable%2520FGFR1%2520dependency%2520in%2520squamous%2520cell%2520lung%2520cancer%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D62ra93%26doi%3D10.1126%2Fscitranslmed.3001451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kunii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorenstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yashiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bacco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elbi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutterbach, B.</span></span> <span> </span><span class="NLM_article-title">FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2340</span>– <span class="NLM_lpage">2348</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-5229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1158%2F0008-5472.CAN-07-5229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=18381441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktV2jsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=2340-2348&author=K.+Kuniiauthor=L.+Davisauthor=J.+Gorensteinauthor=H.+Hatchauthor=M.+Yashiroauthor=A.+Di+Baccoauthor=C.+Elbiauthor=B.+Lutterbach&title=FGFR2-amplified+gastric+cancer+cell+lines+require+FGFR2+and+Erbb3+signaling+for+growth+and+survival&doi=10.1158%2F0008-5472.CAN-07-5229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 Signaling for Growth and Survival</span></div><div class="casAuthors">Kunii, Kaiko; Davis, Lenora; Gorenstein, Julie; Hatch, Harold; Yashiro, Masakazu; Di Bacco, Alessandra; Elbi, Cem; Lutterbach, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2340-2348</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We have identified a crit. role for amplified FGFR2 in gastric cancer cell proliferation and survival.  In a panel of gastric cancer cell lines, fibroblast growth factor receptor 2 (FGFR2) was overexpressed and tyrosine phosphorylated selectively in FGFR2-amplified cell lines KatoIII, Snu16, and OCUM-2M.  FGFR2 kinase inhibition by a specific small-mol. inhibitor resulted in selective and potent growth inhibition in FGFR2-amplified cell lines, resulting in growth arrest in KatoIII cells and prominent induction of apoptosis in both Snu16 and OCUM-2M cells.  FGFR2-amplified cell lines also contained elevated phosphotyrosine in EGFR, Her2, and Erbb3, but the elevated phosphorylation in EGFR could not be inhibited by gefitinib or erlotinib.  We show that the elevated EGFR, Her2, and Erbb3 phosphotyrosine is dependent on FGFR2, revealing EGFR family kinases to be downstream targets of amplified FGFR2.  Moreover, shRNA to Erbb3 resulted in a loss of proliferation, confirming a functional role for the activated EGFR signaling pathway.  These results reveal that both the FGFR2 and EGFR family signaling pathways are activated in FGFR2-amplified gastric cancer cell lines to drive cell proliferation and survival.  Inhibitors of FGFR2 or Erbb3 signaling may have therapeutic efficacy in the subset of gastric cancers contg. FGFR2 amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSCcE3Vd_WrVg90H21EOLACvtfcHk0ljTx9AD304rRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktV2jsr0%253D&md5=621f7b5769cc202e08466c83db3c644c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5229%26sid%3Dliteratum%253Aachs%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DGorenstein%26aufirst%3DJ.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DYashiro%26aufirst%3DM.%26aulast%3DDi%2BBacco%26aufirst%3DA.%26aulast%3DElbi%26aufirst%3DC.%26aulast%3DLutterbach%26aufirst%3DB.%26atitle%3DFGFR2-amplified%2520gastric%2520cancer%2520cell%2520lines%2520require%2520FGFR2%2520and%2520Erbb3%2520signaling%2520for%2520growth%2520and%2520survival%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D2340%26epage%3D2348%26doi%3D10.1158%2F0008-5472.CAN-07-5229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dieci, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnedoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rational to medical perspectives</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1158%2F2159-8290.CD-12-0362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=23418312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=264-279&author=M.+V.+Dieciauthor=M.+Arnedoesauthor=F.+Andreauthor=J.+C.+Soria&title=Fibroblast+growth+factor+receptor+inhibitors+as+a+cancer+treatment%3A+from+a+biologic+rational+to+medical+perspectives&doi=10.1158%2F2159-8290.CD-12-0362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives</span></div><div class="casAuthors">Dieci, Maria Vittoria; Arnedos, Monica; Andre, Fabrice; Soria, Jean Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">264-279</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway plays a fundamental role in many physiol. processes, including embryogenesis, adult tissue homeostasis, and wound healing, by orchestrating angiogenesis.  Ligand-independent and ligand-dependent activation have been implicated in a broad range of human malignancies and promote cancer progression in tumors driven by FGF/FGFR oncogenic mutations or amplifications, tumor neoangiogenesis, and targeted treatment resistance, thereby supporting a strong rationale for anti-FGF/FGFR agent development.  Efforts are being pursued to develop selective approaches for use against this pathway by optimizing the management of emerging, class-specific toxicity profiles and correctly designing clin. trials to address these different issues.  Significance: FGF/FGFR pathway deregulations are increasingly recognized across different human cancers.  Understanding the mechanisms at the basis of these alterations and their multiple roles in cancer promotion and drug resistance is a fundamental step for further implementation of targeted therapies and research strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6bibZKwamTLVg90H21EOLACvtfcHk0ljTx9AD304rRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D&md5=0e694a7641aa83c1540f745576f04bfa</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0362%26sid%3Dliteratum%253Aachs%26aulast%3DDieci%26aufirst%3DM.%2BV.%26aulast%3DArnedoes%26aufirst%3DM.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%2520inhibitors%2520as%2520a%2520cancer%2520treatment%253A%2520from%2520a%2520biologic%2520rational%2520to%2520medical%2520perspectives%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D264%26epage%3D279%26doi%3D10.1158%2F2159-8290.CD-12-0362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachelot, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalenc, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Garcia, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yovine, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1200/jco.2011.29.15_suppl.508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1200%2Fjco.2011.29.15_suppl.508" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=508-508&author=F.+Andreauthor=T.+D.+Bachelotauthor=M.+Camponeauthor=F.+Dalencauthor=J.+M.+Perez-Garciaauthor=S.+A.+Hurvitzauthor=N.+C.+Turnerauthor=H.+S.+Rugoauthor=M.+M.+Shiauthor=Y.+Zhangauthor=A.+C.+M.+Kayauthor=A.+J.+Yovineauthor=J.+Baselga&title=A+multicenter%2C+open-label+phase+II+trial+of+dovitinib%2C+an+FGFR1+inhibitor%2C+in+FGFR1+amplified+and+non-amplified+metastatic+breast+cancer&doi=10.1200%2Fjco.2011.29.15_suppl.508"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2Fjco.2011.29.15_suppl.508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2011.29.15_suppl.508%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DBachelot%26aufirst%3DT.%2BD.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DDalenc%26aufirst%3DF.%26aulast%3DPerez-Garcia%26aufirst%3DJ.%2BM.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DShi%26aufirst%3DM.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKay%26aufirst%3DA.%2BC.%2BM.%26aulast%3DYovine%26aufirst%3DA.%2BJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DA%2520multicenter%252C%2520open-label%2520phase%2520II%2520trial%2520of%2520dovitinib%252C%2520an%2520FGFR1%2520inhibitor%252C%2520in%2520FGFR1%2520amplified%2520and%2520non-amplified%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D508%26epage%3D508%26doi%3D10.1200%2Fjco.2011.29.15_suppl.508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayson, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasquez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokliatchouk, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltquate, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuyten, D. S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbraith, S.</span></span> <span> </span><span class="NLM_article-title">A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1413</span>– <span class="NLM_lpage">1419</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdq599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1093%2Fannonc%2Fmdq599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=21131369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A280%3ADC%252BC3MrkvFOksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=1413-1419&author=D.+J.+Jonkerauthor=L.+S.+Rosenauthor=M.+B.+Sawyerauthor=F.+de+Braudauthor=G.+Wildingauthor=C.+J.+Sweeneyauthor=G.+C.+Jaysonauthor=G.+A.+McArthurauthor=G.+Rustinauthor=G.+Gossauthor=J.+Kantorauthor=L.+Velasquezauthor=S.+Syedauthor=O.+Mokliatchoukauthor=D.+M.+Feltquateauthor=G.+Kolliaauthor=D.+S.+A.+Nuytenauthor=S.+Galbraith&title=A+phase+I+study+to+determine+the+safety%2C+pharmacokinetics+and+pharmacodynamics+of+a+dual+VEGFR+and+FGFR+inhibitor%2C+brivanib%2C+in+patients+with+advanced+or+metastatic+solid+tumors&doi=10.1093%2Fannonc%2Fmdq599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors</span></div><div class="casAuthors">Jonker D J; Rosen L S; Sawyer M B; de Braud F; Wilding G; Sweeney C J; Jayson G C; McArthur G A; Rustin G; Goss G; Kantor J; Velasquez L; Syed S; Mokliatchouk O; Feltquate D M; Kollia G; Nuyten D S A; Galbraith S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1413-1419</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors.  PATIENTS AND METHODS:  Ninety patients enrolled in this two-part, phase I open-label study of oral brivanib alaninate.  The primary objectives of this study were (in part A) dose-limiting toxicity, maximum tolerated dose (MTD) and the lowest biologically active dose level and (in part B) the optimal dose/dose range.  The secondary objectives of this study were preliminary evidence of antitumor activity, PK and PD.  RESULTS:  Across part A (open-label dose escalation and MTD) and part B (open-label dose optimization), 68 patients received brivanib alaninate.  Brivanib demonstrated a manageable toxicity profile at doses of 180-800 mg.  Most toxic effects were mild.  Systemic exposure of the active moiety brivanib increased linearly ≤1000 mg/day.  The MTD was 800 mg/day.  Forty-four patients were treated at the MTD: 20 with 800 mg continuously, 11 with 800 mg intermittently and 13 with 400 mg b.i.d. doses.  Partial responses were confirmed in two patients receiving brivanib ≥600 mg.  Dynamic contrast-enhanced magnetic resonance imaging demonstrated statistically significant decreases in parameters reflecting tumor vascularity and permeability after multiple doses in the 800-mg continuous q.d. and 400-mg b.i.d. dose cohorts.  CONCLUSION:  In patients with advanced/metastatic cancer, brivanib demonstrates promising antiangiogenic and antitumor activity and manageable toxicity at doses ≤800 mg orally q.d., the recommended phase II study dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwkcPypD6aCHwOGIfWJ7-GfW6udTcc2ea1W6WhUrfLP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrkvFOksw%253D%253D&md5=cd9b98bdee01a27111ac906edab19ccc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq599%26sid%3Dliteratum%253Aachs%26aulast%3DJonker%26aufirst%3DD.%2BJ.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26aulast%3DSawyer%26aufirst%3DM.%2BB.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DSweeney%26aufirst%3DC.%2BJ.%26aulast%3DJayson%26aufirst%3DG.%2BC.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DRustin%26aufirst%3DG.%26aulast%3DGoss%26aufirst%3DG.%26aulast%3DKantor%26aufirst%3DJ.%26aulast%3DVelasquez%26aufirst%3DL.%26aulast%3DSyed%26aufirst%3DS.%26aulast%3DMokliatchouk%26aufirst%3DO.%26aulast%3DFeltquate%26aufirst%3DD.%2BM.%26aulast%3DKollia%26aufirst%3DG.%26aulast%3DNuyten%26aufirst%3DD.%2BS.%2BA.%26aulast%3DGalbraith%26aufirst%3DS.%26atitle%3DA%2520phase%2520I%2520study%2520to%2520determine%2520the%2520safety%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520a%2520dual%2520VEGFR%2520and%2520FGFR%2520inhibitor%252C%2520brivanib%252C%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520solid%2520tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D1413%26epage%3D1419%26doi%3D10.1093%2Fannonc%2Fmdq599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">955</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1126/science.276.5314.955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1126%2Fscience.276.5314.955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=9139660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADyaK2sXjt1ans7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=955-960&author=M.+Mohammadiauthor=G.+McMahonauthor=L.+Sunauthor=C.+Tangauthor=P.+Hirthauthor=B.+K.+Yehauthor=S.+R.+Hubbardauthor=J.+Schlessinger&title=Structures+of+the+tyrosine+kinase+domain+of+fibroblast+growth+factor+receptor+in+complex+with+inhibitors&doi=10.1126%2Fscience.276.5314.955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors</span></div><div class="casAuthors">Mohammadi, Moosa; McMahon, Gerald; Sun, Li; Tang, Cho; Hirth, Peter; Yeh, Brian K.; Hubbard, Stevan R.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">5314</span>),
    <span class="NLM_cas:pages">955-960</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A new class of protein tyrosine kinase inhibitors was identified that is based on an oxindole core (indolinones).  Two compds. from this class inhibited the kinase activity of fibroblast growth factor receptor 1 (FGFR1) and showed differential specificity toward others receptor tyrosine kinases.  Crystal structures of the tyrosine kinase domain of FGFR1 in complex with the two compds. were detd.  The oxindole occupies the sites in which the adenine of ATP binds, whereas the moieties that extend from the oxindole contact residues in the hinge region between the two kinase lobes.  The more specific inhibitor of FGFR1 induces a conformational change in the nucleotide-binding loop.  This structural information will facilitate the design of new inhibitors for use in the treatment of cancer and other diseases in which cell signaling by tyrosine kinases plays a crucial role in disease pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDwP7A-FMgDLVg90H21EOLACvtfcHk0liB5nxKvRD9gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjt1ans7w%253D&md5=fdbedba79850d11771677e6d25f3842f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscience.276.5314.955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.276.5314.955%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DYeh%26aufirst%3DB.%2BK.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520fibroblast%2520growth%2520factor%2520receptor%2520in%2520complex%2520with%2520inhibitors%26jtitle%3DScience%26date%3D1997%26volume%3D276%26spage%3D955%26epage%3D960%26doi%3D10.1126%2Fscience.276.5314.955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliseenkova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">5896</span>– <span class="NLM_lpage">5904</span>, <span class="refDoi"> DOI: 10.1093/emboj/17.20.5896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1093%2Femboj%2F17.20.5896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=9774334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1Cmurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1998&pages=5896-5904&author=M.+Mohammadiauthor=S.+Froumauthor=J.+M.+Hambyauthor=M.+C.+Schroederauthor=R.+L.+Panekauthor=G.+H.+Luauthor=A.+V.+Eliseenkovaauthor=D.+Greenauthor=J.+Schlessingerauthor=S.+R.+Hubbard&title=Crystal+structure+of+an+angiogenesis+inhibitor+bound+to+the+FGF+receptor+tyrosine+kinase+domain&doi=10.1093%2Femboj%2F17.20.5896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain</span></div><div class="casAuthors">Mohammadi, Moosa; Froum, Scott; Hamby, James M.; Schroeder, Mel C.; Panek, Robert L.; Lu, Gina H.; Eliseenkova, Anna V.; Green, David; Schlessinger, Joseph; Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5896-5904</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Angiogenesis, the sprouting of new blood vessels from pre-existing ones, is an essential physiol. process in development, yet also plays a major role in the progression of human diseases such as diabetic retinopathy, atherosclerosis and cancer.  The effects of the most potent angiogenic factors, vascular endothelial growth factor (VEGF), angiopoietin and fibroblast growth factor (FGF) are mediated through cell surface receptors that possess intrinsic protein tyrosine kinase activity.  In this report, the authors describe a synthetic compd. of the pyrido[2,3-d]pyrimidine class, designated PD 173074, that selectively inhibits the tyrosine kinase activities of the FGF and VEGF receptors.  The authors show that systemic administration of PD 173074 in mice can effectively block angiogenesis induced by either FGF or VEGF with no apparent toxicity.  To elucidate the determinants of selectivity, the authors have detd. the crystal structure of PD 173074 in complex with the tyrosine kinase domain of FGF receptor 1 at 2.5 Å resoln.  A high degree of surface complementarity between PD 173074 and the hydrophobic, ATP-binding pocket of FGF receptor 1 underlies the potency and selectivity of this inhibitor.  PD 173074 is thus a promising candidate for a therapeutic angiogenesis inhibitor to be used in the treatment of cancer and other diseases whose progression is dependent upon new blood vessel formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4zdEklzyMx7Vg90H21EOLACvtfcHk0lhDaa6Zv3kdyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1Cmurs%253D&md5=a76b085ddc9d352878a2c6bc9d1cd6ff</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F17.20.5896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F17.20.5896%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DFroum%26aufirst%3DS.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DEliseenkova%26aufirst%3DA.%2BV.%26aulast%3DGreen%26aufirst%3DD.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520an%2520angiogenesis%2520inhibitor%2520bound%2520to%2520the%2520FGF%2520receptor%2520tyrosine%2520kinase%2520domain%26jtitle%3DEMBO%2520J.%26date%3D1998%26volume%3D17%26spage%3D5896%26epage%3D5904%26doi%3D10.1093%2Femboj%2F17.20.5896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollebecque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahleda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriot, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaussen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span> <span> </span><span class="NLM_article-title">Facts and new hopes on selective FGFR inhibitors in solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">764</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-2035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1158%2F1078-0432.CCR-19-2035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=31585937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslylsLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=764-774&author=F.+Facchinettiauthor=A.+Hollebecqueauthor=R.+Bahledaauthor=Y.+Loriotauthor=K.+A.+Olaussenauthor=C.+Massardauthor=L.+Friboulet&title=Facts+and+new+hopes+on+selective+FGFR+inhibitors+in+solid+tumors&doi=10.1158%2F1078-0432.CCR-19-2035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Facts and new hopes on selective FGFR inhibitors in solid tumors</span></div><div class="casAuthors">Facchinetti, Francesco; Hollebecque, Antoine; Bahleda, Rastislav; Loriot, Yohann; Olaussen, Ken A.; Massard, Christophe; Friboulet, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">764-774</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Precision oncol. relies on the identification of mol. alterations, responsible for tumor initiation and growth, which are suitable targets of specific inhibitors.  The development of FGFR inhibitors represents an edifying example of the rapid evolution in the field of targeted oncol., with 10 different FGFR tyrosine kinase inhibitors actually under clin. investigation.  In parallel, the discovery of FGFR activating mol. alterations (mainly FGFR3 mutations and FGFR2 fusions) across many tumor types, esp. urothelial carcinomas and intrahepatic cholangiocarcinomas, widens the selection of patients that might benefit from selective FGFR inhibitors.  The ongoing concomitant clin. evaluation of selective FGFR inhibitors in molecularly selected solid tumors brings new hopes for patients with metastatic cancer, for tumors so far excluded from molecularly guided treatments.  Widening our knowledge of the activity, efficacy, and toxicities relative to the selective FGFR tyrosine kinase inhibitors under clin. investigation, according to the exact FGFR mol. alteration, will be crucial to det. the optimal therapeutic strategy for patients suffering from FGFR-driven tumors.  Similarly, identifying with appropriate mol. diagnostic, every single tumor harboring targetable FGFR alterations will be of utmost importance to attain the best outcomes for patients with FGFR-driven cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzgxOc3DEltbVg90H21EOLACvtfcHk0lhDaa6Zv3kdyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslylsLzN&md5=300df1178350a8ae56713e1d6b58f6d9</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-2035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-2035%26sid%3Dliteratum%253Aachs%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DHollebecque%26aufirst%3DA.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DLoriot%26aufirst%3DY.%26aulast%3DOlaussen%26aufirst%3DK.%2BA.%26aulast%3DMassard%26aufirst%3DC.%26aulast%3DFriboulet%26aufirst%3DL.%26atitle%3DFacts%2520and%2520new%2520hopes%2520on%2520selective%2520FGFR%2520inhibitors%2520in%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26spage%3D764%26epage%3D774%26doi%3D10.1158%2F1078-0432.CCR-19-2035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossaer, J. B.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class</span>. <i>J. Oncol. Pharm. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">702</span>– <span class="NLM_lpage">710</span>, <span class="refDoi"> DOI: 10.1177/1078155220983425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1177%2F1078155220983425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=33375902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnsFSgsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2021&pages=702-710&issue=3&author=A.+Weaverauthor=J.+B.+Bossaer&title=Fibroblast+growth+factor+receptor+%28FGFR%29+inhibitors%3A+A+review+of+a+novel+therapeutic+class&doi=10.1177%2F1078155220983425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class</span></div><div class="casAuthors">Weaver, April; Bossaer, John B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Oncology Pharmacy Practice</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">702-710</span>CODEN:
                <span class="NLM_cas:coden">JOPPFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-1552</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review Comprehensive genomic profiling has an emerging role in cancer therapeutics.  As treatment options remain needed for advanced cancers, patients are relying increasingly more on tumor genomic alterations as possible targets for cancer treatment.  Frequent tumor fibroblast growth factor receptor (FGFR) alterations are seen in many cancers, and include genetic amplifications, mutations, rearrangements and fusions.  FGFR inhibitors target these receptor alterations and show promise as a drug class.  Currently 2 medications are currently FDA approved: erdafitinib and pemigatinib.  Through the FDA accelerated approval process, erdafitinib is indicated to treat metastatic urothelial carcinoma with FGFR2 and FGFR3 alterations, whereas pemigatinib is indicated to treat unresectable cholangiocarcinoma with FGFR2 alterations.  Despite growing knowledge about such advanced cancers, treatment is usually palliative.  With multiple FGFR inhibitors in the pipeline, further FDA approvals are possible, and it is likely their role in therapy will extend to other cancer types.  This review outlines erdafitinib, pemigatinib, their role in cancer, as well as outlining the possible future use of other FGFR inhibitors in urothelial carcinoma, cholangiocarcinoma, and other malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV7v2EX5_eM7Vg90H21EOLACvtfcHk0lhDaa6Zv3kdyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnsFSgsr0%253D&md5=c49bb4b0763e86ef49ee7f64df2c4c6a</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1177%2F1078155220983425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1078155220983425%26sid%3Dliteratum%253Aachs%26aulast%3DWeaver%26aufirst%3DA.%26aulast%3DBossaer%26aufirst%3DJ.%2BB.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%2520inhibitors%253A%2520A%2520review%2520of%2520a%2520novel%2520therapeutic%2520class%26jtitle%3DJ.%2520Oncol.%2520Pharm.%2520Pract.%26date%3D2021%26volume%3D27%26issue%3D3%26spage%3D702%26epage%3D710%26doi%3D10.1177%2F1078155220983425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Krook, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeser, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilberding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roychowdhury, S.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1038/s41416-020-01157-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1038%2Fs41416-020-01157-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=33268819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFOrtrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2021&pages=880-892&issue=5&author=M.+A.+Krookauthor=J.+W.+Reeserauthor=G.+Ernstauthor=H.+Barkerauthor=M.+Wilberdingauthor=G.+Liauthor=H.+Z.+Chenauthor=S.+Roychowdhury&title=Fibroblast+growth+factor+receptors+in+cancer%3A+genetic+alterations%2C+diagnostics%2C+therapeutic+targets+and+mechanisms+of+resistance&doi=10.1038%2Fs41416-020-01157-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17cR"><div class="casContent"><span class="casTitleNuber">17c</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance</span></div><div class="casAuthors">Krook, Melanie A.; Reeser, Julie W.; Ernst, Gabrielle; Barker, Hannah; Wilberding, Max; Li, Gary; Chen, Hui-Zi; Roychowdhury, Sameek</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">880-892</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy no. amplifications in 5-10% of all human cancers, although this frequency increases to 10-30% in urothelial carcinoma and intrahepatic cholangiocarcinoma.  We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges assocd. with the development of clin.-grade mol. diagnostic tests to accurately detect these alterations in the tissue and blood of patients.  The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-mol. inhibitors, as well as monoclonal antibodies against the receptors.  We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clin. trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, resp.  However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients.  This phenomenon underscores the need to clearly delineate tumor-intrinsic and tumor-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0DReMO1eCGrVg90H21EOLACvtfcHk0lhTlQTHNZ2iOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFOrtrrL&md5=5c5c76a80bba2a2de9c64526b84c2cba</span></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1038%2Fs41416-020-01157-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-020-01157-0%26sid%3Dliteratum%253Aachs%26aulast%3DKrook%26aufirst%3DM.%2BA.%26aulast%3DReeser%26aufirst%3DJ.%2BW.%26aulast%3DErnst%26aufirst%3DG.%26aulast%3DBarker%26aufirst%3DH.%26aulast%3DWilberding%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DH.%2BZ.%26aulast%3DRoychowdhury%26aufirst%3DS.%26atitle%3DFibroblast%2520growth%2520factor%2520receptors%2520in%2520cancer%253A%2520genetic%2520alterations%252C%2520diagnostics%252C%2520therapeutic%2520targets%2520and%2520mechanisms%2520of%2520resistance%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2021%26volume%3D124%26issue%3D5%26spage%3D880%26epage%3D892%26doi%3D10.1038%2Fs41416-020-01157-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lhTlQTHNZ2iOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunaydin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapointe, B.</span></span> <span> </span><span class="NLM_article-title">Strategy for extending half-life in drug design and its significance</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslGqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=528-533&author=H.+Gunaydinauthor=M.+D.+Altmanauthor=J.+M.+Ellisauthor=P.+Fullerauthor=S.+A.+Johnsonauthor=B.+Lahueauthor=B.+Lapointe&title=Strategy+for+extending+half-life+in+drug+design+and+its+significance&doi=10.1021%2Facsmedchemlett.8b00018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Strategy for extending half-life in drug design and its significance</span></div><div class="casAuthors">Gunaydin, Hakan; Altman, Michael D.; Ellis, J. Michael; Fuller, Peter; Johnson, Scott A.; Lahue, Brian; Lapointe, Blair</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">528-533</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Preclin. optimization of compds. toward viable drug candidates requires an integrated understanding of properties that impact predictions of the clin. efficacious dose.  The importance of optimizing half-life, unbound clearance, and potency and how they impact dose predictions are discussed in this letter.  Modest half-life improvements for short half-life compds. can dramatically lower the efficacious dose.  The relationship between dose and half-life is nonlinear when unbound clearance is kept const., whereas the relationship between dose and unbound clearance is linear when half-life is kept const.  Due to this difference, we show that dose is more sensitive to changes in half-life than changes in unbound clearance when half-lives are shorter than 2 h.  Through matched mol. pair analyses, we also show that the strategic introduction of halogens is likely to increase half-life and lower projected human dose even though increased lipophilicity does not guarantee extended half-life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJU1an5zslYbVg90H21EOLACvtfcHk0lhTlQTHNZ2iOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslGqsLk%253D&md5=497178d9c523a58e1fa70e34cdf09281</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00018%26sid%3Dliteratum%253Aachs%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DEllis%26aufirst%3DJ.%2BM.%26aulast%3DFuller%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DS.%2BA.%26aulast%3DLahue%26aufirst%3DB.%26aulast%3DLapointe%26aufirst%3DB.%26atitle%3DStrategy%2520for%2520extending%2520half-life%2520in%2520drug%2520design%2520and%2520its%2520significance%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D528%26epage%3D533%26doi%3D10.1021%2Facsmedchemlett.8b00018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Relevance of half-life in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4273</span>– <span class="NLM_lpage">4282</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00969</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00969" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOnsrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4273-4282&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Relevance+of+half-life+in+drug+design&doi=10.1021%2Facs.jmedchem.7b00969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Relevance of Half-Life in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4273-4282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state.  A half-life of 12-48 h is generally ideal for once daily dosing of oral drugs.  If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concns.  This may pose challenges to achieving optimal efficacy, safety, and patient compliance.  If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged.  This may pose problems with managing adverse effects and the design of efficient clin. trials.  Half-life is a key parameter for optimization in research and development.  Structural modification to affect clearance, and to a lesser extent vol. of distribution, is the preferred means of modulating half-life.  An effective approach to half-life optimization requires an understanding of the many pitfalls assocd. with its estn. and interpretation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7kT9hNLRzb7Vg90H21EOLACvtfcHk0lii2lwFY6Xp2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOnsrnN&md5=ff748cbebc765f4fa3c3d7b3831f51c8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00969%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DRelevance%2520of%2520half-life%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4273%26epage%3D4282%26doi%3D10.1021%2Facs.jmedchem.7b00969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, Li</span></span> <span> </span><span class="NLM_article-title">Volume of distribution in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5691</span>– <span class="NLM_lpage">5698</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=Li+Di&title=Volume+of+distribution+in+drug+design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0lii2lwFY6Xp2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DLi%26atitle%3DVolume%2520of%2520distribution%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
de Waterbeemd, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. K.</span></span> <span> </span><span class="NLM_article-title">Property-based design: optimization of drug absorption and pharmacokinetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1333</span>, <span class="refDoi"> DOI: 10.1021/jm000407e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000407e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD3MXit1Whu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=1313-1333&author=H.+van%0Ade+Waterbeemdauthor=D.+A.+Smithauthor=K.+Beaumontauthor=D.+K.+Walker&title=Property-based+design%3A+optimization+of+drug+absorption+and+pharmacokinetics&doi=10.1021%2Fjm000407e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Property-based design: optimization of drug absorption and pharmacokinetics</span></div><div class="casAuthors">van de Waterbeemd, Han; Smith, Dennis A.; Beaumont, Kevin; Walker, Don K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1313-1333</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 223 refs.  The authors discuss some aspects of the properties of biol. barriers.  In different sections the estn. of drug absorption via important barriers including gastrointestinal tract, blood-brain barrier, and skin are reviewed.  Various approaches for the measurement and computation of physicochem. and mol. properties currently used in the optimization of absorption as well as the use of physicochem. properties in the design of optimal pharmacokinetic profiles are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaQwsmoX0-mbVg90H21EOLACvtfcHk0lii2lwFY6Xp2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXit1Whu7c%253D&md5=3183baedca70020f4ce27f306ba0997e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm000407e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000407e%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DD.%2BK.%26atitle%3DProperty-based%2520design%253A%2520optimization%2520of%2520drug%2520absorption%2520and%2520pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D1313%26epage%3D1333%26doi%3D10.1021%2Fjm000407e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veber, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopple, K. D.</span></span> <span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2615</span>– <span class="NLM_lpage">2623</span>, <span class="refDoi"> DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0lii2lwFY6Xp2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiowetz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span> <span> </span><span class="NLM_article-title">Deep understanding of structure-solubility relationships for a diverse set of organic compounds using matched molecular pairs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5763</span>– <span class="NLM_lpage">5770</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.08.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1016%2Fj.bmc.2011.08.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=21906951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFyntbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=5763-5770&author=L.+Zhangauthor=H.+Zhuauthor=A.+Mathiowetzauthor=H.+Gao&title=Deep+understanding+of+structure-solubility+relationships+for+a+diverse+set+of+organic+compounds+using+matched+molecular+pairs&doi=10.1016%2Fj.bmc.2011.08.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Deep understanding of structure-solubility relationship for a diverse set of organic compounds using matched molecular pairs</span></div><div class="casAuthors">Zhang, Liying; Zhu, Hongyao; Mathiowetz, Alan; Gao, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5763-5770</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aq. soly. is an important biopharmaceutical property in drug discovery and development.  Although it has been studied for decades, the impact on soly. by the substructures (or fragments) of compds. are still not fully understood and characterized.  This study aims to obtain fragment-soly. relationships using matched mol. pairs, and to provide further insight and suggestions for chemists on structural modifications to improve soly. profiles of drug-like mols.  A set of 2794 compds. with measured intrinsic aq. soly. (log S) was fragmented into rings, linkers, and R groups using a controlled hierarchical fragmentation method.  Then matched mol. pairs that differ by only one chem. transformation (i.e., addn. or substitution of fragments) were identified and analyzed.  The difference in soly. for each matched mol. pair was calcd., and the impact of the corresponding chem. transformation on soly. was investigated.  The final product of this study was a fragment-soly. knowledge-base contg. relative contributions to soly. of various medicinal chem. design elements (R-groups, linkers, and rings).  Structural modifications that might improve soly. profiles, i.e., addn./deletion/substitution of fragments, could be derived from this knowledge-base.  This knowledge-base could be used as an expert tool in lead optimization to improve soly. profiles of compds., and the anal. method could be applied to study other biol. and ADMET properties of org. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVAAga6a67JLVg90H21EOLACvtfcHk0ljidiyHfS8jYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFyntbrI&md5=029038a43df73f822d1d216dd66ee2ce</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.08.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.08.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DMathiowetz%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DH.%26atitle%3DDeep%2520understanding%2520of%2520structure-solubility%2520relationships%2520for%2520a%2520diverse%2520set%2520of%2520organic%2520compounds%2520using%2520matched%2520molecular%2520pairs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D5763%26epage%3D5770%26doi%3D10.1016%2Fj.bmc.2011.08.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. A.</span></span> <span> </span><span class="NLM_article-title">Novel tactics for designing water-soluble molecules in drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1421</span>– <span class="NLM_lpage">1433</span>, <span class="refDoi"> DOI: 10.1517/17460441.2014.960839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1517%2F17460441.2014.960839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=25226793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2ltbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1421-1433&author=M.+A.+Walker&title=Novel+tactics+for+designing+water-soluble+molecules+in+drug+discovery&doi=10.1517%2F17460441.2014.960839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Novel tactics for designing water-soluble molecules in drug discovery</span></div><div class="casAuthors">Walker, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1421-1433</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Physiochem. drug properties, such as aq. soly. are considered to be a major factor in detg. the ultimate success or failure of exptl. agents.  Soly. is important because it dets. the max. dose which can be taken up.  As the size and hydrophobicity of drug candidates has increased over the years, poor soly. has become a more prevalent issue.  Recent examples from the literature show that an improved understanding of the relationship between mol. structure and soly. allows this issue to be approached using rational design.  Areas covered: This review provides selected examples from the recent drug discovery literature that demonstrate various tactics, which have been applied successfully towards improving drug soly.  The examples that were selected demonstrate the underlying principles behind aq. soly., such as hydrophobicity and cryst. stability.  Expert opinion: From a strategic point of view, improving the soly. of a compd. should be straightforward because it can be accomplished by simply reducing hydrophobicity or cryst. stability.  However, the structural elements and phys. properties which control soly. also influence potency, pharmacokinetics and toxicity.  Furthermore, there are practical aspects such as the quantity and quality of soly.-related data, which hamper the development of structure-soly. relationships.  Given that poor aq. soly. remains a primary issue in drug discovery, there is a continuous need for novel methods to overcome it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcCkPIepQBjLVg90H21EOLACvtfcHk0ljidiyHfS8jYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2ltbfO&md5=373cda72cecfa7b5077ed1551a6d1dd9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.960839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.960839%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DM.%2BA.%26atitle%3DNovel%2520tactics%2520for%2520designing%2520water-soluble%2520molecules%2520in%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D1421%26epage%3D1433%26doi%3D10.1517%2F17460441.2014.960839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manallack, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prankerd, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuriev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, D. K.</span></span> <span> </span><span class="NLM_article-title">The significance of acid/base properties in drug discovery</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1039/C2CS35348B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1039%2FC2CS35348B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=23099561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKmtb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=485-496&author=D.+T.+Manallackauthor=R.+J.+Prankerdauthor=E.+Yurievauthor=T.+I.+Opreaauthor=D.+K.+Chalmers&title=The+significance+of+acid%2Fbase+properties+in+drug+discovery&doi=10.1039%2FC2CS35348B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The significance of acid/base properties in drug discovery</span></div><div class="casAuthors">Manallack, David T.; Prankerd, Richard J.; Yuriev, Elizabeth; Oprea, Tudor I.; Chalmers, David K.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">485-496</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  While drug discovery scientists take heed of various guidelines concerning drug-like character, the influence of acid/base properties often remains under-scrutinized.  Ionisation consts. (pKa values) are fundamental to the variability of the biopharmaceutical characteristics of drugs and to underlying parameters such as logD and soly. pKa values affect physicochem. properties such as aq. soly., which in turn influences drug formulation approaches.  More importantly, absorption, distribution, metab., excretion and toxicity (ADMET) are profoundly affected by the charge state of compds. under varying pH conditions.  Consideration of pKa values in conjunction with other mol. properties is of great significance and has the potential to be used to further improve the efficiency of drug discovery.  Given the recent low annual output of new drugs from pharmaceutical companies, this review will provide a timely reminder of an important mol. property that influences clin. success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKAwdQSoeZxLVg90H21EOLACvtfcHk0li_Cjc0Rb_ZxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKmtb7N&md5=48d72c5bdae09cc3969cffaea36cf30f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FC2CS35348B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2CS35348B%26sid%3Dliteratum%253Aachs%26aulast%3DManallack%26aufirst%3DD.%2BT.%26aulast%3DPrankerd%26aufirst%3DR.%2BJ.%26aulast%3DYuriev%26aufirst%3DE.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DChalmers%26aufirst%3DD.%2BK.%26atitle%3DThe%2520significance%2520of%2520acid%252Fbase%2520properties%2520in%2520drug%2520discovery%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2013%26volume%3D42%26spage%3D485%26epage%3D496%26doi%3D10.1039%2FC2CS35348B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0li_Cjc0Rb_ZxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">St.
Jean, D. J. Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span> <span> </span><span class="NLM_article-title">Mitigating heterocycle metabolism in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6002</span>– <span class="NLM_lpage">6020</span>, <span class="refDoi"> DOI: 10.1021/jm300343m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300343m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFWhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6002-6020&author=D.+J.+Jr.+St.%0AJeanauthor=C.+Fotsch&title=Mitigating+heterocycle+metabolism+in+drug+discovery&doi=10.1021%2Fjm300343m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mitigating Heterocycle Metabolism in Drug Discovery</span></div><div class="casAuthors">St. Jean, David J.; Fotsch, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6002-6020</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Extensive data from metab. studies have allowed medicinal chemists to develop general principles for reducing compd. metab.  These methods include, but are not limited to, reducing lipophilicity, altering sterics and electronics, introducing a conformational constraint, and altering the stereochem. of their compds.  While no single method is able to solve every metabolic problem, these principles do give medicinal chemists guidance on how to improve the metabolic liabilities of their compds.  If the specific site of metab. is known, medicinal chemists block the site, typically with a fluorine, or replace the metabolically labile group with a bioisostere.  While several authors have reviewed these techniques for reducing metab., there is no review that summarizes different approaches to improving them metabolic stability of heterocycles.  In this review, we summarize examples where changes were made at or near the heterocycle to improve metabolic stability.  By summarizing these examples, we hope to provide a useful guide to medicinal chemists as they attempt to improve the metabolic profile of their own heterocyclic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovQjdBBgXtPbVg90H21EOLACvtfcHk0li_Cjc0Rb_ZxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFWhsL0%253D&md5=48c262556b8a2cc7dc5539ff91a53a71</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm300343m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300343m%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BJean%26aufirst%3DD.%2BJ.%2BJr.%26aulast%3DFotsch%26aufirst%3DC.%26atitle%3DMitigating%2520heterocycle%2520metabolism%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6002%26epage%3D6020%26doi%3D10.1021%2Fjm300343m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnihotri, S. A.</span></span> <span> </span><span class="NLM_article-title">Recent advances and novel strategies in pre-clinical formulation development: an overview</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2011.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1016%2Fj.jconrel.2011.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=21763367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFGlt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2011&pages=281-296&author=A.+K.+Shahauthor=S.+A.+Agnihotri&title=Recent+advances+and+novel+strategies+in+pre-clinical+formulation+development%3A+an+overview&doi=10.1016%2Fj.jconrel.2011.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances and novel strategies in pre-clinical formulation development: An overview</span></div><div class="casAuthors">Shah, Amit K.; Agnihotri, Sunil A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">281-296</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Preclin. profiling for a New Chem. Entity (NCE), if carried out carefully, can be a good predictor of human clin. outcome.  Along with the pre-clin. study design a thorough understanding of the physico-chem. properties of the drug candidate and a careful selection of the formulation development strategy are of high importance.  The study scientist can experience various challenges in executing a pre-clin. study.  This review article provides an overview of the significance of pre-formulation study parameters and their relevance to preclin. studies.  Various physico-chem. properties such as soly., partition co-efficient, and permeability are attributes crit. to the performance of the drug substance.  This article presents unique formulation development strategies for the successful completion of pre-clin. studies.  Formulation development approach for a pre-clin. study involves taking into consideration various important factors such as duration of the study, Biopharmaceutics Classification System (BCS) of the drug, intended duration of action and the desired route of administration.  These parameters play key role in the selection of solubilizers, surfactants, co-solvents and optimum pH for the formulation.  Two most common routes of administration in the early screening of pharmaceuticals viz., oral and i.v. are emphasized.  The article also describes recent advances in preclin. formulation development including selected examples of in vivo preclin. models for anti-cancer, anti-viral, anti-diabetic and anti-hypertensive drugs.  Adherence to the regulatory requirement is also the key to successful completion of the preclin. development.  An overview of preclin. formulation development along with basic concepts and the recent studies conducted in the past decade are presented in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWmISnQUsuPrVg90H21EOLACvtfcHk0li_Cjc0Rb_ZxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFGlt77J&md5=5d694f8878476329e5d240518a74c6db</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2011.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2011.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DA.%2BK.%26aulast%3DAgnihotri%26aufirst%3DS.%2BA.%26atitle%3DRecent%2520advances%2520and%2520novel%2520strategies%2520in%2520pre-clinical%2520formulation%2520development%253A%2520an%2520overview%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2011%26volume%3D156%26spage%3D281%26epage%3D296%26doi%3D10.1016%2Fj.jconrel.2011.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripp, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based inactiviation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4896</span>– <span class="NLM_lpage">4933</span>, <span class="refDoi"> DOI: 10.1021/jm300065h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300065h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wlur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4896-4933&author=S.+T.+M.+Orrauthor=S.+L.+Rippauthor=T.+E.+Ballardauthor=J.+L.+Hendersonauthor=D.+O.+Scottauthor=R.+S.+Obachauthor=H.+Sunauthor=A.+S.+Kalgutkar&title=Mechanism-based+inactiviation+%28MBI%29+of+cytochrome+P450+enzymes%3A+structure-activity+relationships+and+discovery+strategies+to+mitigate+drug-drug+interaction+risks&doi=10.1021%2Fjm300065h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks</span></div><div class="casAuthors">Orr, Suvi T. M.; Ripp, Sharon L.; Ballard, T. Eric; Henderson, Jaclyn L.; Scott, Dennis O.; Obach, R. Scott; Sun, Hao; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4896-4933</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The importance of mitigating drug-drug interaction (DDI) risks, which arise from inhibition of major human cytochrome P 450 enzymes is a well-established component of the lead optimization process in drug discovery.  More recently, there has been much interest in clin. DDIs potentially arising via time- and concn.-dependent cytochrome P 450 inhibition, a phenomenon consistent with mechanism-based inactivation.  Inactivated P 450 is catalytically incompetent and must be replenished by newly synthesized protein.  Consequently, time-dependent inhibition of P450s presents a greater safety concern compared to reversible inhibition because of the increased propensity for pharmacokinetic interactions upon multiple dosing and the sustained duration of these interactions after discontinuation of the mechanism-based inactivator.  Mechanism-based or time-dependent P 450 inhibitors pose an addnl. risk of idiosyncratic drug toxicity since the mechanism of time-dependency often involves the formation of reactive metabolites, which can react with proteins other than the P 450 isoenzyme responsible for catalysis. in vitro time-dependent inhibition (TDI) of P 450 enzymes is now routinely assessed as part of lead optimization efforts in preclin. drug discovery.  However, identification of an in vitro TDI liability can raise several questions such as: What is the mechanism of TDI.  Does it involve the formation of reactive metabolites.  Is there a 1:1 correlation between P 450 TDI and RM formation (as measured from reactive metabolite trapping studies).  What is the likelihood that a P 450 time-dependent inhibitor will also cause toxicity.  What are the DDI risk mitigation options when dealing with P 450 inactivators in drug discovery - compd. progression or termination.  Several drugs exhibit in vitro TDI of P 450 enzymes, but only a fraction thereof causes clin. DDIs.  Hence, when do we initiate labor-intensive medicinal chem. efforts to design compds. devoid of P 450 TDI liability.  What are the best methods to precisely predict the likelihood of occurrence of clin. DDIs with drug candidates that inactivate P 450 enzymes.  What are (if any) the qualifying considerations for clin. progression of a P 450 time-dependent inactivator with projected clin. DDI risks.  In an effort to address these questions and hopefully provide answers to some of them, we embarked on the present venture wherein we highlight the current state-of-the-art knowledge in this field with a special emphasis on (a) available biochem. and mechanistic approaches in drug discovery to examine TDI of P 450 isoenzymes with new chem. entities, (b) structure-activity relationship studies with marketed drugs assocd. with DDIs via P 450 inactivation, (c) case studies of medicinal chem. tactics to abrogate P 450 inactivation liability, (d) strategies for progression of P 450 TDI-pos. drug candidates, and (e) the utility of in silico methodol., including the use of physiol.-based pharmacokinetic simulators, in drug discovery to predict the magnitude of clin. DDIs risks anticipated with new clin. candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDO60qqRvpS7Vg90H21EOLACvtfcHk0ljKKwv_jSIQuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wlur8%253D&md5=aa4aa4f633b3b4f73b3d79917327b0de</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm300065h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300065h%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26aulast%3DBallard%26aufirst%3DT.%2BE.%26aulast%3DHenderson%26aufirst%3DJ.%2BL.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DMechanism-based%2520inactiviation%2520%2528MBI%2529%2520of%2520cytochrome%2520P450%2520enzymes%253A%2520structure-activity%2520relationships%2520and%2520discovery%2520strategies%2520to%2520mitigate%2520drug-drug%2520interaction%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4896%26epage%3D4933%26doi%3D10.1021%2Fjm300065h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMatteo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloviev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volgina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G.</span></span> <span> </span><span class="NLM_article-title">INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e0231877</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0231877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1371%2Fjournal.pone.0231877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=32315352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BB3cXos1KgsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&issue=4&author=P.+C.+Liuauthor=H.+Koblishauthor=L.+Wuauthor=K.+Bowmanauthor=S.+Diamondauthor=D.+DiMatteoauthor=Y.+Zhangauthor=M.+Hansburyauthor=M.+Ruparauthor=X.+Wenauthor=P.+Collierauthor=P.+Feldmanauthor=R.+Klabeauthor=K.+A.+Burkeauthor=M.+Solovievauthor=C.+Gardinerauthor=X.+Heauthor=A.+Volginaauthor=M.+Covingtonauthor=B.+Ruggeriauthor=R.+Wynnauthor=T.+C.+Burnauthor=P.+Scherleauthor=S.+Yeleswaramauthor=W.+Yaoauthor=R.+Huberauthor=G.+Hollis&title=INCB054828+%28pemigatinib%29%2C+a+potent+and+selective+inhibitor+of+fibroblast+growth+factor+receptors+1%2C+2%2C+and+3%2C+displays+activity+against+genetically+defined+tumor+models&doi=10.1371%2Fjournal.pone.0231877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models</span></div><div class="casAuthors">Liu, Phillip C. C.; Koblish, Holly; Wu, Liangxing; Bowman, Kevin; Diamond, Sharon; DiMatteo, Darlise; Zhang, Yue; Hansbury, Michael; Rupar, Mark; Wen, Xiaoming; Collier, Paul; Feldman, Patricia; Klabe, Ronald; Burke, Krista A.; Soloviev, Maxim; Gardiner, Christine; He, Xin; Volgina, Alla; Covington, Maryanne; Ruggeri, Bruce; Wynn, Richard; Burn, Timothy C.; Scherle, Peggy; Yeleswaram, Swamy; Yao, Wenqing; Huber, Reid; Hollis, Gregory</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0231877</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Alterations in fibroblast growth factor receptor (FGFR) genes have been identified as potential driver oncogenes.  Pharmacol. targeting of FGFRs may therefore provide therapeutic benefit to selected cancer patients, and proof-of-concept has been established in early clin. trials of FGFR inhibitors.  Here, we present the mol. structure and preclin. characterization of INCB054828 (pemigatinib), a novel, selective inhibitor of FGFR 1, 2, and 3, currently in phase 2 clin. trials.  INCB054828 pharmacokinetics and pharmacodynamics were investigated using cell lines and tumor models, and the antitumor effect of oral INCB054828 was investigated using xenograft tumor models with genetic alterations in FGFR1, 2, or 3.  INCB054828 selectively inhibited growth of tumor cell lines with activation of FGFR signaling compared with cell lines lacking FGFR aberrations.  The preclin. pharmacokinetic profile suggests target inhibition is achievable by INCB054828 in vivo with low oral doses.  INCB054828 suppressed the growth of xenografted tumor models with FGFR1, 2, or 3 alterations as monotherapy, and the combination of INCB054828 with cisplatin provided significant benefit over either single agent, with an acceptable tolerability.  The preclin. data presented for INCB054828, together with preliminary clin. observations, support continued investigation in patients with FGFR alterations, such as fusions and activating mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqapC0pvfnBhLVg90H21EOLACvtfcHk0ljKKwv_jSIQuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXos1KgsLw%253D&md5=6250f833911f7fe8b9a8ad880b9d9b67</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0231877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0231877%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DDiMatteo%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHansbury%26aufirst%3DM.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFeldman%26aufirst%3DP.%26aulast%3DKlabe%26aufirst%3DR.%26aulast%3DBurke%26aufirst%3DK.%2BA.%26aulast%3DSoloviev%26aufirst%3DM.%26aulast%3DGardiner%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DVolgina%26aufirst%3DA.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DG.%26atitle%3DINCB054828%2520%2528pemigatinib%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptors%25201%252C%25202%252C%2520and%25203%252C%2520displays%2520activity%2520against%2520genetically%2520defined%2520tumor%2520models%26jtitle%3DPLoS%2520One%26date%3D2020%26volume%3D15%26issue%3D4%26doi%3D10.1371%2Fjournal.pone.0231877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asatiani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lihou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemunaitis, J.</span></span> <span> </span><span class="NLM_article-title">Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">13 suppl</span>),  <span class="NLM_fpage">CT111</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-CT111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1158%2F1538-7445.AM2017-CT111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=CT111&issue=13+suppl&author=M.+Salehauthor=M.+E.+Gutierrezauthor=V.+Subbiahauthor=D.+C.+Smithauthor=E.+Asatianiauthor=C.+F.+Lihouauthor=H.+Zhenauthor=S.+Yeleswaramauthor=T.+Jiauthor=J.+Nemunaitis&title=Preliminary+results+from+a+phase+1%2F2+study+of+INCB054828%2C+a+highly+selective+fibroblast+growth+factor+receptor+%28FGFR%29+inhibitor%2C+in+patients+with+advanced+malignancies&doi=10.1158%2F1538-7445.AM2017-CT111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-CT111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-CT111%26sid%3Dliteratum%253Aachs%26aulast%3DSaleh%26aufirst%3DM.%26aulast%3DGutierrez%26aufirst%3DM.%2BE.%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DAsatiani%26aufirst%3DE.%26aulast%3DLihou%26aufirst%3DC.%2BF.%26aulast%3DZhen%26aufirst%3DH.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DT.%26aulast%3DNemunaitis%26aufirst%3DJ.%26atitle%3DPreliminary%2520results%2520from%2520a%2520phase%25201%252F2%2520study%2520of%2520INCB054828%252C%2520a%2520highly%2520selective%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D13%2520suppl%26spage%3DCT111%26doi%3D10.1158%2F1538-7445.AM2017-CT111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Alfa, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahai, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollebecque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melisi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Rajabi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catenacci, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Cutsem, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lihou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feliz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, A.</span></span> <span> </span><span class="NLM_article-title">Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicenter, open-label, phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(20)30109-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1016%2FS1470-2045%2820%2930109-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=32203698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFehu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=671-684&author=G.+K.+Abou-Alfaauthor=V.+Sahaiauthor=A.+Hollebecqueauthor=G.+Vaccaroauthor=D.+Melisiauthor=R.+Al-Rajabiauthor=A.+S.+Paulsonauthor=M.+Boradauthor=D.+Gallinsonauthor=A.+G.+Murphyauthor=D.+Ohauthor=E.+Dotanauthor=D.+V.+Catenacciauthor=E.+Van+Cutsemauthor=T.+Jiauthor=C.+F.+Lihouauthor=H.+Zhenauthor=L.+Felizauthor=A.+Vogel&title=Pemigatinib+for+previously+treated%2C+locally+advanced+or+metastatic+cholangiocarcinoma%3A+a+multicenter%2C+open-label%2C+phase+2+study&doi=10.1016%2FS1470-2045%2820%2930109-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study</span></div><div class="casAuthors">Abou-Alfa, Ghassan K.; Sahai, Vaibhav; Hollebecque, Antoine; Vaccaro, Gina; Melisi, Davide; Al-Rajabi, Raed; Paulson, Andrew S.; Borad, Mitesh J.; Gallinson, David; Murphy, Adrian G.; Oh, Do-Youn; Dotan, Efrat; Catenacci, Daniel V.; Van Cutsem, Eric; Ji, Tao; Lihou, Christine F.; Zhen, Huiling; Feliz, Luis; Vogel, Arndt</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">671-684</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma.  Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3.  This study evaluated the safety and antitumor activity of pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with and without FGFR2 fusions or rearrangements.  In this multicentre, open-label, single-arm, multicohort, phase 2 study (FIGHT-202), patients aged 18 years or older with disease progression following at least one previous treatment and an Eastern Cooperative Oncol. Group (ECOG) performance status of 0-2 recruited from 146 academic or community-based sites in the USA, Europe, the Middle East, and Asia were assigned to one of three cohorts: patients with FGFR2 fusions or rearrangements, patients with other FGF/FGFR alterations, or patients with no FGF/FGFR alterations.  All enrolled patients received a starting dose of 13·5 mg oral pemigatinib once daily (21-day cycle; 2 wk on, 1 wk off) until disease progression, unacceptable toxicity, withdrawal of consent, or physician decision.  The primary endpoint was the proportion of patients who achieved an objective response among those with FGFR2 fusions or rearrangements, assessed centrally in all patients who received at least one dose of pemigatinib.  This study is registered with ClinicalTrials.gov, NCT02924376, and enrolment is completed.  Between Jan 17, 2017, and March 22, 2019, 146 patients were enrolled: 107 with FGFR2 fusions or rearrangements, 20 with other FGF/FGFR alterations, 18 with no FGF/FGFR alterations, and one with an undetd. FGF/FGFR alteration.  The median follow-up was 17·8 mo (IQR 11·6-21·3). 38 (35·5% [95% CI 26·5-45·4]) patients with FGFR2 fusions or rearrangements achieved an objective response (three complete responses and 35 partial responses).  Overall, hyperphosphatemia was the most common all-grade adverse event irresp. of cause (88 [60%] of 146 patients).  Ninty three (64%) patients had a grade 3 or worse adverse event (irresp. of cause); the most frequent were hypophosphatemia (18 [12%]), arthralgia (nine [6%]), stomatitis (eight [5%]), hyponatremia (eight [5%]), abdominal pain (seven [5%]), and fatigue (seven [5%]). 65 (45%) patients had serious adverse events; the most frequent were abdominal pain (seven [5%]), pyrexia (seven [5%]), cholangitis (five [3%]), and pleural effusion (five [3%]).  Overall, 71 (49%) patients died during the study, most frequently because of disease progression (61 [42%]); no deaths were deemed to be treatment related.  These data support the therapeutic potential of pemigatinib in previously treated patients with cholangiocarcinoma who have FGFR2 fusions or rearrangements.Incyte Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr28ylbW5yBxLVg90H21EOLACvtfcHk0lgAyNmgXTWy8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFehu7g%253D&md5=872884a01e01dad2c7864709d6da57e0</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2820%2930109-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252820%252930109-1%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Alfa%26aufirst%3DG.%2BK.%26aulast%3DSahai%26aufirst%3DV.%26aulast%3DHollebecque%26aufirst%3DA.%26aulast%3DVaccaro%26aufirst%3DG.%26aulast%3DMelisi%26aufirst%3DD.%26aulast%3DAl-Rajabi%26aufirst%3DR.%26aulast%3DPaulson%26aufirst%3DA.%2BS.%26aulast%3DBorad%26aufirst%3DM.%26aulast%3DGallinson%26aufirst%3DD.%26aulast%3DMurphy%26aufirst%3DA.%2BG.%26aulast%3DOh%26aufirst%3DD.%26aulast%3DDotan%26aufirst%3DE.%26aulast%3DCatenacci%26aufirst%3DD.%2BV.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DJi%26aufirst%3DT.%26aulast%3DLihou%26aufirst%3DC.%2BF.%26aulast%3DZhen%26aufirst%3DH.%26aulast%3DFeliz%26aufirst%3DL.%26aulast%3DVogel%26aufirst%3DA.%26atitle%3DPemigatinib%2520for%2520previously%2520treated%252C%2520locally%2520advanced%2520or%2520metastatic%2520cholangiocarcinoma%253A%2520a%2520multicenter%252C%2520open-label%252C%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2020%26volume%3D21%26spage%3D671%26epage%3D684%26doi%3D10.1016%2FS1470-2045%2820%2930109-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="ref34_1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blom, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A.</span></span> <span> </span><span class="NLM_article-title">Preparative LC-MS Purification: Improved Compound Specific Method Optimization</span>. <i>J. Comb. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">883</span>, <span class="refDoi"> DOI: 10.1021/cc049890v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc049890v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/ref34_1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsVaitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=874-883&author=K.+Blomauthor=B.+Glassauthor=R.+Sparksauthor=A.+Combs&title=Preparative+LC-MS+Purification%3A+Improved+Compound+Specific+Method+Optimization&doi=10.1021%2Fcc049890v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_ref34_1R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Preparative LC-MS purification: Improved compound-specific method optimization</span></div><div class="casAuthors">Blom, Karl F.; Glass, Brian; Sparks, Richard; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">874-883</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the remaining challenges in providing effective preparative LC-MS purifn. is balancing throughput and compd. purity.  We describe here an approach to optimizing preparative LC-MS methods that provides significantly better chromatog. resoln. and, hence, better compd. purity than generic preparative LC methods consuming the same amt. of time.  This approach is easier to implement, is more rugged, and permits significantly greater flexibility than previously reported approaches.  The instrument configurations and protocols presented here are specifically tailored for open access support, but the basic approach is equally suitable and effective in high-throughput situations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl2AKyIh0Ro7Vg90H21EOLACvtfcHk0lgAyNmgXTWy8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsVaitLs%253D&md5=05a543bb87c8498e2dce8c24edefd836</span></div><a href="/servlet/linkout?suffix=ref34_1&amp;dbid=16384&amp;doi=10.1021%2Fcc049890v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc049890v%26sid%3Dliteratum%253Aachs%26aulast%3DBlom%26aufirst%3DK.%26aulast%3DGlass%26aufirst%3DB.%26aulast%3DSparks%26aufirst%3DR.%26aulast%3DCombs%26aufirst%3DA.%26atitle%3DPreparative%2520LC-MS%2520Purification%253A%2520Improved%2520Compound%2520Specific%2520Method%2520Optimization%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D2004%26volume%3D6%26spage%3D874%26epage%3D883%26doi%3D10.1021%2Fcc049890v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b','cit17c'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['ref34_1']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative FGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of representative pan-FGFR selective inhibitors in clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structure of screening hit <b>1</b> and subsequent design of a tricyclic series as potent and selective FGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>38</b> (INCB054828, Pemigatinib)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethylamine, 2-methoxyethanol, 130 °C, 92%; (b) camphorsulfonic acid, xylenes, reflux; (c) LiAlH<sub>4</sub>, THF, 50 °C, 82% (two steps); (d) triphosgene, THF, RT, 92%; (e) NaH, PhSO<sub>2</sub>Cl, DMF, 0 °C, 98%; (f) lithium diisopropylamide (LDA), DMF, THF, −78 °C, 91%; (g) morpholine, acetic acid, Na(OAc)<sub>3</sub>BH, DCM, RT, 95%; (h) tetra-<i>n</i>-butylammonium fluoride (TBAF), THF, 50 °C.</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Proposed binding mode of compound <b>38</b> in the ATP pocket of FGFR1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Data were initially published in ref <a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a>. (a) PK/PD analyses for compound <b>38</b>. KatoIII human gastric xenografts were established in female severe combined immunodeficient (SCID) mice in 5 independent experiments. Once tumors were well established, mice (<i>n</i> = 3–5/group) were treated with a single oral dose of compound <b>38</b> at dose levels of 0.01, 0.03, 0.1, 0.3, and 1 mg/kg. Four hours after the single dose, mice were sacrificed and the tumors were collected to analyze levels of pFGFR2 relative to vehicle treated controls. In addition, plasma samples were collected for PK analysis. Data were process from all studies. (b) Efficacy of compound <b>38</b> in female SCID mice bearing KatoIII tumors. Compound <b>38</b> was administered orally once daily for 10 days. The mean tumor size is plotted for each group of 8 mice. ***<i>P</i> < 0.001 vs vehicle. Adapted from Liu, P. C., et al. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2 and 3, displays activity against genetically defined tumor models. <i>PLoS One</i>, <b>2020</b>, 15(4), e0231877, <a href="https://doi.org/10.1371/journal.pone.0231877" class="extLink">10.1371/journal.pone.0231877</a>, under Creative Commons Attribution License (<a href="https://creativecommons.org/licenses/by/4.0/" class="ext-link">https://creativecommons.org/licenses/by/4.0/</a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/medium/jm1c00713_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Best percentage change from baseline in target lesion size for individual patients with FGFR2 fusions or rearrangements treated with pemigatinib. (Colored bars indicate confirmed responses accessed by RECIST 1.1. *Patient had a decrease in target lesion size but was not evaluable for response using RECIST.) Reprinted from <i>Lancet Oncol.</i>, <b>2020</b>, 21, Abou-Alfa, G. K., et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicenter, open-label, phase 2 study, 671–684, Copyright (2020), with permission from Elsevier.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00713/20210716/images/large/jm1c00713_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00713&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27722" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27722" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eswarakumar, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lax, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cellular signaling by fibroblast growth factor receptors</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2005.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1016%2Fj.cytogfr.2005.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=15863030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=139-149&author=V.+P.+Eswarakumarauthor=I.+Laxauthor=J.+Schlessinger&title=Cellular+signaling+by+fibroblast+growth+factor+receptors&doi=10.1016%2Fj.cytogfr.2005.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular signaling by fibroblast growth factor receptors</span></div><div class="casAuthors">Eswarakumar, V. P.; Lax, I.; Schlessinger, J.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-149</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The 22 members of the fibroblast growth factor (FGF) family of growth factors mediate their cellular responses by binding to and activating the different isoforms encoded by the four receptor tyrosine kinases (RTKs) designated FGFR1, FGFR2, FGFR3 and FGFR4.  Unlike other growth factors, FGFs act in concert with heparin or heparan sulfate proteoglycan (HSPG) to activate FGFRs and to induce the pleiotropic responses that lead to the variety of cellular responses induced by this large family of growth factors.  A variety of human skeletal dysplasias have been linked to specific point mutations in FGFR1, FGFR2 and FGFR3 leading to severe impairment in cranial, digital and skeletal development.  Gain of function mutations in FGFRs were also identified in a variety of human cancers such as myeloproliferative syndromes, lymphomas, prostate and breast cancers as well as other malignant diseases.  The binding of FGF and HSPG to the extracellular ligand domain of FGFR induces receptor dimerization, activation and autophosphorylation of multiple tyrosine residues in the cytoplasmic domain of the receptor mol.  A variety of signaling proteins are phosphorylated in response to FGF stimulation including Shc, phospholipase-Cγ, STAT1, Gab1 and FRS2α leading to stimulation of intracellular signaling pathways that control cell proliferation, cell differentiation, cell migration, cell survival and cell shape.  The docking proteins FRS2α and FRS2β are major mediators of the Ras/MAPK and PI-3 kinase/Akt signaling pathways as well as neg. feedback mechanisms that fine-tune the signal that is initiated at the cell surface following FGFR stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4Sa2I4Dn5d7Vg90H21EOLACvtfcHk0lhgsrIKDVS7pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOns7k%253D&md5=996be3a82a79a00173bc4e9d38dcb993</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2005.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2005.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DEswarakumar%26aufirst%3DV.%2BP.%26aulast%3DLax%26aufirst%3DI.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCellular%2520signaling%2520by%2520fibroblast%2520growth%2520factor%2520receptors%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2005%26volume%3D16%26spage%3D139%26epage%3D149%26doi%3D10.1016%2Fj.cytogfr.2005.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powers, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeskey, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellstein, A.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factors, their receptors and signaling</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1677/erc.0.0070165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1677%2Ferc.0.0070165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=11021964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot1Wrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=165-197&author=C.+J.+Powersauthor=S.+W.+McLeskeyauthor=A.+Wellstein&title=Fibroblast+growth+factors%2C+their+receptors+and+signaling&doi=10.1677%2Ferc.0.0070165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factors, their receptors and signaling</span></div><div class="casAuthors">Powers, C. J.; McLeskey, S. W.; Wellstein, A.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">165-197</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review with ∼300 refs.  Fibroblast growth factors (FGFs) are small polypeptide growth factors, all of whom share in common certain structural characteristics, and most of whom bind heparin avidly.  Many FGFs contain signal peptides for secretion and are secreted into the extracellular environment, where they can bind to the heparan-like glycosaminoglycans (HLGAGs) of the extracellular matrix (ECM).  From this reservoir, FGFs may act directly on target cells, or they can be released through digestion of the ECM or the activity of a carrier protein, a secreted FGF binding protein.  FGFs bind specific receptor tyrosine kinases in the context of HLGAGs and this binding induces receptor dimerization and activation, ultimately resulting in the activation of various signal transduction cascades.  Some FGFs are potent angiogenic factors and most play important roles in embryonic development and wound healing.  FGF signaling also appears to play a role in tumor growth and angiogenesis, and autocrine FGF signaling may be particularly important in the progression of steroid hormone-dependent cancers to a hormone-independent state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobr9vLkJC5X7Vg90H21EOLACvtfcHk0lhgsrIKDVS7pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot1Wrs7c%253D&md5=bc2a29bca57b545886a177913d762f6c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0070165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0070165%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DC.%2BJ.%26aulast%3DMcLeskey%26aufirst%3DS.%2BW.%26aulast%3DWellstein%26aufirst%3DA.%26atitle%3DFibroblast%2520growth%2520factors%252C%2520their%2520receptors%2520and%2520signaling%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2000%26volume%3D7%26spage%3D165%26epage%3D197%26doi%3D10.1677%2Ferc.0.0070165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, C.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor signaling in tumorigenesis</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2005.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1016%2Fj.cytogfr.2005.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=15863033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=179-186&author=R.+Groseauthor=C.+Dickson&title=Fibroblast+growth+factor+signaling+in+tumorigenesis&doi=10.1016%2Fj.cytogfr.2005.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signaling in tumorigenesis</span></div><div class="casAuthors">Grose, Richard; Dickson, Clive</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-186</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors and their signaling receptors have been assocd. with multiple biol. activities, including proliferation, differentiation and motility.  Consequently, they have evoked interest as candidate oncogenes with the potential to initiate and/or promote tumorigenesis.  This has resulted in a large literature describing the presence of these growth factors and their receptors in cancer cell lines and primary tumors of diverse origin.  However, it is only recently that compelling evidence has emerged to implicate the fibroblast growth factors (Fgfs) and their receptors in the genesis of human cancers.  Here, the authors outline the model systems that demonstrate the potential oncogenic nature of Fgf signaling and summarize recent evidence that implicates aberrant Fgf signaling as important in the natural history of some common human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq61HT0TPuctLVg90H21EOLACvtfcHk0ljRNSoGkojxrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOnsL4%253D&md5=89f3283bea5a1ef1db871e5d98a03c1b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2005.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2005.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DGrose%26aufirst%3DR.%26aulast%3DDickson%26aufirst%3DC.%26atitle%3DFibroblast%2520growth%2520factor%2520signaling%2520in%2520tumorigenesis%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2005%26volume%3D16%26spage%3D179%26epage%3D186%26doi%3D10.1016%2Fj.cytogfr.2005.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knights, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, S. J.</span></span> <span> </span><span class="NLM_article-title">De-regulated FGF receptors as therapeutic targets in cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2009.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1016%2Fj.pharmthera.2009.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=19874848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyiu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2010&pages=105-117&author=V.+Knightsauthor=S.+J.+Cook&title=De-regulated+FGF+receptors+as+therapeutic+targets+in+cancer&doi=10.1016%2Fj.pharmthera.2009.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">De-regulated FGF receptors as therapeutic targets in cancer</span></div><div class="casAuthors">Knights, Victoria; Cook, Simon J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-117</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) acting through their cognate receptors (FGFRs) play vital roles in development and de-regulation of FGF/FGFR signaling is assocd. with many developmental syndromes.  In addn. there is much interest in inhibiting FGF/FGFR signaling as a therapeutic approach to cancer.  FGF/FGFR signaling is certainly important in tumor angiogenesis but studies in the last few years have uncovered increasing evidence that FGFRs are driving oncogenes in certain cancers and act in a cell autonomous fashion to maintain the malignant properties of tumor cells.  These observations make FGFRs increasingly attractive as targets for therapeutic intervention in cancer.  In this article, we review FGFR signaling and describe recent advances in cancer genomics and cancer cell biol. that demonstrate that specific tumor types are dependent upon or addicted to de-regulated FGFR.  We also describe the range of therapeutic strategies currently employed or in development to antagonize de-regulated FGFRs including antibodies and small mol. tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruZBKTl9d0BbVg90H21EOLACvtfcHk0ljRNSoGkojxrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyiu77P&md5=5712b2b98c18ffc56cd59ea09b3fe0d2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnights%26aufirst%3DV.%26aulast%3DCook%26aufirst%3DS.%2BJ.%26atitle%3DDe-regulated%2520FGF%2520receptors%2520as%2520therapeutic%2520targets%2520in%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D125%26spage%3D105%26epage%3D117%26doi%3D10.1016%2Fj.pharmthera.2009.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beenken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span> <span> </span><span class="NLM_article-title">The FGF family: biology, pathophysiology and therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1038/nrd2792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1038%2Fnrd2792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=19247306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVShur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=235-253&author=A.+Beenkenauthor=M.+Mohammadi&title=The+FGF+family%3A+biology%2C+pathophysiology+and+therapy&doi=10.1038%2Fnrd2792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The FGF family: biology, pathophysiology and therapy</span></div><div class="casAuthors">Beenken, Andrew; Mohammadi, Moosa</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-253</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The family of fibroblast growth factors (FGFs) regulates a plethora of developmental processes, including brain patterning, branching morphogenesis and limb development.  Several mitogenic, cytoprotective and angiogenic therapeutic applications of FGFs are already being explored, and the recent discovery of the crucial roles of the endocrine-acting FGF19 subfamily in bile acid, glucose and phosphate homeostasis has sparked renewed interest in the pharmacol. potential of this family.  This review discusses traditional applications of recombinant FGFs and small-mol. FGF receptor kinase inhibitors in the treatment of cancer and cardiovascular disease and their emerging potential in the treatment of metabolic syndrome and hypophosphatemic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmidKyrdG0lbVg90H21EOLACvtfcHk0ljRNSoGkojxrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVShur4%253D&md5=4789ed4cb521a92114063a400a138645</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd2792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2792%26sid%3Dliteratum%253Aachs%26aulast%3DBeenken%26aufirst%3DA.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DThe%2520FGF%2520family%253A%2520biology%252C%2520pathophysiology%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D235%26epage%3D253%26doi%3D10.1038%2Fnrd2792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, R.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor signaling: from development to cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signaling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0lhl8U3FrZdngw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signaling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, N. C.</span></span> <span> </span><span class="NLM_article-title">The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1</span>. <i>Acta Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1159/000046639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1159%2F000046639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=11919391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD38XitlGmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2002&pages=101-107&author=D.+Macdonaldauthor=A.+Reiterauthor=N.+C.+Cross&title=The+8p11+myeloproliferative+syndrome%3A+a+distinct+clinical+entity+caused+by+constitutive+activation+of+FGFR1&doi=10.1159%2F000046639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of FGFR1</span></div><div class="casAuthors">MacDonald, Donald; Reiter, Andreas; Cross, Nicholas C. P.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Haematologica</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-107</span>CODEN:
                <span class="NLM_cas:coden">ACHAAH</span>;
        ISSN:<span class="NLM_cas:issn">0001-5792</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Several recurrent translocations that involve chromosome band 8p11 have been described in myeloid malignancies.  These translocations target two distinct genes: (1) FGFR1, a receptor tyrosine kinase for fibroblast growth factors, and (2) MOZ, a putative histone acetyltransferase whose precise function remains to be defined.  Disruption of FGFR1 is assocd. with a disease entity known as the 8p11 myeloproliferative syndrome (EMS)/stem cell leukemia-lymphoma syndrome, a chronic myeloproliferative disorder that frequently presents with eosinophilia and assocd. T-cell lymphoblastic lymphoma.  The disease is aggressive and rapidly transforms to acute leukemia, usually of myeloid phenotype.  Currently, only allogeneic stem cell transplantation appears to be effective in eradicating or suppressing the malignant clone.  To date, four gene fusions assocd. with distinct translocations have been described in EMS: the t(8;13)(p11;q12), t(8;9)(p11;q33), t(6;8)(q27;p11) and t(8;22)(p11q22) fuse ZNF198, CEP110, FOP and BCR, resp., to FGFR1.  The resulting fusion proteins have constitutive tyrosine kinase activity and activate multiple signal transduction pathways.  These pathways and the fusion proteins are attractive targets for targeted signal transduction therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTYUEf9Qh_kLVg90H21EOLACvtfcHk0lhl8U3FrZdngw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitlGmsLY%253D&md5=8e053c10889b3854ebf4d009f5f16221</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1159%2F000046639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000046639%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DD.%26aulast%3DReiter%26aufirst%3DA.%26aulast%3DCross%26aufirst%3DN.%2BC.%26atitle%3DThe%25208p11%2520myeloproliferative%2520syndrome%253A%2520a%2520distinct%2520clinical%2520entity%2520caused%2520by%2520constitutive%2520activation%2520of%2520FGFR1%26jtitle%3DActa%2520Haematol.%26date%3D2002%26volume%3D107%26spage%3D101%26epage%3D107%26doi%3D10.1159%2F000046639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okusaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosuge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, T.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1434</span>, <span class="refDoi"> DOI: 10.1002/hep.26890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1002%2Fhep.26890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=24122810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVGls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=1427-1434&author=Y.+Araiauthor=Y.+Totokiauthor=F.+Hosodaauthor=T.+Shirotaauthor=N.+Hamaauthor=H.+Nakamuraauthor=H.+Ojimaauthor=K.+Furutaauthor=K.+Shimadaauthor=T.+Okusakaauthor=T.+Kosugeauthor=T.+Shibata&title=Fibroblast+growth+factor+receptor+2+tyrosine+kinase+fusions+define+a+unique+molecular+subtype+of+cholangiocarcinoma&doi=10.1002%2Fhep.26890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma</span></div><div class="casAuthors">Arai, Yasuhito; Totoki, Yasushi; Hosoda, Fumie; Shirota, Tomoki; Hama, Natsuko; Nakamura, Hiromi; Ojima, Hidenori; Furuta, Koh; Shimada, Kazuaki; Okusaka, Takuji; Kosuge, Tomoo; Shibata, Tatsuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1427-1434</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Cholangiocarcinoma is an intractable cancer, with limited therapeutic options, in which the mol. mechanisms underlying tumor development remain poorly understood.  Identification of a novel driver oncogene and applying it to targeted therapies for molecularly defined cancers might lead to improvements in the outcome of patients.  We performed massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients without KRAS/BRAF/ROS1 alterations and identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1.  In reverse-transcriptase polymerase chain reaction (RT-PCR) screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%), rarely in colorectal (1/149) and hepatocellular carcinoma (1/96), and none in gastric cancer (0/212).  The rearrangements were mutually exclusive with KRAS/BRAF mutations.  Expression of the fusion kinases in NIH3T3 cells activated MAPK and conferred anchorage-independent growth and in vivo tumorigenesis of s.c. transplanted cells in immune-compromised mice.  This transforming ability was attributable to its kinase activity.  Treatment with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074 effectively suppressed transformation.  Conclusion: FGFR2 fusions occur in 13.6% of intrahepatic cholangiocarcinoma.  The expression pattern of these fusions in assocn. with sensitivity to FGFR inhibitors warrant a new mol. classification of cholangiocarcinoma and suggest a new therapeutic approach to the disease. (Hepatol. 2014;59:1427-1434).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEDCAkciiWArVg90H21EOLACvtfcHk0lhl8U3FrZdngw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVGls7w%253D&md5=2fd4e9cffd55540fae88e9771864954b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fhep.26890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26890%26sid%3Dliteratum%253Aachs%26aulast%3DArai%26aufirst%3DY.%26aulast%3DTotoki%26aufirst%3DY.%26aulast%3DHosoda%26aufirst%3DF.%26aulast%3DShirota%26aufirst%3DT.%26aulast%3DHama%26aufirst%3DN.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DOjima%26aufirst%3DH.%26aulast%3DFuruta%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DK.%26aulast%3DOkusaka%26aufirst%3DT.%26aulast%3DKosuge%26aufirst%3DT.%26aulast%3DShibata%26aufirst%3DT.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%25202%2520tyrosine%2520kinase%2520fusions%2520define%2520a%2520unique%2520molecular%2520subtype%2520of%2520cholangiocarcinoma%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D1427%26epage%3D1434%26doi%3D10.1002%2Fhep.26890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Rhijn, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tilborg, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lurkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventure, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiery, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Kwast, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwarthoff, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radvanyi, F.</span></span> <span> </span><span class="NLM_article-title">Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal Disorders</span>. <i>Eur. J. Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">824</span>, <span class="refDoi"> DOI: 10.1038/sj.ejhg.5200883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1038%2Fsj.ejhg.5200883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=12461689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD38XptFKmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2002&pages=819-824&author=B.+W.+van%0ARhijnauthor=A.+A.+van+Tilborgauthor=I.+Lurkinauthor=J.+Bonaventureauthor=A.+de+Vriesauthor=J.+P.+Thieryauthor=T.+H.+van+der+Kwastauthor=E.+C.+Zwarthoffauthor=F.+Radvanyi&title=Novel+fibroblast+growth+factor+receptor+3+%28FGFR3%29+mutations+in+bladder+cancer+previously+identified+in+non-lethal+skeletal+Disorders&doi=10.1038%2Fsj.ejhg.5200883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders</span></div><div class="casAuthors">van Rhijn, Bas W. G.; van Tilborg, Angela A. G.; Lurkin, Irene; Bonaventure, Jacky; de Vries, Annie; Thiery, Jean-Paul; van der Kwast, Theodorus H.; Zwarthoff, Ellen C.; Radvanyi, Francois</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">819-824</span>CODEN:
                <span class="NLM_cas:coden">EJHGEU</span>;
        ISSN:<span class="NLM_cas:issn">1018-4813</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in the fibroblast growth factor receptor 3 (FGFR3) gene are responsible for several autosomal dominant craniosynostosis syndromes and chondrodysplasias, i.e., hypochondroplasia, achondroplasia, SADDAN and thanatophoric dysplasia - a neonatal lethal dwarfism syndrome.  Recently, activating FGFR3 mutations have also been present in cancer, i.e., at high frequency in carcinoma of the bladder and rarely in multiple myeloma and carcinoma of the cervix.  Almost all reported mutations in carcinomas corresponded to the mutations identified in thanatophoric dysplasia.  The authors here screened a series of 297 bladder tumors and found three FGFR3 somatic mutations (G380/382R; K650/652M and K650/652T) that were not previously identified in carcinomas or thanatophoric dysplasia.  Another novel finding was the occurrence of two simultaneous FGFR3 mutations in four tumors.  Two of the three new mutations in bladder cancer, the G380/382R and the K650/652M mutations, were previously reported in achondroplasia and SADDAN, resp.  These syndromes entail a longer life span than thanatophoric dysplasia.  The K650/652T mutation has not previously been detected in patients with skeletal disorders, but affects a codon that has been shown to be affected in some cases of thanatophoric dysplasia, SADDAN and hypochondroplasia.  From a clin. perspective, the patients with FGFR3-related, non-lethal skeletal disorders might be at a higher risk for development of bladder tumors than the general population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOHiG-fm4F8rVg90H21EOLACvtfcHk0lgHLga9OV81yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptFKmtbw%253D&md5=2162a6066af5ba88aa0ba2eb57d6970f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fsj.ejhg.5200883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ejhg.5200883%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BRhijn%26aufirst%3DB.%2BW.%26aulast%3Dvan%2BTilborg%26aufirst%3DA.%2BA.%26aulast%3DLurkin%26aufirst%3DI.%26aulast%3DBonaventure%26aufirst%3DJ.%26aulast%3Dde%2BVries%26aufirst%3DA.%26aulast%3DThiery%26aufirst%3DJ.%2BP.%26aulast%3Dvan%2Bder%2BKwast%26aufirst%3DT.%2BH.%26aulast%3DZwarthoff%26aufirst%3DE.%2BC.%26aulast%3DRadvanyi%26aufirst%3DF.%26atitle%3DNovel%2520fibroblast%2520growth%2520factor%2520receptor%25203%2520%2528FGFR3%2529%2520mutations%2520in%2520bladder%2520cancer%2520previously%2520identified%2520in%2520non-lethal%2520skeletal%2520Disorders%26jtitle%3DEur.%2520J.%2520Hum.%2520Genet.%26date%3D2002%26volume%3D10%26spage%3D819%26epage%3D824%26doi%3D10.1038%2Fsj.ejhg.5200883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zander, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soltermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schottle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leenders, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabow, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Querings, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heukamp, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balke-Want, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baessmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorimier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sollberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brustugun, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel-Riedel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timens, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sietsma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thunnissen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heideman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligorio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damiani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beroukhim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernestus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoelben, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurnberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span> <span> </span><span class="NLM_article-title">Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">62ra93</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3001451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1126%2Fscitranslmed.3001451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=21160078" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=62ra93&author=J.+Weissauthor=M.+L.+Sosauthor=D.+Seidelauthor=M.+Peiferauthor=T.+Zanderauthor=J.+M.+Heuckmannauthor=R.+T.+Ullrichauthor=R.+Menonauthor=S.+Maierauthor=A.+Soltermannauthor=H.+Mochauthor=P.+Wagenerauthor=F.+Fischerauthor=S.+Heynckauthor=M.+Kokerauthor=J.+Schottleauthor=F.+Leendersauthor=F.+Gablerauthor=I.+Dabowauthor=S.+Queringsauthor=L.+C.+Heukampauthor=H.+Balke-Wantauthor=S.+Ansenauthor=D.+Rauhauthor=I.+Baessmannauthor=J.+Altmullerauthor=Z.+Wainerauthor=M.+Conronauthor=G.+Wrightauthor=O.+Russellauthor=B.+Solomonauthor=E.+Brambillaauthor=C.+Brambillaauthor=P.+Lorimierauthor=S.+Sollbergauthor=O.+T.+Brustugunauthor=W.+Engel-Riedelauthor=C.+Ludwigauthor=I.+Petersenauthor=J.+Sangerauthor=J.+Clementauthor=H.+Groenauthor=W.+Timensauthor=H.+Sietsmaauthor=E.+Thunnissenauthor=E.+Smitauthor=D.+Heidemanauthor=F.+Cappuzzoauthor=C.+Ligorioauthor=S.+Damianiauthor=M.+Hallekauthor=R.+Beroukhimauthor=W.+Paoauthor=B.+Kleblauthor=M.+Baumannauthor=R.+Buettnerauthor=K.+Ernestusauthor=E.+Stoelbenauthor=J.+Wolfauthor=P.+Nurnbergauthor=S.+Pernerauthor=R.+K.+Thomas&title=Frequent+and+focal+FGFR1+amplification+associates+with+therapeutically+tractable+FGFR1+dependency+in+squamous+cell+lung+cancer&doi=10.1126%2Fscitranslmed.3001451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3001451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3001451%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DSeidel%26aufirst%3DD.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DUllrich%26aufirst%3DR.%2BT.%26aulast%3DMenon%26aufirst%3DR.%26aulast%3DMaier%26aufirst%3DS.%26aulast%3DSoltermann%26aufirst%3DA.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DWagener%26aufirst%3DP.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSchottle%26aufirst%3DJ.%26aulast%3DLeenders%26aufirst%3DF.%26aulast%3DGabler%26aufirst%3DF.%26aulast%3DDabow%26aufirst%3DI.%26aulast%3DQuerings%26aufirst%3DS.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DBalke-Want%26aufirst%3DH.%26aulast%3DAnsen%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DBaessmann%26aufirst%3DI.%26aulast%3DAltmuller%26aufirst%3DJ.%26aulast%3DWainer%26aufirst%3DZ.%26aulast%3DConron%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DRussell%26aufirst%3DO.%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DBrambilla%26aufirst%3DE.%26aulast%3DBrambilla%26aufirst%3DC.%26aulast%3DLorimier%26aufirst%3DP.%26aulast%3DSollberg%26aufirst%3DS.%26aulast%3DBrustugun%26aufirst%3DO.%2BT.%26aulast%3DEngel-Riedel%26aufirst%3DW.%26aulast%3DLudwig%26aufirst%3DC.%26aulast%3DPetersen%26aufirst%3DI.%26aulast%3DSanger%26aufirst%3DJ.%26aulast%3DClement%26aufirst%3DJ.%26aulast%3DGroen%26aufirst%3DH.%26aulast%3DTimens%26aufirst%3DW.%26aulast%3DSietsma%26aufirst%3DH.%26aulast%3DThunnissen%26aufirst%3DE.%26aulast%3DSmit%26aufirst%3DE.%26aulast%3DHeideman%26aufirst%3DD.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DDamiani%26aufirst%3DS.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DErnestus%26aufirst%3DK.%26aulast%3DStoelben%26aufirst%3DE.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DNurnberg%26aufirst%3DP.%26aulast%3DPerner%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DFrequent%2520and%2520focal%2520FGFR1%2520amplification%2520associates%2520with%2520therapeutically%2520tractable%2520FGFR1%2520dependency%2520in%2520squamous%2520cell%2520lung%2520cancer%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D62ra93%26doi%3D10.1126%2Fscitranslmed.3001451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kunii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorenstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yashiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bacco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elbi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutterbach, B.</span></span> <span> </span><span class="NLM_article-title">FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2340</span>– <span class="NLM_lpage">2348</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-5229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1158%2F0008-5472.CAN-07-5229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=18381441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktV2jsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=2340-2348&author=K.+Kuniiauthor=L.+Davisauthor=J.+Gorensteinauthor=H.+Hatchauthor=M.+Yashiroauthor=A.+Di+Baccoauthor=C.+Elbiauthor=B.+Lutterbach&title=FGFR2-amplified+gastric+cancer+cell+lines+require+FGFR2+and+Erbb3+signaling+for+growth+and+survival&doi=10.1158%2F0008-5472.CAN-07-5229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 Signaling for Growth and Survival</span></div><div class="casAuthors">Kunii, Kaiko; Davis, Lenora; Gorenstein, Julie; Hatch, Harold; Yashiro, Masakazu; Di Bacco, Alessandra; Elbi, Cem; Lutterbach, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2340-2348</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We have identified a crit. role for amplified FGFR2 in gastric cancer cell proliferation and survival.  In a panel of gastric cancer cell lines, fibroblast growth factor receptor 2 (FGFR2) was overexpressed and tyrosine phosphorylated selectively in FGFR2-amplified cell lines KatoIII, Snu16, and OCUM-2M.  FGFR2 kinase inhibition by a specific small-mol. inhibitor resulted in selective and potent growth inhibition in FGFR2-amplified cell lines, resulting in growth arrest in KatoIII cells and prominent induction of apoptosis in both Snu16 and OCUM-2M cells.  FGFR2-amplified cell lines also contained elevated phosphotyrosine in EGFR, Her2, and Erbb3, but the elevated phosphorylation in EGFR could not be inhibited by gefitinib or erlotinib.  We show that the elevated EGFR, Her2, and Erbb3 phosphotyrosine is dependent on FGFR2, revealing EGFR family kinases to be downstream targets of amplified FGFR2.  Moreover, shRNA to Erbb3 resulted in a loss of proliferation, confirming a functional role for the activated EGFR signaling pathway.  These results reveal that both the FGFR2 and EGFR family signaling pathways are activated in FGFR2-amplified gastric cancer cell lines to drive cell proliferation and survival.  Inhibitors of FGFR2 or Erbb3 signaling may have therapeutic efficacy in the subset of gastric cancers contg. FGFR2 amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSCcE3Vd_WrVg90H21EOLACvtfcHk0lin_Wtz0GZgaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktV2jsr0%253D&md5=621f7b5769cc202e08466c83db3c644c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5229%26sid%3Dliteratum%253Aachs%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DGorenstein%26aufirst%3DJ.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DYashiro%26aufirst%3DM.%26aulast%3DDi%2BBacco%26aufirst%3DA.%26aulast%3DElbi%26aufirst%3DC.%26aulast%3DLutterbach%26aufirst%3DB.%26atitle%3DFGFR2-amplified%2520gastric%2520cancer%2520cell%2520lines%2520require%2520FGFR2%2520and%2520Erbb3%2520signaling%2520for%2520growth%2520and%2520survival%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D2340%26epage%3D2348%26doi%3D10.1158%2F0008-5472.CAN-07-5229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dieci, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnedoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rational to medical perspectives</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1158%2F2159-8290.CD-12-0362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=23418312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=264-279&author=M.+V.+Dieciauthor=M.+Arnedoesauthor=F.+Andreauthor=J.+C.+Soria&title=Fibroblast+growth+factor+receptor+inhibitors+as+a+cancer+treatment%3A+from+a+biologic+rational+to+medical+perspectives&doi=10.1158%2F2159-8290.CD-12-0362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives</span></div><div class="casAuthors">Dieci, Maria Vittoria; Arnedos, Monica; Andre, Fabrice; Soria, Jean Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">264-279</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway plays a fundamental role in many physiol. processes, including embryogenesis, adult tissue homeostasis, and wound healing, by orchestrating angiogenesis.  Ligand-independent and ligand-dependent activation have been implicated in a broad range of human malignancies and promote cancer progression in tumors driven by FGF/FGFR oncogenic mutations or amplifications, tumor neoangiogenesis, and targeted treatment resistance, thereby supporting a strong rationale for anti-FGF/FGFR agent development.  Efforts are being pursued to develop selective approaches for use against this pathway by optimizing the management of emerging, class-specific toxicity profiles and correctly designing clin. trials to address these different issues.  Significance: FGF/FGFR pathway deregulations are increasingly recognized across different human cancers.  Understanding the mechanisms at the basis of these alterations and their multiple roles in cancer promotion and drug resistance is a fundamental step for further implementation of targeted therapies and research strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6bibZKwamTLVg90H21EOLACvtfcHk0lin_Wtz0GZgaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOktL4%253D&md5=0e694a7641aa83c1540f745576f04bfa</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0362%26sid%3Dliteratum%253Aachs%26aulast%3DDieci%26aufirst%3DM.%2BV.%26aulast%3DArnedoes%26aufirst%3DM.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%2520inhibitors%2520as%2520a%2520cancer%2520treatment%253A%2520from%2520a%2520biologic%2520rational%2520to%2520medical%2520perspectives%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D264%26epage%3D279%26doi%3D10.1158%2F2159-8290.CD-12-0362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachelot, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalenc, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Garcia, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yovine, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1200/jco.2011.29.15_suppl.508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1200%2Fjco.2011.29.15_suppl.508" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=508-508&author=F.+Andreauthor=T.+D.+Bachelotauthor=M.+Camponeauthor=F.+Dalencauthor=J.+M.+Perez-Garciaauthor=S.+A.+Hurvitzauthor=N.+C.+Turnerauthor=H.+S.+Rugoauthor=M.+M.+Shiauthor=Y.+Zhangauthor=A.+C.+M.+Kayauthor=A.+J.+Yovineauthor=J.+Baselga&title=A+multicenter%2C+open-label+phase+II+trial+of+dovitinib%2C+an+FGFR1+inhibitor%2C+in+FGFR1+amplified+and+non-amplified+metastatic+breast+cancer&doi=10.1200%2Fjco.2011.29.15_suppl.508"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2Fjco.2011.29.15_suppl.508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2011.29.15_suppl.508%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DBachelot%26aufirst%3DT.%2BD.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DDalenc%26aufirst%3DF.%26aulast%3DPerez-Garcia%26aufirst%3DJ.%2BM.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DShi%26aufirst%3DM.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKay%26aufirst%3DA.%2BC.%2BM.%26aulast%3DYovine%26aufirst%3DA.%2BJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DA%2520multicenter%252C%2520open-label%2520phase%2520II%2520trial%2520of%2520dovitinib%252C%2520an%2520FGFR1%2520inhibitor%252C%2520in%2520FGFR1%2520amplified%2520and%2520non-amplified%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D508%26epage%3D508%26doi%3D10.1200%2Fjco.2011.29.15_suppl.508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayson, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasquez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokliatchouk, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltquate, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuyten, D. S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbraith, S.</span></span> <span> </span><span class="NLM_article-title">A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1413</span>– <span class="NLM_lpage">1419</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdq599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1093%2Fannonc%2Fmdq599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=21131369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A280%3ADC%252BC3MrkvFOksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=1413-1419&author=D.+J.+Jonkerauthor=L.+S.+Rosenauthor=M.+B.+Sawyerauthor=F.+de+Braudauthor=G.+Wildingauthor=C.+J.+Sweeneyauthor=G.+C.+Jaysonauthor=G.+A.+McArthurauthor=G.+Rustinauthor=G.+Gossauthor=J.+Kantorauthor=L.+Velasquezauthor=S.+Syedauthor=O.+Mokliatchoukauthor=D.+M.+Feltquateauthor=G.+Kolliaauthor=D.+S.+A.+Nuytenauthor=S.+Galbraith&title=A+phase+I+study+to+determine+the+safety%2C+pharmacokinetics+and+pharmacodynamics+of+a+dual+VEGFR+and+FGFR+inhibitor%2C+brivanib%2C+in+patients+with+advanced+or+metastatic+solid+tumors&doi=10.1093%2Fannonc%2Fmdq599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors</span></div><div class="casAuthors">Jonker D J; Rosen L S; Sawyer M B; de Braud F; Wilding G; Sweeney C J; Jayson G C; McArthur G A; Rustin G; Goss G; Kantor J; Velasquez L; Syed S; Mokliatchouk O; Feltquate D M; Kollia G; Nuyten D S A; Galbraith S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1413-1419</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors.  PATIENTS AND METHODS:  Ninety patients enrolled in this two-part, phase I open-label study of oral brivanib alaninate.  The primary objectives of this study were (in part A) dose-limiting toxicity, maximum tolerated dose (MTD) and the lowest biologically active dose level and (in part B) the optimal dose/dose range.  The secondary objectives of this study were preliminary evidence of antitumor activity, PK and PD.  RESULTS:  Across part A (open-label dose escalation and MTD) and part B (open-label dose optimization), 68 patients received brivanib alaninate.  Brivanib demonstrated a manageable toxicity profile at doses of 180-800 mg.  Most toxic effects were mild.  Systemic exposure of the active moiety brivanib increased linearly ≤1000 mg/day.  The MTD was 800 mg/day.  Forty-four patients were treated at the MTD: 20 with 800 mg continuously, 11 with 800 mg intermittently and 13 with 400 mg b.i.d. doses.  Partial responses were confirmed in two patients receiving brivanib ≥600 mg.  Dynamic contrast-enhanced magnetic resonance imaging demonstrated statistically significant decreases in parameters reflecting tumor vascularity and permeability after multiple doses in the 800-mg continuous q.d. and 400-mg b.i.d. dose cohorts.  CONCLUSION:  In patients with advanced/metastatic cancer, brivanib demonstrates promising antiangiogenic and antitumor activity and manageable toxicity at doses ≤800 mg orally q.d., the recommended phase II study dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwkcPypD6aCHwOGIfWJ7-GfW6udTcc2eZ79WuQD8O1XLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrkvFOksw%253D%253D&md5=cd9b98bdee01a27111ac906edab19ccc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq599%26sid%3Dliteratum%253Aachs%26aulast%3DJonker%26aufirst%3DD.%2BJ.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26aulast%3DSawyer%26aufirst%3DM.%2BB.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DSweeney%26aufirst%3DC.%2BJ.%26aulast%3DJayson%26aufirst%3DG.%2BC.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DRustin%26aufirst%3DG.%26aulast%3DGoss%26aufirst%3DG.%26aulast%3DKantor%26aufirst%3DJ.%26aulast%3DVelasquez%26aufirst%3DL.%26aulast%3DSyed%26aufirst%3DS.%26aulast%3DMokliatchouk%26aufirst%3DO.%26aulast%3DFeltquate%26aufirst%3DD.%2BM.%26aulast%3DKollia%26aufirst%3DG.%26aulast%3DNuyten%26aufirst%3DD.%2BS.%2BA.%26aulast%3DGalbraith%26aufirst%3DS.%26atitle%3DA%2520phase%2520I%2520study%2520to%2520determine%2520the%2520safety%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520a%2520dual%2520VEGFR%2520and%2520FGFR%2520inhibitor%252C%2520brivanib%252C%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520solid%2520tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D1413%26epage%3D1419%26doi%3D10.1093%2Fannonc%2Fmdq599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">955</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1126/science.276.5314.955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1126%2Fscience.276.5314.955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=9139660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADyaK2sXjt1ans7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=955-960&author=M.+Mohammadiauthor=G.+McMahonauthor=L.+Sunauthor=C.+Tangauthor=P.+Hirthauthor=B.+K.+Yehauthor=S.+R.+Hubbardauthor=J.+Schlessinger&title=Structures+of+the+tyrosine+kinase+domain+of+fibroblast+growth+factor+receptor+in+complex+with+inhibitors&doi=10.1126%2Fscience.276.5314.955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors</span></div><div class="casAuthors">Mohammadi, Moosa; McMahon, Gerald; Sun, Li; Tang, Cho; Hirth, Peter; Yeh, Brian K.; Hubbard, Stevan R.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">5314</span>),
    <span class="NLM_cas:pages">955-960</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A new class of protein tyrosine kinase inhibitors was identified that is based on an oxindole core (indolinones).  Two compds. from this class inhibited the kinase activity of fibroblast growth factor receptor 1 (FGFR1) and showed differential specificity toward others receptor tyrosine kinases.  Crystal structures of the tyrosine kinase domain of FGFR1 in complex with the two compds. were detd.  The oxindole occupies the sites in which the adenine of ATP binds, whereas the moieties that extend from the oxindole contact residues in the hinge region between the two kinase lobes.  The more specific inhibitor of FGFR1 induces a conformational change in the nucleotide-binding loop.  This structural information will facilitate the design of new inhibitors for use in the treatment of cancer and other diseases in which cell signaling by tyrosine kinases plays a crucial role in disease pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDwP7A-FMgDLVg90H21EOLACvtfcHk0liTlPH_Xx9pgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjt1ans7w%253D&md5=fdbedba79850d11771677e6d25f3842f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscience.276.5314.955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.276.5314.955%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DYeh%26aufirst%3DB.%2BK.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520fibroblast%2520growth%2520factor%2520receptor%2520in%2520complex%2520with%2520inhibitors%26jtitle%3DScience%26date%3D1997%26volume%3D276%26spage%3D955%26epage%3D960%26doi%3D10.1126%2Fscience.276.5314.955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliseenkova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">5896</span>– <span class="NLM_lpage">5904</span>, <span class="refDoi"> DOI: 10.1093/emboj/17.20.5896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1093%2Femboj%2F17.20.5896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=9774334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1Cmurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1998&pages=5896-5904&author=M.+Mohammadiauthor=S.+Froumauthor=J.+M.+Hambyauthor=M.+C.+Schroederauthor=R.+L.+Panekauthor=G.+H.+Luauthor=A.+V.+Eliseenkovaauthor=D.+Greenauthor=J.+Schlessingerauthor=S.+R.+Hubbard&title=Crystal+structure+of+an+angiogenesis+inhibitor+bound+to+the+FGF+receptor+tyrosine+kinase+domain&doi=10.1093%2Femboj%2F17.20.5896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain</span></div><div class="casAuthors">Mohammadi, Moosa; Froum, Scott; Hamby, James M.; Schroeder, Mel C.; Panek, Robert L.; Lu, Gina H.; Eliseenkova, Anna V.; Green, David; Schlessinger, Joseph; Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5896-5904</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Angiogenesis, the sprouting of new blood vessels from pre-existing ones, is an essential physiol. process in development, yet also plays a major role in the progression of human diseases such as diabetic retinopathy, atherosclerosis and cancer.  The effects of the most potent angiogenic factors, vascular endothelial growth factor (VEGF), angiopoietin and fibroblast growth factor (FGF) are mediated through cell surface receptors that possess intrinsic protein tyrosine kinase activity.  In this report, the authors describe a synthetic compd. of the pyrido[2,3-d]pyrimidine class, designated PD 173074, that selectively inhibits the tyrosine kinase activities of the FGF and VEGF receptors.  The authors show that systemic administration of PD 173074 in mice can effectively block angiogenesis induced by either FGF or VEGF with no apparent toxicity.  To elucidate the determinants of selectivity, the authors have detd. the crystal structure of PD 173074 in complex with the tyrosine kinase domain of FGF receptor 1 at 2.5 Å resoln.  A high degree of surface complementarity between PD 173074 and the hydrophobic, ATP-binding pocket of FGF receptor 1 underlies the potency and selectivity of this inhibitor.  PD 173074 is thus a promising candidate for a therapeutic angiogenesis inhibitor to be used in the treatment of cancer and other diseases whose progression is dependent upon new blood vessel formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4zdEklzyMx7Vg90H21EOLACvtfcHk0liTlPH_Xx9pgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1Cmurs%253D&md5=a76b085ddc9d352878a2c6bc9d1cd6ff</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F17.20.5896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F17.20.5896%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DFroum%26aufirst%3DS.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DEliseenkova%26aufirst%3DA.%2BV.%26aulast%3DGreen%26aufirst%3DD.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520an%2520angiogenesis%2520inhibitor%2520bound%2520to%2520the%2520FGF%2520receptor%2520tyrosine%2520kinase%2520domain%26jtitle%3DEMBO%2520J.%26date%3D1998%26volume%3D17%26spage%3D5896%26epage%3D5904%26doi%3D10.1093%2Femboj%2F17.20.5896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollebecque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahleda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriot, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaussen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span> <span> </span><span class="NLM_article-title">Facts and new hopes on selective FGFR inhibitors in solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">764</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-2035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1158%2F1078-0432.CCR-19-2035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=31585937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslylsLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=764-774&author=F.+Facchinettiauthor=A.+Hollebecqueauthor=R.+Bahledaauthor=Y.+Loriotauthor=K.+A.+Olaussenauthor=C.+Massardauthor=L.+Friboulet&title=Facts+and+new+hopes+on+selective+FGFR+inhibitors+in+solid+tumors&doi=10.1158%2F1078-0432.CCR-19-2035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Facts and new hopes on selective FGFR inhibitors in solid tumors</span></div><div class="casAuthors">Facchinetti, Francesco; Hollebecque, Antoine; Bahleda, Rastislav; Loriot, Yohann; Olaussen, Ken A.; Massard, Christophe; Friboulet, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">764-774</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Precision oncol. relies on the identification of mol. alterations, responsible for tumor initiation and growth, which are suitable targets of specific inhibitors.  The development of FGFR inhibitors represents an edifying example of the rapid evolution in the field of targeted oncol., with 10 different FGFR tyrosine kinase inhibitors actually under clin. investigation.  In parallel, the discovery of FGFR activating mol. alterations (mainly FGFR3 mutations and FGFR2 fusions) across many tumor types, esp. urothelial carcinomas and intrahepatic cholangiocarcinomas, widens the selection of patients that might benefit from selective FGFR inhibitors.  The ongoing concomitant clin. evaluation of selective FGFR inhibitors in molecularly selected solid tumors brings new hopes for patients with metastatic cancer, for tumors so far excluded from molecularly guided treatments.  Widening our knowledge of the activity, efficacy, and toxicities relative to the selective FGFR tyrosine kinase inhibitors under clin. investigation, according to the exact FGFR mol. alteration, will be crucial to det. the optimal therapeutic strategy for patients suffering from FGFR-driven tumors.  Similarly, identifying with appropriate mol. diagnostic, every single tumor harboring targetable FGFR alterations will be of utmost importance to attain the best outcomes for patients with FGFR-driven cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzgxOc3DEltbVg90H21EOLACvtfcHk0liTlPH_Xx9pgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslylsLzN&md5=300df1178350a8ae56713e1d6b58f6d9</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-2035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-2035%26sid%3Dliteratum%253Aachs%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DHollebecque%26aufirst%3DA.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DLoriot%26aufirst%3DY.%26aulast%3DOlaussen%26aufirst%3DK.%2BA.%26aulast%3DMassard%26aufirst%3DC.%26aulast%3DFriboulet%26aufirst%3DL.%26atitle%3DFacts%2520and%2520new%2520hopes%2520on%2520selective%2520FGFR%2520inhibitors%2520in%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26spage%3D764%26epage%3D774%26doi%3D10.1158%2F1078-0432.CCR-19-2035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossaer, J. B.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class</span>. <i>J. Oncol. Pharm. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">702</span>– <span class="NLM_lpage">710</span>, <span class="refDoi"> DOI: 10.1177/1078155220983425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1177%2F1078155220983425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=33375902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnsFSgsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2021&pages=702-710&issue=3&author=A.+Weaverauthor=J.+B.+Bossaer&title=Fibroblast+growth+factor+receptor+%28FGFR%29+inhibitors%3A+A+review+of+a+novel+therapeutic+class&doi=10.1177%2F1078155220983425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class</span></div><div class="casAuthors">Weaver, April; Bossaer, John B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Oncology Pharmacy Practice</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">702-710</span>CODEN:
                <span class="NLM_cas:coden">JOPPFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-1552</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review Comprehensive genomic profiling has an emerging role in cancer therapeutics.  As treatment options remain needed for advanced cancers, patients are relying increasingly more on tumor genomic alterations as possible targets for cancer treatment.  Frequent tumor fibroblast growth factor receptor (FGFR) alterations are seen in many cancers, and include genetic amplifications, mutations, rearrangements and fusions.  FGFR inhibitors target these receptor alterations and show promise as a drug class.  Currently 2 medications are currently FDA approved: erdafitinib and pemigatinib.  Through the FDA accelerated approval process, erdafitinib is indicated to treat metastatic urothelial carcinoma with FGFR2 and FGFR3 alterations, whereas pemigatinib is indicated to treat unresectable cholangiocarcinoma with FGFR2 alterations.  Despite growing knowledge about such advanced cancers, treatment is usually palliative.  With multiple FGFR inhibitors in the pipeline, further FDA approvals are possible, and it is likely their role in therapy will extend to other cancer types.  This review outlines erdafitinib, pemigatinib, their role in cancer, as well as outlining the possible future use of other FGFR inhibitors in urothelial carcinoma, cholangiocarcinoma, and other malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV7v2EX5_eM7Vg90H21EOLACvtfcHk0lgOS3WOZxbVwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnsFSgsr0%253D&md5=c49bb4b0763e86ef49ee7f64df2c4c6a</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1177%2F1078155220983425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1078155220983425%26sid%3Dliteratum%253Aachs%26aulast%3DWeaver%26aufirst%3DA.%26aulast%3DBossaer%26aufirst%3DJ.%2BB.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%2520inhibitors%253A%2520A%2520review%2520of%2520a%2520novel%2520therapeutic%2520class%26jtitle%3DJ.%2520Oncol.%2520Pharm.%2520Pract.%26date%3D2021%26volume%3D27%26issue%3D3%26spage%3D702%26epage%3D710%26doi%3D10.1177%2F1078155220983425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Krook, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeser, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilberding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roychowdhury, S.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1038/s41416-020-01157-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1038%2Fs41416-020-01157-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=33268819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFOrtrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2021&pages=880-892&issue=5&author=M.+A.+Krookauthor=J.+W.+Reeserauthor=G.+Ernstauthor=H.+Barkerauthor=M.+Wilberdingauthor=G.+Liauthor=H.+Z.+Chenauthor=S.+Roychowdhury&title=Fibroblast+growth+factor+receptors+in+cancer%3A+genetic+alterations%2C+diagnostics%2C+therapeutic+targets+and+mechanisms+of+resistance&doi=10.1038%2Fs41416-020-01157-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17cR"><div class="casContent"><span class="casTitleNuber">17c</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance</span></div><div class="casAuthors">Krook, Melanie A.; Reeser, Julie W.; Ernst, Gabrielle; Barker, Hannah; Wilberding, Max; Li, Gary; Chen, Hui-Zi; Roychowdhury, Sameek</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">880-892</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy no. amplifications in 5-10% of all human cancers, although this frequency increases to 10-30% in urothelial carcinoma and intrahepatic cholangiocarcinoma.  We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges assocd. with the development of clin.-grade mol. diagnostic tests to accurately detect these alterations in the tissue and blood of patients.  The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-mol. inhibitors, as well as monoclonal antibodies against the receptors.  We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clin. trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, resp.  However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients.  This phenomenon underscores the need to clearly delineate tumor-intrinsic and tumor-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0DReMO1eCGrVg90H21EOLACvtfcHk0lgOS3WOZxbVwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFOrtrrL&md5=5c5c76a80bba2a2de9c64526b84c2cba</span></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1038%2Fs41416-020-01157-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-020-01157-0%26sid%3Dliteratum%253Aachs%26aulast%3DKrook%26aufirst%3DM.%2BA.%26aulast%3DReeser%26aufirst%3DJ.%2BW.%26aulast%3DErnst%26aufirst%3DG.%26aulast%3DBarker%26aufirst%3DH.%26aulast%3DWilberding%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DH.%2BZ.%26aulast%3DRoychowdhury%26aufirst%3DS.%26atitle%3DFibroblast%2520growth%2520factor%2520receptors%2520in%2520cancer%253A%2520genetic%2520alterations%252C%2520diagnostics%252C%2520therapeutic%2520targets%2520and%2520mechanisms%2520of%2520resistance%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2021%26volume%3D124%26issue%3D5%26spage%3D880%26epage%3D892%26doi%3D10.1038%2Fs41416-020-01157-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lgOS3WOZxbVwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunaydin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapointe, B.</span></span> <span> </span><span class="NLM_article-title">Strategy for extending half-life in drug design and its significance</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslGqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=528-533&author=H.+Gunaydinauthor=M.+D.+Altmanauthor=J.+M.+Ellisauthor=P.+Fullerauthor=S.+A.+Johnsonauthor=B.+Lahueauthor=B.+Lapointe&title=Strategy+for+extending+half-life+in+drug+design+and+its+significance&doi=10.1021%2Facsmedchemlett.8b00018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Strategy for extending half-life in drug design and its significance</span></div><div class="casAuthors">Gunaydin, Hakan; Altman, Michael D.; Ellis, J. Michael; Fuller, Peter; Johnson, Scott A.; Lahue, Brian; Lapointe, Blair</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">528-533</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Preclin. optimization of compds. toward viable drug candidates requires an integrated understanding of properties that impact predictions of the clin. efficacious dose.  The importance of optimizing half-life, unbound clearance, and potency and how they impact dose predictions are discussed in this letter.  Modest half-life improvements for short half-life compds. can dramatically lower the efficacious dose.  The relationship between dose and half-life is nonlinear when unbound clearance is kept const., whereas the relationship between dose and unbound clearance is linear when half-life is kept const.  Due to this difference, we show that dose is more sensitive to changes in half-life than changes in unbound clearance when half-lives are shorter than 2 h.  Through matched mol. pair analyses, we also show that the strategic introduction of halogens is likely to increase half-life and lower projected human dose even though increased lipophilicity does not guarantee extended half-life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJU1an5zslYbVg90H21EOLACvtfcHk0lhAAJXZPHr7kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslGqsLk%253D&md5=497178d9c523a58e1fa70e34cdf09281</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00018%26sid%3Dliteratum%253Aachs%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DEllis%26aufirst%3DJ.%2BM.%26aulast%3DFuller%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DS.%2BA.%26aulast%3DLahue%26aufirst%3DB.%26aulast%3DLapointe%26aufirst%3DB.%26atitle%3DStrategy%2520for%2520extending%2520half-life%2520in%2520drug%2520design%2520and%2520its%2520significance%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D528%26epage%3D533%26doi%3D10.1021%2Facsmedchemlett.8b00018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Relevance of half-life in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4273</span>– <span class="NLM_lpage">4282</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00969</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00969" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOnsrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4273-4282&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Relevance+of+half-life+in+drug+design&doi=10.1021%2Facs.jmedchem.7b00969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Relevance of Half-Life in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4273-4282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state.  A half-life of 12-48 h is generally ideal for once daily dosing of oral drugs.  If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concns.  This may pose challenges to achieving optimal efficacy, safety, and patient compliance.  If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged.  This may pose problems with managing adverse effects and the design of efficient clin. trials.  Half-life is a key parameter for optimization in research and development.  Structural modification to affect clearance, and to a lesser extent vol. of distribution, is the preferred means of modulating half-life.  An effective approach to half-life optimization requires an understanding of the many pitfalls assocd. with its estn. and interpretation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7kT9hNLRzb7Vg90H21EOLACvtfcHk0lhAAJXZPHr7kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOnsrnN&md5=ff748cbebc765f4fa3c3d7b3831f51c8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00969%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DRelevance%2520of%2520half-life%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4273%26epage%3D4282%26doi%3D10.1021%2Facs.jmedchem.7b00969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, Li</span></span> <span> </span><span class="NLM_article-title">Volume of distribution in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5691</span>– <span class="NLM_lpage">5698</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=Li+Di&title=Volume+of+distribution+in+drug+design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0lhAAJXZPHr7kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DLi%26atitle%3DVolume%2520of%2520distribution%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
de Waterbeemd, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. K.</span></span> <span> </span><span class="NLM_article-title">Property-based design: optimization of drug absorption and pharmacokinetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1333</span>, <span class="refDoi"> DOI: 10.1021/jm000407e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000407e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD3MXit1Whu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=1313-1333&author=H.+van%0Ade+Waterbeemdauthor=D.+A.+Smithauthor=K.+Beaumontauthor=D.+K.+Walker&title=Property-based+design%3A+optimization+of+drug+absorption+and+pharmacokinetics&doi=10.1021%2Fjm000407e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Property-based design: optimization of drug absorption and pharmacokinetics</span></div><div class="casAuthors">van de Waterbeemd, Han; Smith, Dennis A.; Beaumont, Kevin; Walker, Don K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1313-1333</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 223 refs.  The authors discuss some aspects of the properties of biol. barriers.  In different sections the estn. of drug absorption via important barriers including gastrointestinal tract, blood-brain barrier, and skin are reviewed.  Various approaches for the measurement and computation of physicochem. and mol. properties currently used in the optimization of absorption as well as the use of physicochem. properties in the design of optimal pharmacokinetic profiles are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaQwsmoX0-mbVg90H21EOLACvtfcHk0lgceS1upTRlKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXit1Whu7c%253D&md5=3183baedca70020f4ce27f306ba0997e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm000407e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000407e%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DD.%2BK.%26atitle%3DProperty-based%2520design%253A%2520optimization%2520of%2520drug%2520absorption%2520and%2520pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D1313%26epage%3D1333%26doi%3D10.1021%2Fjm000407e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veber, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopple, K. D.</span></span> <span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2615</span>– <span class="NLM_lpage">2623</span>, <span class="refDoi"> DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0lgceS1upTRlKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiowetz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span> <span> </span><span class="NLM_article-title">Deep understanding of structure-solubility relationships for a diverse set of organic compounds using matched molecular pairs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5763</span>– <span class="NLM_lpage">5770</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.08.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1016%2Fj.bmc.2011.08.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=21906951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFyntbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=5763-5770&author=L.+Zhangauthor=H.+Zhuauthor=A.+Mathiowetzauthor=H.+Gao&title=Deep+understanding+of+structure-solubility+relationships+for+a+diverse+set+of+organic+compounds+using+matched+molecular+pairs&doi=10.1016%2Fj.bmc.2011.08.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Deep understanding of structure-solubility relationship for a diverse set of organic compounds using matched molecular pairs</span></div><div class="casAuthors">Zhang, Liying; Zhu, Hongyao; Mathiowetz, Alan; Gao, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5763-5770</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aq. soly. is an important biopharmaceutical property in drug discovery and development.  Although it has been studied for decades, the impact on soly. by the substructures (or fragments) of compds. are still not fully understood and characterized.  This study aims to obtain fragment-soly. relationships using matched mol. pairs, and to provide further insight and suggestions for chemists on structural modifications to improve soly. profiles of drug-like mols.  A set of 2794 compds. with measured intrinsic aq. soly. (log S) was fragmented into rings, linkers, and R groups using a controlled hierarchical fragmentation method.  Then matched mol. pairs that differ by only one chem. transformation (i.e., addn. or substitution of fragments) were identified and analyzed.  The difference in soly. for each matched mol. pair was calcd., and the impact of the corresponding chem. transformation on soly. was investigated.  The final product of this study was a fragment-soly. knowledge-base contg. relative contributions to soly. of various medicinal chem. design elements (R-groups, linkers, and rings).  Structural modifications that might improve soly. profiles, i.e., addn./deletion/substitution of fragments, could be derived from this knowledge-base.  This knowledge-base could be used as an expert tool in lead optimization to improve soly. profiles of compds., and the anal. method could be applied to study other biol. and ADMET properties of org. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVAAga6a67JLVg90H21EOLACvtfcHk0lgceS1upTRlKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFyntbrI&md5=029038a43df73f822d1d216dd66ee2ce</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.08.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.08.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DMathiowetz%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DH.%26atitle%3DDeep%2520understanding%2520of%2520structure-solubility%2520relationships%2520for%2520a%2520diverse%2520set%2520of%2520organic%2520compounds%2520using%2520matched%2520molecular%2520pairs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D5763%26epage%3D5770%26doi%3D10.1016%2Fj.bmc.2011.08.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. A.</span></span> <span> </span><span class="NLM_article-title">Novel tactics for designing water-soluble molecules in drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1421</span>– <span class="NLM_lpage">1433</span>, <span class="refDoi"> DOI: 10.1517/17460441.2014.960839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1517%2F17460441.2014.960839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=25226793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2ltbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1421-1433&author=M.+A.+Walker&title=Novel+tactics+for+designing+water-soluble+molecules+in+drug+discovery&doi=10.1517%2F17460441.2014.960839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Novel tactics for designing water-soluble molecules in drug discovery</span></div><div class="casAuthors">Walker, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1421-1433</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Physiochem. drug properties, such as aq. soly. are considered to be a major factor in detg. the ultimate success or failure of exptl. agents.  Soly. is important because it dets. the max. dose which can be taken up.  As the size and hydrophobicity of drug candidates has increased over the years, poor soly. has become a more prevalent issue.  Recent examples from the literature show that an improved understanding of the relationship between mol. structure and soly. allows this issue to be approached using rational design.  Areas covered: This review provides selected examples from the recent drug discovery literature that demonstrate various tactics, which have been applied successfully towards improving drug soly.  The examples that were selected demonstrate the underlying principles behind aq. soly., such as hydrophobicity and cryst. stability.  Expert opinion: From a strategic point of view, improving the soly. of a compd. should be straightforward because it can be accomplished by simply reducing hydrophobicity or cryst. stability.  However, the structural elements and phys. properties which control soly. also influence potency, pharmacokinetics and toxicity.  Furthermore, there are practical aspects such as the quantity and quality of soly.-related data, which hamper the development of structure-soly. relationships.  Given that poor aq. soly. remains a primary issue in drug discovery, there is a continuous need for novel methods to overcome it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcCkPIepQBjLVg90H21EOLACvtfcHk0lgceS1upTRlKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2ltbfO&md5=373cda72cecfa7b5077ed1551a6d1dd9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.960839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.960839%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DM.%2BA.%26atitle%3DNovel%2520tactics%2520for%2520designing%2520water-soluble%2520molecules%2520in%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D1421%26epage%3D1433%26doi%3D10.1517%2F17460441.2014.960839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manallack, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prankerd, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuriev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, D. K.</span></span> <span> </span><span class="NLM_article-title">The significance of acid/base properties in drug discovery</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1039/C2CS35348B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1039%2FC2CS35348B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=23099561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKmtb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=485-496&author=D.+T.+Manallackauthor=R.+J.+Prankerdauthor=E.+Yurievauthor=T.+I.+Opreaauthor=D.+K.+Chalmers&title=The+significance+of+acid%2Fbase+properties+in+drug+discovery&doi=10.1039%2FC2CS35348B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The significance of acid/base properties in drug discovery</span></div><div class="casAuthors">Manallack, David T.; Prankerd, Richard J.; Yuriev, Elizabeth; Oprea, Tudor I.; Chalmers, David K.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">485-496</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  While drug discovery scientists take heed of various guidelines concerning drug-like character, the influence of acid/base properties often remains under-scrutinized.  Ionisation consts. (pKa values) are fundamental to the variability of the biopharmaceutical characteristics of drugs and to underlying parameters such as logD and soly. pKa values affect physicochem. properties such as aq. soly., which in turn influences drug formulation approaches.  More importantly, absorption, distribution, metab., excretion and toxicity (ADMET) are profoundly affected by the charge state of compds. under varying pH conditions.  Consideration of pKa values in conjunction with other mol. properties is of great significance and has the potential to be used to further improve the efficiency of drug discovery.  Given the recent low annual output of new drugs from pharmaceutical companies, this review will provide a timely reminder of an important mol. property that influences clin. success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKAwdQSoeZxLVg90H21EOLACvtfcHk0lhFS4GWS9PClQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKmtb7N&md5=48d72c5bdae09cc3969cffaea36cf30f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FC2CS35348B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2CS35348B%26sid%3Dliteratum%253Aachs%26aulast%3DManallack%26aufirst%3DD.%2BT.%26aulast%3DPrankerd%26aufirst%3DR.%2BJ.%26aulast%3DYuriev%26aufirst%3DE.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DChalmers%26aufirst%3DD.%2BK.%26atitle%3DThe%2520significance%2520of%2520acid%252Fbase%2520properties%2520in%2520drug%2520discovery%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2013%26volume%3D42%26spage%3D485%26epage%3D496%26doi%3D10.1039%2FC2CS35348B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0lhFS4GWS9PClQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">St.
Jean, D. J. Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span> <span> </span><span class="NLM_article-title">Mitigating heterocycle metabolism in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6002</span>– <span class="NLM_lpage">6020</span>, <span class="refDoi"> DOI: 10.1021/jm300343m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300343m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFWhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6002-6020&author=D.+J.+Jr.+St.%0AJeanauthor=C.+Fotsch&title=Mitigating+heterocycle+metabolism+in+drug+discovery&doi=10.1021%2Fjm300343m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mitigating Heterocycle Metabolism in Drug Discovery</span></div><div class="casAuthors">St. Jean, David J.; Fotsch, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6002-6020</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Extensive data from metab. studies have allowed medicinal chemists to develop general principles for reducing compd. metab.  These methods include, but are not limited to, reducing lipophilicity, altering sterics and electronics, introducing a conformational constraint, and altering the stereochem. of their compds.  While no single method is able to solve every metabolic problem, these principles do give medicinal chemists guidance on how to improve the metabolic liabilities of their compds.  If the specific site of metab. is known, medicinal chemists block the site, typically with a fluorine, or replace the metabolically labile group with a bioisostere.  While several authors have reviewed these techniques for reducing metab., there is no review that summarizes different approaches to improving them metabolic stability of heterocycles.  In this review, we summarize examples where changes were made at or near the heterocycle to improve metabolic stability.  By summarizing these examples, we hope to provide a useful guide to medicinal chemists as they attempt to improve the metabolic profile of their own heterocyclic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovQjdBBgXtPbVg90H21EOLACvtfcHk0lhFS4GWS9PClQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFWhsL0%253D&md5=48c262556b8a2cc7dc5539ff91a53a71</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm300343m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300343m%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BJean%26aufirst%3DD.%2BJ.%2BJr.%26aulast%3DFotsch%26aufirst%3DC.%26atitle%3DMitigating%2520heterocycle%2520metabolism%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6002%26epage%3D6020%26doi%3D10.1021%2Fjm300343m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnihotri, S. A.</span></span> <span> </span><span class="NLM_article-title">Recent advances and novel strategies in pre-clinical formulation development: an overview</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2011.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1016%2Fj.jconrel.2011.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=21763367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFGlt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2011&pages=281-296&author=A.+K.+Shahauthor=S.+A.+Agnihotri&title=Recent+advances+and+novel+strategies+in+pre-clinical+formulation+development%3A+an+overview&doi=10.1016%2Fj.jconrel.2011.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances and novel strategies in pre-clinical formulation development: An overview</span></div><div class="casAuthors">Shah, Amit K.; Agnihotri, Sunil A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">281-296</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Preclin. profiling for a New Chem. Entity (NCE), if carried out carefully, can be a good predictor of human clin. outcome.  Along with the pre-clin. study design a thorough understanding of the physico-chem. properties of the drug candidate and a careful selection of the formulation development strategy are of high importance.  The study scientist can experience various challenges in executing a pre-clin. study.  This review article provides an overview of the significance of pre-formulation study parameters and their relevance to preclin. studies.  Various physico-chem. properties such as soly., partition co-efficient, and permeability are attributes crit. to the performance of the drug substance.  This article presents unique formulation development strategies for the successful completion of pre-clin. studies.  Formulation development approach for a pre-clin. study involves taking into consideration various important factors such as duration of the study, Biopharmaceutics Classification System (BCS) of the drug, intended duration of action and the desired route of administration.  These parameters play key role in the selection of solubilizers, surfactants, co-solvents and optimum pH for the formulation.  Two most common routes of administration in the early screening of pharmaceuticals viz., oral and i.v. are emphasized.  The article also describes recent advances in preclin. formulation development including selected examples of in vivo preclin. models for anti-cancer, anti-viral, anti-diabetic and anti-hypertensive drugs.  Adherence to the regulatory requirement is also the key to successful completion of the preclin. development.  An overview of preclin. formulation development along with basic concepts and the recent studies conducted in the past decade are presented in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWmISnQUsuPrVg90H21EOLACvtfcHk0lhFS4GWS9PClQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFGlt77J&md5=5d694f8878476329e5d240518a74c6db</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2011.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2011.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DA.%2BK.%26aulast%3DAgnihotri%26aufirst%3DS.%2BA.%26atitle%3DRecent%2520advances%2520and%2520novel%2520strategies%2520in%2520pre-clinical%2520formulation%2520development%253A%2520an%2520overview%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2011%26volume%3D156%26spage%3D281%26epage%3D296%26doi%3D10.1016%2Fj.jconrel.2011.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripp, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based inactiviation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4896</span>– <span class="NLM_lpage">4933</span>, <span class="refDoi"> DOI: 10.1021/jm300065h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300065h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wlur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4896-4933&author=S.+T.+M.+Orrauthor=S.+L.+Rippauthor=T.+E.+Ballardauthor=J.+L.+Hendersonauthor=D.+O.+Scottauthor=R.+S.+Obachauthor=H.+Sunauthor=A.+S.+Kalgutkar&title=Mechanism-based+inactiviation+%28MBI%29+of+cytochrome+P450+enzymes%3A+structure-activity+relationships+and+discovery+strategies+to+mitigate+drug-drug+interaction+risks&doi=10.1021%2Fjm300065h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks</span></div><div class="casAuthors">Orr, Suvi T. M.; Ripp, Sharon L.; Ballard, T. Eric; Henderson, Jaclyn L.; Scott, Dennis O.; Obach, R. Scott; Sun, Hao; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4896-4933</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The importance of mitigating drug-drug interaction (DDI) risks, which arise from inhibition of major human cytochrome P 450 enzymes is a well-established component of the lead optimization process in drug discovery.  More recently, there has been much interest in clin. DDIs potentially arising via time- and concn.-dependent cytochrome P 450 inhibition, a phenomenon consistent with mechanism-based inactivation.  Inactivated P 450 is catalytically incompetent and must be replenished by newly synthesized protein.  Consequently, time-dependent inhibition of P450s presents a greater safety concern compared to reversible inhibition because of the increased propensity for pharmacokinetic interactions upon multiple dosing and the sustained duration of these interactions after discontinuation of the mechanism-based inactivator.  Mechanism-based or time-dependent P 450 inhibitors pose an addnl. risk of idiosyncratic drug toxicity since the mechanism of time-dependency often involves the formation of reactive metabolites, which can react with proteins other than the P 450 isoenzyme responsible for catalysis. in vitro time-dependent inhibition (TDI) of P 450 enzymes is now routinely assessed as part of lead optimization efforts in preclin. drug discovery.  However, identification of an in vitro TDI liability can raise several questions such as: What is the mechanism of TDI.  Does it involve the formation of reactive metabolites.  Is there a 1:1 correlation between P 450 TDI and RM formation (as measured from reactive metabolite trapping studies).  What is the likelihood that a P 450 time-dependent inhibitor will also cause toxicity.  What are the DDI risk mitigation options when dealing with P 450 inactivators in drug discovery - compd. progression or termination.  Several drugs exhibit in vitro TDI of P 450 enzymes, but only a fraction thereof causes clin. DDIs.  Hence, when do we initiate labor-intensive medicinal chem. efforts to design compds. devoid of P 450 TDI liability.  What are the best methods to precisely predict the likelihood of occurrence of clin. DDIs with drug candidates that inactivate P 450 enzymes.  What are (if any) the qualifying considerations for clin. progression of a P 450 time-dependent inactivator with projected clin. DDI risks.  In an effort to address these questions and hopefully provide answers to some of them, we embarked on the present venture wherein we highlight the current state-of-the-art knowledge in this field with a special emphasis on (a) available biochem. and mechanistic approaches in drug discovery to examine TDI of P 450 isoenzymes with new chem. entities, (b) structure-activity relationship studies with marketed drugs assocd. with DDIs via P 450 inactivation, (c) case studies of medicinal chem. tactics to abrogate P 450 inactivation liability, (d) strategies for progression of P 450 TDI-pos. drug candidates, and (e) the utility of in silico methodol., including the use of physiol.-based pharmacokinetic simulators, in drug discovery to predict the magnitude of clin. DDIs risks anticipated with new clin. candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDO60qqRvpS7Vg90H21EOLACvtfcHk0lhGrYvUgjAhuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wlur8%253D&md5=aa4aa4f633b3b4f73b3d79917327b0de</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm300065h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300065h%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26aulast%3DBallard%26aufirst%3DT.%2BE.%26aulast%3DHenderson%26aufirst%3DJ.%2BL.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DMechanism-based%2520inactiviation%2520%2528MBI%2529%2520of%2520cytochrome%2520P450%2520enzymes%253A%2520structure-activity%2520relationships%2520and%2520discovery%2520strategies%2520to%2520mitigate%2520drug-drug%2520interaction%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4896%26epage%3D4933%26doi%3D10.1021%2Fjm300065h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMatteo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloviev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volgina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G.</span></span> <span> </span><span class="NLM_article-title">INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e0231877</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0231877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1371%2Fjournal.pone.0231877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=32315352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BB3cXos1KgsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&issue=4&author=P.+C.+Liuauthor=H.+Koblishauthor=L.+Wuauthor=K.+Bowmanauthor=S.+Diamondauthor=D.+DiMatteoauthor=Y.+Zhangauthor=M.+Hansburyauthor=M.+Ruparauthor=X.+Wenauthor=P.+Collierauthor=P.+Feldmanauthor=R.+Klabeauthor=K.+A.+Burkeauthor=M.+Solovievauthor=C.+Gardinerauthor=X.+Heauthor=A.+Volginaauthor=M.+Covingtonauthor=B.+Ruggeriauthor=R.+Wynnauthor=T.+C.+Burnauthor=P.+Scherleauthor=S.+Yeleswaramauthor=W.+Yaoauthor=R.+Huberauthor=G.+Hollis&title=INCB054828+%28pemigatinib%29%2C+a+potent+and+selective+inhibitor+of+fibroblast+growth+factor+receptors+1%2C+2%2C+and+3%2C+displays+activity+against+genetically+defined+tumor+models&doi=10.1371%2Fjournal.pone.0231877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models</span></div><div class="casAuthors">Liu, Phillip C. C.; Koblish, Holly; Wu, Liangxing; Bowman, Kevin; Diamond, Sharon; DiMatteo, Darlise; Zhang, Yue; Hansbury, Michael; Rupar, Mark; Wen, Xiaoming; Collier, Paul; Feldman, Patricia; Klabe, Ronald; Burke, Krista A.; Soloviev, Maxim; Gardiner, Christine; He, Xin; Volgina, Alla; Covington, Maryanne; Ruggeri, Bruce; Wynn, Richard; Burn, Timothy C.; Scherle, Peggy; Yeleswaram, Swamy; Yao, Wenqing; Huber, Reid; Hollis, Gregory</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0231877</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Alterations in fibroblast growth factor receptor (FGFR) genes have been identified as potential driver oncogenes.  Pharmacol. targeting of FGFRs may therefore provide therapeutic benefit to selected cancer patients, and proof-of-concept has been established in early clin. trials of FGFR inhibitors.  Here, we present the mol. structure and preclin. characterization of INCB054828 (pemigatinib), a novel, selective inhibitor of FGFR 1, 2, and 3, currently in phase 2 clin. trials.  INCB054828 pharmacokinetics and pharmacodynamics were investigated using cell lines and tumor models, and the antitumor effect of oral INCB054828 was investigated using xenograft tumor models with genetic alterations in FGFR1, 2, or 3.  INCB054828 selectively inhibited growth of tumor cell lines with activation of FGFR signaling compared with cell lines lacking FGFR aberrations.  The preclin. pharmacokinetic profile suggests target inhibition is achievable by INCB054828 in vivo with low oral doses.  INCB054828 suppressed the growth of xenografted tumor models with FGFR1, 2, or 3 alterations as monotherapy, and the combination of INCB054828 with cisplatin provided significant benefit over either single agent, with an acceptable tolerability.  The preclin. data presented for INCB054828, together with preliminary clin. observations, support continued investigation in patients with FGFR alterations, such as fusions and activating mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqapC0pvfnBhLVg90H21EOLACvtfcHk0lhGrYvUgjAhuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXos1KgsLw%253D&md5=6250f833911f7fe8b9a8ad880b9d9b67</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0231877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0231877%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DDiMatteo%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHansbury%26aufirst%3DM.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFeldman%26aufirst%3DP.%26aulast%3DKlabe%26aufirst%3DR.%26aulast%3DBurke%26aufirst%3DK.%2BA.%26aulast%3DSoloviev%26aufirst%3DM.%26aulast%3DGardiner%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DVolgina%26aufirst%3DA.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DG.%26atitle%3DINCB054828%2520%2528pemigatinib%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptors%25201%252C%25202%252C%2520and%25203%252C%2520displays%2520activity%2520against%2520genetically%2520defined%2520tumor%2520models%26jtitle%3DPLoS%2520One%26date%3D2020%26volume%3D15%26issue%3D4%26doi%3D10.1371%2Fjournal.pone.0231877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asatiani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lihou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemunaitis, J.</span></span> <span> </span><span class="NLM_article-title">Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">13 suppl</span>),  <span class="NLM_fpage">CT111</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-CT111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1158%2F1538-7445.AM2017-CT111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=CT111&issue=13+suppl&author=M.+Salehauthor=M.+E.+Gutierrezauthor=V.+Subbiahauthor=D.+C.+Smithauthor=E.+Asatianiauthor=C.+F.+Lihouauthor=H.+Zhenauthor=S.+Yeleswaramauthor=T.+Jiauthor=J.+Nemunaitis&title=Preliminary+results+from+a+phase+1%2F2+study+of+INCB054828%2C+a+highly+selective+fibroblast+growth+factor+receptor+%28FGFR%29+inhibitor%2C+in+patients+with+advanced+malignancies&doi=10.1158%2F1538-7445.AM2017-CT111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-CT111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-CT111%26sid%3Dliteratum%253Aachs%26aulast%3DSaleh%26aufirst%3DM.%26aulast%3DGutierrez%26aufirst%3DM.%2BE.%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DAsatiani%26aufirst%3DE.%26aulast%3DLihou%26aufirst%3DC.%2BF.%26aulast%3DZhen%26aufirst%3DH.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DT.%26aulast%3DNemunaitis%26aufirst%3DJ.%26atitle%3DPreliminary%2520results%2520from%2520a%2520phase%25201%252F2%2520study%2520of%2520INCB054828%252C%2520a%2520highly%2520selective%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D13%2520suppl%26spage%3DCT111%26doi%3D10.1158%2F1538-7445.AM2017-CT111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Alfa, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahai, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollebecque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melisi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Rajabi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catenacci, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Cutsem, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lihou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feliz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, A.</span></span> <span> </span><span class="NLM_article-title">Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicenter, open-label, phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(20)30109-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=10.1016%2FS1470-2045%2820%2930109-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=32203698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFehu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=671-684&author=G.+K.+Abou-Alfaauthor=V.+Sahaiauthor=A.+Hollebecqueauthor=G.+Vaccaroauthor=D.+Melisiauthor=R.+Al-Rajabiauthor=A.+S.+Paulsonauthor=M.+Boradauthor=D.+Gallinsonauthor=A.+G.+Murphyauthor=D.+Ohauthor=E.+Dotanauthor=D.+V.+Catenacciauthor=E.+Van+Cutsemauthor=T.+Jiauthor=C.+F.+Lihouauthor=H.+Zhenauthor=L.+Felizauthor=A.+Vogel&title=Pemigatinib+for+previously+treated%2C+locally+advanced+or+metastatic+cholangiocarcinoma%3A+a+multicenter%2C+open-label%2C+phase+2+study&doi=10.1016%2FS1470-2045%2820%2930109-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study</span></div><div class="casAuthors">Abou-Alfa, Ghassan K.; Sahai, Vaibhav; Hollebecque, Antoine; Vaccaro, Gina; Melisi, Davide; Al-Rajabi, Raed; Paulson, Andrew S.; Borad, Mitesh J.; Gallinson, David; Murphy, Adrian G.; Oh, Do-Youn; Dotan, Efrat; Catenacci, Daniel V.; Van Cutsem, Eric; Ji, Tao; Lihou, Christine F.; Zhen, Huiling; Feliz, Luis; Vogel, Arndt</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">671-684</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma.  Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3.  This study evaluated the safety and antitumor activity of pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with and without FGFR2 fusions or rearrangements.  In this multicentre, open-label, single-arm, multicohort, phase 2 study (FIGHT-202), patients aged 18 years or older with disease progression following at least one previous treatment and an Eastern Cooperative Oncol. Group (ECOG) performance status of 0-2 recruited from 146 academic or community-based sites in the USA, Europe, the Middle East, and Asia were assigned to one of three cohorts: patients with FGFR2 fusions or rearrangements, patients with other FGF/FGFR alterations, or patients with no FGF/FGFR alterations.  All enrolled patients received a starting dose of 13·5 mg oral pemigatinib once daily (21-day cycle; 2 wk on, 1 wk off) until disease progression, unacceptable toxicity, withdrawal of consent, or physician decision.  The primary endpoint was the proportion of patients who achieved an objective response among those with FGFR2 fusions or rearrangements, assessed centrally in all patients who received at least one dose of pemigatinib.  This study is registered with ClinicalTrials.gov, NCT02924376, and enrolment is completed.  Between Jan 17, 2017, and March 22, 2019, 146 patients were enrolled: 107 with FGFR2 fusions or rearrangements, 20 with other FGF/FGFR alterations, 18 with no FGF/FGFR alterations, and one with an undetd. FGF/FGFR alteration.  The median follow-up was 17·8 mo (IQR 11·6-21·3). 38 (35·5% [95% CI 26·5-45·4]) patients with FGFR2 fusions or rearrangements achieved an objective response (three complete responses and 35 partial responses).  Overall, hyperphosphatemia was the most common all-grade adverse event irresp. of cause (88 [60%] of 146 patients).  Ninty three (64%) patients had a grade 3 or worse adverse event (irresp. of cause); the most frequent were hypophosphatemia (18 [12%]), arthralgia (nine [6%]), stomatitis (eight [5%]), hyponatremia (eight [5%]), abdominal pain (seven [5%]), and fatigue (seven [5%]). 65 (45%) patients had serious adverse events; the most frequent were abdominal pain (seven [5%]), pyrexia (seven [5%]), cholangitis (five [3%]), and pleural effusion (five [3%]).  Overall, 71 (49%) patients died during the study, most frequently because of disease progression (61 [42%]); no deaths were deemed to be treatment related.  These data support the therapeutic potential of pemigatinib in previously treated patients with cholangiocarcinoma who have FGFR2 fusions or rearrangements.Incyte Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr28ylbW5yBxLVg90H21EOLACvtfcHk0lhne60fpBiriw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFehu7g%253D&md5=872884a01e01dad2c7864709d6da57e0</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2820%2930109-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252820%252930109-1%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Alfa%26aufirst%3DG.%2BK.%26aulast%3DSahai%26aufirst%3DV.%26aulast%3DHollebecque%26aufirst%3DA.%26aulast%3DVaccaro%26aufirst%3DG.%26aulast%3DMelisi%26aufirst%3DD.%26aulast%3DAl-Rajabi%26aufirst%3DR.%26aulast%3DPaulson%26aufirst%3DA.%2BS.%26aulast%3DBorad%26aufirst%3DM.%26aulast%3DGallinson%26aufirst%3DD.%26aulast%3DMurphy%26aufirst%3DA.%2BG.%26aulast%3DOh%26aufirst%3DD.%26aulast%3DDotan%26aufirst%3DE.%26aulast%3DCatenacci%26aufirst%3DD.%2BV.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DJi%26aufirst%3DT.%26aulast%3DLihou%26aufirst%3DC.%2BF.%26aulast%3DZhen%26aufirst%3DH.%26aulast%3DFeliz%26aufirst%3DL.%26aulast%3DVogel%26aufirst%3DA.%26atitle%3DPemigatinib%2520for%2520previously%2520treated%252C%2520locally%2520advanced%2520or%2520metastatic%2520cholangiocarcinoma%253A%2520a%2520multicenter%252C%2520open-label%252C%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2020%26volume%3D21%26spage%3D671%26epage%3D684%26doi%3D10.1016%2FS1470-2045%2820%2930109-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-ref34_1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blom, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A.</span></span> <span> </span><span class="NLM_article-title">Preparative LC-MS Purification: Improved Compound Specific Method Optimization</span>. <i>J. Comb. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">883</span>, <span class="refDoi"> DOI: 10.1021/cc049890v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc049890v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/ref34_1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsVaitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=874-883&author=K.+Blomauthor=B.+Glassauthor=R.+Sparksauthor=A.+Combs&title=Preparative+LC-MS+Purification%3A+Improved+Compound+Specific+Method+Optimization&doi=10.1021%2Fcc049890v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_ref34_1R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Preparative LC-MS purification: Improved compound-specific method optimization</span></div><div class="casAuthors">Blom, Karl F.; Glass, Brian; Sparks, Richard; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">874-883</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the remaining challenges in providing effective preparative LC-MS purifn. is balancing throughput and compd. purity.  We describe here an approach to optimizing preparative LC-MS methods that provides significantly better chromatog. resoln. and, hence, better compd. purity than generic preparative LC methods consuming the same amt. of time.  This approach is easier to implement, is more rugged, and permits significantly greater flexibility than previously reported approaches.  The instrument configurations and protocols presented here are specifically tailored for open access support, but the basic approach is equally suitable and effective in high-throughput situations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl2AKyIh0Ro7Vg90H21EOLACvtfcHk0ljVqocu8OEmkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsVaitLs%253D&md5=05a543bb87c8498e2dce8c24edefd836</span></div><a href="/servlet/linkout?suffix=ref34_1&amp;dbid=16384&amp;doi=10.1021%2Fcc049890v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc049890v%26sid%3Dliteratum%253Aachs%26aulast%3DBlom%26aufirst%3DK.%26aulast%3DGlass%26aufirst%3DB.%26aulast%3DSparks%26aufirst%3DR.%26aulast%3DCombs%26aufirst%3DA.%26atitle%3DPreparative%2520LC-MS%2520Purification%253A%2520Improved%2520Compound%2520Specific%2520Method%2520Optimization%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D2004%26volume%3D6%26spage%3D874%26epage%3D883%26doi%3D10.1021%2Fcc049890v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI','PDB','2FGI'); return false;">PDB: 2FGI</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i20"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00713">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_72741"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00713?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00713</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental details for in vitro and in vivo studies; synthetic procedures and characterization for compounds <b>1</b>–<b>37</b>; in vitro potency, ADME properties and PK profiles for compounds <b>2</b>-<b>38</b>; Detailed characterization for compound <b>38</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00713/suppl_file/jm1c00713_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and in vitro biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00713/suppl_file/jm1c00713_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00713/suppl_file/jm1c00713_si_001.pdf">jm1c00713_si_001.pdf (1.82 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00713/suppl_file/jm1c00713_si_002.csv">jm1c00713_si_002.csv (3.61 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00713&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00713%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00713" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67993b6e0c06d197","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
